

### Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request cder\_mpl1r\_wp029\_nsdp\_v01

**Request ID:** cder\_mpl1r\_wp029\_nsdp\_v01

**Request Description:** This request investigated indications of use among oral antifungal drug users in the Sentinel Distributed Database (SDD).

**Sentinel Modular Program Tool Used:** Modular Program 7, Version 5.1

**Data Source:** The query was run against the Sentinel Distributed Database for the time period of January 1, 2009- September 16, 2015. The request was distributed to 16 Data Partners on July 26, 2016. See Appendix A for a list of the latest dates of available data for each Data Partner.

**Study Design:** This request was designed to describe the frequency of diagnosis codes that occurred before, on the day of, or after the index date. The number of patients eligible for an exposure, the number of member years contributed by those eligible patients, and the number of patients exposed to the drugs of interest were calculated. Moreover, the number of codes and the number and percentage of exposed patients with each diagnosis of interest that occurred before, on the day of, or after the index date were calculated. These results were stratified by year, sex, and age group.

**Index Date:** The index date was defined as the date of an oral antifungal drug dispensing. Five cohorts were created, each defined by an index date for one of the following oral antifungal drugs: ketoconazole, fluconazole, griseofulvin, itraconazole, or terbinafine. All five oral antifungal drugs were also grouped together to create a sixth cohort. Only the first valid index date per patient was included in the results. Please see Appendix B for a list of brand and generic drug names.

**Cohort Eligibility Criteria:** Prevalent cohorts were identified for each antifungal drug cohort, where no washout period prior to the index date was used. For the prevalent cohorts, patients were required to be continuously enrolled in plans with both medical and drug coverage for 45 days before their index date, during which gaps in coverage of up to 45 days were allowed. Incident cohorts were also identified for each antifungal drug cohort, where patients were required to have had no prior antifungal use in the 90, 180, or 365 days before their index date. For the incident cohorts, patients were required to be continuously enrolled in plans with both medical and drug coverage for the length of the washout period, during which gaps in coverage of up to 45 days were allowed. Please see appendix C for a list of drug names and Healthcare Common Procedure Coding System (HCPCS) codes used to define antifungal incidence criteria.

**Pre and Post-Index Assessment Periods:** For the prevalent cohorts, the frequency of 85 diagnosis codes were assessed during pre- and post-index assessment periods. The pre-index assessment period captured diagnoses that occurred within 45 days to the day before the index date. The post-index assessment period captured diagnoses that occurred on the index date to 14 days after the index date. Please see Appendix D for a list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes.

**Please see the Appendix E for the specifications of parameters that were used in the analyses for this request.**

**Notes:** Please contact the Sentinel Operations Center Query Fulfillment Team (production@mini-sentinel.org) for questions and to provide comments/suggestions for future enhancements to this document.

**Table of Contents**

<b><u>Glossary</u></b>	List of Terms Found in this Report and their Definitions
<b><u>Table 1</u></b>	Counts of Eligible Members, Member Years, and Prevalent and Incident Antifungal Users by Drug and Washout Period
<b><u>Table 2a</u></b>	Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database
<b><u>Table 2a_year</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Year
<b><u>Table 2a_sex</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Sex
<b><u>Table 2a_age</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Age Group
<b><u>Table 2b</u></b>	Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database
<b><u>Table 2b_year</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Year
<b><u>Table 2b_sex</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Sex
<b><u>Table 2b_age</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Age Group
<b><u>Table 2c</u></b>	Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database
<b><u>Table 2c_year</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Year
<b><u>Table 2c_sex</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Sex
<b><u>Table 2c_age</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Age Group
<b><u>Table 2d</u></b>	Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database
<b><u>Table 2d_year</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Year
<b><u>Table 2d_sex</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Sex
<b><u>Table 2d_age</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Age Group
<b><u>Table 2e</u></b>	Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database
<b><u>Table 2e_year</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Year
<b><u>Table 2e_sex</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Sex
<b><u>Table 2e_age</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Age Group
<b><u>Table 2f</u></b>	Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database
<b><u>Table 2f_year</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Year
<b><u>Table 2f_sex</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Sex
<b><u>Table 2f_age</u></b>	Number of Codes and Number of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Age Group
<b><u>Appendix A</u></b>	Data Partner Data Availability End Dates as of Request Distribution Date
<b><u>Appendix B</u></b>	Generic and Brand Names use to Define Oral Antifungal Drugs in this Request
<b><u>Appendix C</u></b>	Generic Names, Brand Names, and Procedure Codes used to Define Define Antifungal Incidence Criteria in this Request
<b><u>Appendix D</u></b>	Diagnosis Codes used to Define Indications in this Request
<b><u>Appendix E</u></b>	Specifications with List of Parameters used in this Request

## Glossary of Terms in Modular Program 7

**Query Period** - period in which the modular program looks for exposures and outcomes of interest

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

**Coverage Requirement** - specifies the type of coverage (medical, drug, or both) required of members

**Age Stratifications** - age group categories for reporting

**Incident Exposure** - exposure for index claim of interest

**Incident w/ respect to:** - Exposure that the exposure of interest is incident with respect to. For example, if an exposure is Drug X, we could examine Drug X incident with respect to itself (new Drug X users who do not have a Drug X dispensing in the prior washout period days), or we could examine Drug X incident with respect to both Drug X and Drug Y (new Drug X users who do not have a Drug X or Drug Y dispensing in the prior washout period days).

**Washout Period** - number of days a user is required to have no evidence of prior exposure/event (drug dispensing/procedure/diagnosis/anniversary date)

**Incidence Type** - *Minimum incidence type* considers the first exposure/event as long as it is the first such exposure/event in the user's entire available history. *Single incidence type* identifies and reports metrics only for the first valid incident index claim during the query period, and uses claims observed during the specified washout period days to determine incidence.

**Enrollment Days** - number of days of continuous enrollment required before the occurrence of an incident claim used to define the index date

**Most Frequent Procedures** - procedures to be ranked in the pre/post-index periods

**Pre/Post-Index Incidence Type** - defines how incidence is evaluated for the pre- and post-index codes. A value of MIN identifies and reports metrics only for the first valid incident pre/post code during the query prior, and uses all previously observed codes, even those before the query period start date, to determine incidence. A value of MULT identifies and reports metrics for all valid incident pre/post codes during the query period, and uses codes observed during the specified washout period to determine incidence.

**Pre/Post-Index Washout Period** - number of washout days to determine pre/post period code incidence when the pre/post index incidence type = MULT

**Pre/Post-Index Lookup Periods** - number of days before and after the index date to consider and rank exposures/events (dispensings, procedures, diagnoses)

**Pre/Post-Index Enrollment Requirements** - number of days of continuous enrollment required before/after an index date claim to include the claim in the output metrics for prevalent or incident pre/post claims

**Pre/Post Index Care Setting** - type of medical encounter or facility where the procedure or diagnosis code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA)

**Post-Index Blackout Period** - number of days at the beginning of the post-index period that dispensings, procedures, or diagnoses are to be ignored. The index date will be included in the post-index lookup period if Blackout = 0.

**Table 1. Counts of Eligible Members, Member Years, and Prevalent and Incident Antifungal Users by Drug and Washout Period**

<b>Group</b>	<b>Number of Eligible Members</b>	<b>Number of Eligible Member Years</b>	<b>Number of Users</b>
Prevalent Oral Antifungal Use	116,362,677	253,824,574	6,611,493
Incident Oral Antifungal Use in 90 Days	110,974,297	243,278,855	6,178,606
Incident Oral Antifungal Use in 180 Days	102,732,346	223,928,648	5,526,762
Incident Oral Antifungal Use in 365 Days	81,473,054	190,237,650	4,392,850
Prevalent Oral Ketoconazole Use	116,362,677	266,652,176	318,701
Incident Oral Ketoconazole Use in 90 Days	110,974,373	252,808,071	278,730
Incident Oral Ketoconazole Use in 180 Days	102,732,405	231,072,173	245,631
Incident Oral Ketoconazole Use in 365 Days	81,473,090	194,380,952	191,840
Prevalent Oral Fluconazole Use	116,362,677	256,267,008	5,489,965
Incident Oral Fluconazole Use in 90 Days	110,974,315	245,136,943	5,142,349
Incident Oral Fluconazole Use in 180 Days	102,732,363	225,398,369	4,581,485
Incident Oral Fluconazole Use in 365 Days	81,473,063	191,169,548	3,601,711
Prevalent Oral Griseofulvin Use	116,362,677	266,863,772	204,729
Incident Oral Griseofulvin Use in 90 Days	110,974,372	252,943,943	178,558
Incident Oral Griseofulvin Use in 180 Days	102,732,404	231,158,511	160,372
Incident Oral Griseofulvin Use in 365 Days	81,473,088	194,409,318	132,621
Prevalent Oral Itraconazole Use	116,362,677	267,230,365	54,465
Incident Oral Itraconazole Use in 90 Days	110,974,379	253,236,327	42,166
Incident Oral Itraconazole Use in 180 Days	102,732,411	231,395,061	35,494
Incident Oral Itraconazole Use in 365 Days	81,473,092	194,566,684	26,976
Prevalent Oral Terbinafine Use	116,362,677	265,762,772	773,190
Incident Oral Terbinafine Use in 90 Days	110,974,377	252,176,948	682,892
Incident Oral Terbinafine Use in 180 Days	102,732,411	230,572,533	609,293
Incident Oral Terbinafine Use in 365 Days	81,473,093	194,054,836	497,144

**Table 2a. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Antifungal Use			0 to 14 Days Post Prevalent Antifungal Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Antifungal Users</i>		<i>N/A</i>	<i>6,611,493</i>	<i>100%</i>	<i>N/A</i>	<i>6,611,493</i>	<i>100%</i>
-	Diagnosis outside of pre-determined list	40,263,620	4,616,273	69.82%	19,191,455	4,304,033	65.10%
110	Dermatophytosis	30	30	0.00%	30	30	0.00%
110.0	Dermatophytosis of scalp and beard	35,653	33,519	0.51%	78,422	74,837	1.13%
110.1	Dermatophytosis of nail	285,902	238,560	3.61%	238,402	228,306	3.45%
110.2	Dermatophytosis of hand	2,930	2,750	0.04%	4,969	4,803	0.07%
110.3	Dermatophytosis of groin and perianal area	21,183	19,584	0.30%	57,036	54,482	0.82%
110.4	Dermatophytosis of foot	67,452	60,211	0.91%	89,580	84,648	1.28%
110.5	Dermatophytosis of the body	55,661	51,418	0.78%	120,291	115,748	1.75%
110.6	Deep seated dermatophytosis	1,054	985	0.01%	1,550	1,492	0.02%
110.8	Dermatophytosis of other specified sites	3,446	3,239	0.05%	5,057	4,850	0.07%
110.9	Dermatophytosis of unspecified site	20,381	19,232	0.29%	34,685	33,712	0.51%
111	Dermatomycosis, other and unspecified	20	20	0.00%	22	22	0.00%
111.0	Pityriasis versicolor	45,943	44,540	0.67%	106,475	105,075	1.59%
111.1	Tinea nigra	410	379	0.01%	654	637	0.01%
111.2	Tinea blanca	566	538	0.01%	1,256	1,227	0.02%
111.3	Black piedra	12	12	0.00%	14	14	0.00%
111.8	Other specified dermatomycoses	920	758	0.01%	1,443	1,189	0.02%
111.9	Unspecified dermatomycosis	5,591	5,134	0.08%	12,184	11,426	0.17%
112	Candidiasis	103	98	0.00%	200	182	0.00%
112.0	Candidiasis of mouth	68,087	55,680	0.84%	104,438	94,227	1.43%
112.1	Candidiasis of vulva and vagina	142,400	137,993	2.09%	629,238	612,284	9.26%
112.2	Candidiasis of other urogenital sites	15,109	13,835	0.21%	22,539	21,465	0.32%
112.3	Candidiasis of skin and nails	19,478	17,810	0.27%	48,991	46,077	0.70%
112.4	Candidiasis of lung	1,486	1,194	0.02%	500	403	0.01%
112.5	Disseminated candidiasis	2,691	1,868	0.03%	1,337	1,085	0.02%
112.8	Candidiasis of other specified sites	21	21	0.00%	33	29	0.00%
112.81	Candidal endocarditis	177	102	0.00%	162	135	0.00%
112.82	Candidal otitis externa	428	347	0.01%	914	774	0.01%
112.83	Candidal meningitis	49	28	0.00%	28	19	0.00%
112.84	Candidiasis of the esophagus	25,059	20,566	0.31%	18,128	15,730	0.24%
112.85	Candidiasis of the intestine	1,593	1,336	0.02%	1,307	1,202	0.02%
112.89	Other candidiasis of other specified sites	8,134	7,011	0.11%	10,813	9,987	0.15%
112.9	Candidiasis of unspecified site	27,327	24,890	0.38%	85,381	82,414	1.25%
114	Coccidioidomycosis	2	2	0.00%	2	2	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	2,955	1,985	0.03%	2,821	2,104	0.03%
114.1	Primary extrapulmonary coccidioidomycosis	79	60	0.00%	96	77	0.00%
114.2	Coccidioidal meningitis	237	124	0.00%	154	89	0.00%
114.3	Other forms of progressive coccidioidomycosis	500	284	0.00%	317	231	0.00%
114.4	Chronic pulmonary coccidioidomycosis	232	183	0.00%	118	95	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	1,071	754	0.01%	902	713	0.01%
114.9	Unspecified coccidioidomycosis	1,882	1,272	0.02%	1,918	1,512	0.02%
115	Histoplasmosis	4	4	0.00%	5	5	0.00%
115.0	Histoplasma capsulatum	2	2	0.00%	5	4	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	229	156	0.00%	143	106	0.00%
115.01	Histoplasma capsulatum meningitis	29	4	0.00%	13	8	0.00%
115.02	Histoplasma capsulatum retinitis	137	126	0.00%	31	31	0.00%
115.03	Histoplasma capsulatum pericarditis	1	1	0.00%	5	5	0.00%
115.04	Histoplasma capsulatum endocarditis	21	5	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	625	426	0.01%	270	214	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	91	61	0.00%	34	30	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	1	1	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	4	4	0.00%	3	3	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	1	1	0.00%
115.12	Histoplasma duboisii retinitis	2	2	0.00%	1	1	0.00%
115.13	Histoplasma duboisii pericarditis	1	1	0.00%	0	0	0.00%

**Table 2a. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Antifungal Use			0 to 14 Days Post Prevalent Antifungal Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	5	5	0.00%	3	3	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	9	3	0.00%	2	1	0.00%
115.9	Unspecified Histoplasmosis	3	3	0.00%	1	1	0.00%
115.91	Unspecified Histoplasmosis meningitis	48	16	0.00%	7	6	0.00%
115.92	Unspecified Histoplasmosis retinitis	210	193	0.00%	59	55	0.00%
115.93	Unspecified Histoplasmosis pericarditis	12	12	0.00%	5	4	0.00%
115.94	Unspecified Histoplasmosis endocarditis	35	6	0.00%	10	2	0.00%
115.95	Unspecified Histoplasmosis pneumonia	327	187	0.00%	145	105	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	2,422	1,197	0.02%	1,258	827	0.01%
116	Blastomycotic infection	1	1	0.00%	1	1	0.00%
116.0	Blastomycosis	1,047	457	0.01%	577	350	0.01%
116.1	Paracoccidioidomycosis	32	31	0.00%	42	39	0.00%
116.2	Lobomycosis	3	3	0.00%	3	3	0.00%
117	Other mycoses	2	2	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	27	25	0.00%	19	19	0.00%
117.1	Sporotrichosis	346	299	0.00%	621	506	0.01%
117.2	Chromoblastomycosis	50	43	0.00%	25	23	0.00%
117.3	Aspergillosis	1,739	982	0.01%	940	717	0.01%
117.4	Mycotic mycetomas	131	121	0.00%	70	66	0.00%
117.5	Cryptococcosis	2,291	858	0.01%	1,048	629	0.01%
117.6	Allescheriosis (Petriellidiosis)	10	9	0.00%	15	8	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	30	24	0.00%	29	27	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	297	271	0.00%	420	400	0.01%
117.9	Other and unspecified mycoses	11,145	8,616	0.13%	14,179	13,005	0.20%
118	Opportunistic mycoses	143	95	0.00%	80	63	0.00%
185	Malignant neoplasm of prostate	42,815	13,723	0.21%	15,683	8,539	0.13%
233.4	Carcinoma in situ of prostate	506	376	0.01%	206	177	0.00%
255.0	Cushing's syndrome	2,248	1,169	0.02%	970	653	0.01%
V10.46	Personal history of malignant neoplasm of prostate	7,132	4,550	0.07%	2,646	2,036	0.03%

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

Table 2a\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Year

DX Code	Diagnosis Description	2009						2010					
		45 Days to 1 Day Prior to Prevalent Antifungal Use			0 to 14 Days Post Prevalent Antifungal Use*			45 Days to 1 Day Prior to Prevalent Antifungal Use			0 to 14 Days Post Prevalent Antifungal Use*		
		Codes	Users	% of Users	Codes	Users	% of Users	Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Antifungal Users</i>		N/A 1,361,500			N/A 1,361,500			N/A 992,717			N/A 992,717		
-	Diagnosis outside of pre-determined list	7,477,672	958,845	70.43%	3,421,268	838,717	61.60%	5,684,107	696,955	70.21%	2,684,028	636,007	64.07%
110	Dermatophytosis	6	6	0.00%	10	10	0.00%	11	11	0.00%	6	6	0.00%
110.0	Dermatophytosis of scalp and beard	8,364	7,793	0.57%	16,263	15,558	1.14%	6,212	5,881	0.59%	13,378	12,825	1.29%
110.1	Dermatophytosis of nail	59,929	49,563	3.64%	36,590	34,978	2.57%	44,388	37,008	3.73%	30,988	29,678	2.99%
110.2	Dermatophytosis of hand	583	542	0.04%	827	796	0.06%	446	427	0.04%	708	694	0.07%
110.3	Dermatophytosis of groin and perianal area	3,768	3,500	0.26%	8,861	8,472	0.62%	3,106	2,881	0.29%	7,931	7,574	0.76%
110.4	Dermatophytosis of foot	13,303	11,794	0.87%	13,983	13,169	0.97%	10,216	9,128	0.92%	12,008	11,291	1.14%
110.5	Dermatophytosis of the body	10,688	9,893	0.73%	19,787	19,044	1.40%	8,675	7,991	0.80%	17,250	16,620	1.67%
110.6	Deep seated dermatophytosis	181	170	0.01%	211	205	0.02%	145	138	0.01%	215	213	0.02%
110.8	Dermatophytosis of other specified sites	609	565	0.04%	732	696	0.05%	505	486	0.05%	647	623	0.06%
110.9	Dermatophytosis of unspecified site	4,399	4,142	0.30%	6,064	5,913	0.43%	3,158	2,980	0.30%	5,071	4,934	0.50%
111	Dermatormycosis, other and unspecified	5	5	0.00%	4	4	0.00%	4	4	0.00%	4	4	0.00%
111.0	Pityriasis versicolor	10,062	9,768	0.72%	18,154	17,913	1.32%	7,630	7,437	0.75%	15,169	14,955	1.51%
111.1	Tinea nigra	110	98	0.01%	129	125	0.01%	60	51	0.01%	115	112	0.01%
111.2	Tinea blanca	108	106	0.01%	217	211	0.02%	80	79	0.01%	200	195	0.02%
111.3	Black piedra	3	3	0.00%	2	2	0.00%	3	3	0.00%	3	3	0.00%
111.8	Other specified dermatomycoses	155	121	0.01%	221	188	0.01%	118	108	0.01%	199	168	0.02%
111.9	Unspecified dermatomycosis	1,153	1,067	0.08%	2,173	2,047	0.15%	949	853	0.09%	1,800	1,704	0.17%
112	Candidiasis	38	35	0.00%	47	46	0.00%	16	16	0.00%	37	34	0.00%
112.0	Candidiasis of mouth	11,752	9,889	0.73%	17,130	15,594	1.15%	9,693	8,077	0.81%	14,751	13,402	1.35%
112.1	Candidiasis of vulva and vagina	32,927	31,858	2.34%	112,152	108,977	8.00%	22,966	22,320	2.25%	92,433	89,965	9.06%
112.2	Candidiasis of other urogenital sites	2,569	2,383	0.18%	3,088	2,959	0.22%	2,149	1,971	0.20%	2,897	2,756	0.28%
112.3	Candidiasis of skin and nails	3,328	3,048	0.22%	7,030	6,654	0.49%	2,747	2,557	0.26%	6,332	5,957	0.60%
112.4	Candidiasis of lung	282	225	0.02%	98	81	0.01%	235	186	0.02%	93	66	0.01%
112.5	Disseminated candidiasis	607	417	0.03%	305	250	0.02%	360	270	0.03%	168	154	0.02%
112.8	Candidiasis of other specified sites	7	7	0.00%	14	14	0.00%	5	5	0.00%	5	5	0.00%
112.81	Candidal endocarditis	34	19	0.00%	28	22	0.00%	20	13	0.00%	15	15	0.00%
112.82	Candidal otitis externa	67	58	0.00%	111	94	0.01%	74	57	0.01%	139	116	0.01%
112.83	Candidal meningitis	11	8	0.00%	1	1	0.00%	16	4	0.00%	5	4	0.00%
112.84	Candidiasis of the esophagus	3,699	3,104	0.23%	2,498	2,182	0.16%	3,440	2,869	0.29%	2,366	2,012	0.20%
112.85	Candidiasis of the intestine	342	285	0.02%	219	202	0.01%	308	250	0.03%	225	207	0.02%
112.89	Other candidiasis of other specified sites	1,443	1,283	0.09%	1,617	1,519	0.11%	1,191	1,009	0.10%	1,412	1,296	0.13%
112.9	Candidiasis of unspecified site	5,576	5,005	0.37%	13,662	13,173	0.97%	3,896	3,630	0.37%	11,475	11,082	1.12%
114	Coccidioidomycosis	1	1	0.00%	0	0	0.00%	1	1	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	769	491	0.04%	576	438	0.03%	454	329	0.03%	499	366	0.04%
114.1	Primary extrapulmonary coccidioidomycosis	13	12	0.00%	22	17	0.00%	8	6	0.00%	8	6	0.00%
114.2	Coccidioid meningitis	55	36	0.00%	41	24	0.00%	45	26	0.00%	34	14	0.00%
114.3	Other forms of progressive coccidioidomycosis	175	100	0.01%	71	54	0.00%	35	26	0.00%	44	31	0.00%
114.4	Chronic pulmonary coccidioidomycosis	72	60	0.00%	33	28	0.00%	52	31	0.00%	21	15	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	270	194	0.01%	179	151	0.01%	144	109	0.01%	132	107	0.01%
114.9	Unspecified coccidioidomycosis	488	315	0.02%	371	299	0.02%	288	201	0.02%	289	224	0.02%
115	Histoplasmosis	2	2	0.00%	2	2	0.00%	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	1	1	0.00%	1	1	0.00%	1	1	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	38	32	0.00%	19	11	0.00%	27	22	0.00%	12	10	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	3	3	0.00%	2	1	0.00%	1	1	0.00%
115.02	Histoplasma capsulatum retinitis	25	24	0.00%	8	8	0.00%	25	19	0.00%	7	7	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	1	1	0.00%
115.04	Histoplasma capsulatum endocarditis	17	1	0.00%	0	0	0.00%	1	1	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	122	89	0.01%	47	40	0.00%	66	57	0.01%	30	28	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	32	13	0.00%	9	9	0.00%	13	8	0.00%	3	3	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	1	1	0.00%	1	1	0.00%	1	1	0.00%	1	1	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	2	2	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	3	3	0.00%	1	1	0.00%	2	2	0.00%	1	1	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	3	2	0.00%	2	1	0.00%	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	1	1	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	1	1	0.00%	0	0	0.00%	2	2	0.00%	1	1	0.00%
115.92	Unspecified Histoplasmosis retinitis	21	20	0.00%	16	13	0.00%	28	26	0.00%	7	7	0.00%
115.93	Unspecified Histoplasmosis pericarditis	2	2	0.00%	0	0	0.00%	1	1	0.00%	1	1	0.00%
115.94	Unspecified Histoplasmosis endocarditis	19	2	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	38	35	0.00%	11	10	0.00%	25	23	0.00%	25	16	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	467	260	0.02%	219	158	0.01%	296	173	0.02%	201	121	0.01%
116	Blastomycotic infection	0	0	0.00%	1	1	0.00%	1	1	0.00%	0	0	0.00%
116.0	Blastomycosis	219	111	0.01%	117	79	0.01%	195	74	0.01%	101	61	0.01%
116.1	Paracoccidioidomycosis	10	10	0.00%	10	10	0.00%	2	2	0.00%	10	8	0.00%
116.2	Lobomycosis	1	1	0.00%	3	3	0.00%	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	6	4	0.00%	7	7	0.00%	3	3	0.00%	1	1	0.00%
117.1	Sporotrichosis	66	50	0.00%	103	86	0.01%	43	41	0.00%	66	54	0.01%
117.2	Chromoblastomycosis	7	6	0.00%	7	6	0.00%	12	9	0.00%	3	3	0.00%
117.3	Aspergillosis	340	220	0.02%	190	140	0.01%	202	128	0.01%	125	107	0.01%
117.4	Mycotic mycetomas	18	17	0.00%	10	10	0.00%	14	13	0.00%	10	10	0.00%
117.5	Cryptococcosis	452	199	0.01%	184	122	0.01%	317	105	0.01%	127	76	0.01%
117.6	Allescheriosis (Petriellidiosis)	2	2	0.00%	8	2	0.00%	2	1	0.00%	1	1	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	11	6	0.00%	4	4	0.00%	2	2	0.00%	7	5	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	68	65	0.00%	64	60	0.00%	48	45	0.00%	57	56	0.01%
117.9	Other and unspecified mycoses	1,923	1,439	0.11%	1,474	1,314	0.10%	1,500	1,138	0.11%	1,258	1,117	0.11%
118	Opportunistic mycoses	45	26	0.00%	16	11	0.00%	8	8	0.00%	11	9	0.00%
185	Malignant neoplasm of prostate	8,601	2,807	0.21%	3,143	1,747	0.13%	7,081	2,214	0.22%	2,569	1,410	0.14%
233.4	Carcinoma in situ of prostate	114	85	0.01%	36	36	0.00%	87	59	0.01%	31	25	0.00%
255.0	Cushing's syndrome	509	275	0.02%	200	137	0.01%	343	190	0.02%	125	87	0.01%
V10.46	Personal history of malignant neoplasm of prostate	1,132	720	0.05%									







Table 2a\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Year

Table with columns for DX Code, Diagnosis Description, and data for 2013 and 2014. 2013 data is split into '45 Days to 1 Day Prior to Prevalent Antifungal Use' and '0 to 14 Days Post Prevalent Antifungal Use\*'. 2014 data is split into '45 Days to 1 Day Prior to Prevalent Antifungal Use' and '0 to 14 Days Post Prevalent Antifungal Use\*'. Each category includes sub-columns for Codes, Users, and % of Users.

Table 2a\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Year

		2015					
DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Antifungal Use			0 to 14 Days Post Prevalent Antifungal Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Antifungal Users</i>		<i>N/A</i>	<i>619,759</i>		<i>N/A</i>	<i>619,759</i>	
-	Diagnosis outside of pre-determined list	4,215,081	427,687	69.01%	2,052,909	416,803	67.25%
110	Dermatophytosis	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	2,401	2,233	0.36%	4,904	4,662	0.75%
110.1	Dermatophytosis of nail	27,912	23,431	3.78%	29,806	28,609	4.62%
110.2	Dermatophytosis of hand	246	232	0.04%	497	483	0.08%
110.3	Dermatophytosis of groin and perianal area	2,126	1,924	0.31%	5,855	5,599	0.90%
110.4	Dermatophytosis of foot	6,262	5,617	0.91%	9,796	9,316	1.50%
110.5	Dermatophytosis of the body	4,858	4,478	0.72%	11,766	11,290	1.82%
110.6	Deep seated dermatophytosis	80	72	0.01%	164	155	0.03%
110.8	Dermatophytosis of other specified sites	313	295	0.05%	531	517	0.08%
110.9	Dermatophytosis of unspecified site	1,579	1,487	0.24%	2,929	2,842	0.46%
111	Dermatomycosis, other and unspecified	2	2	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	3,644	3,515	0.57%	10,463	10,331	1.67%
111.1	Tinea nigra	14	12	0.00%	48	48	0.01%
111.2	Tinea blanca	48	42	0.01%	90	89	0.01%
111.3	Black piedra	0	0	0.00%	1	1	0.00%
111.8	Other specified dermatomycoses	90	72	0.01%	159	130	0.02%
111.9	Unspecified dermatomycosis	490	453	0.07%	1,291	1,206	0.19%
112	Candidiasis	6	6	0.00%	16	14	0.00%
112.0	Candidiasis of mouth	6,643	5,326	0.86%	11,112	9,939	1.60%
112.1	Candidiasis of vulva and vagina	12,265	11,863	1.91%	63,897	62,221	10.04%
112.2	Candidiasis of other urogenital sites	1,466	1,322	0.21%	2,620	2,485	0.40%
112.3	Candidiasis of skin and nails	2,224	1,999	0.32%	6,250	5,894	0.95%
112.4	Candidiasis of lung	121	101	0.02%	27	24	0.00%
112.5	Disseminated candidiasis	280	176	0.03%	119	86	0.01%
112.8	Candidiasis of other specified sites	1	1	0.00%	6	2	0.00%
112.81	Candidal endocarditis	29	13	0.00%	23	19	0.00%
112.82	Candidal otitis externa	37	31	0.01%	81	70	0.01%
112.83	Candidal meningitis	2	2	0.00%	3	3	0.00%
112.84	Candidiasis of the esophagus	2,873	2,253	0.36%	2,339	2,002	0.32%
112.85	Candidiasis of the intestine	95	81	0.01%	102	93	0.02%
112.89	Other candidiasis of other specified sites	811	717	0.12%	1,305	1,240	0.20%
112.9	Candidiasis of unspecified site	2,885	2,575	0.42%	11,526	11,156	1.80%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	183	141	0.02%	174	131	0.02%
114.1	Primary extrapulmonary coccidioidomycosis	8	6	0.00%	8	7	0.00%
114.2	Coccidioid meningitis	13	6	0.00%	5	5	0.00%
114.3	Other forms of progressive coccidioidomycosis	19	17	0.00%	16	12	0.00%
114.4	Chronic pulmonary coccidioidomycosis	17	14	0.00%	10	6	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	102	64	0.01%	80	60	0.01%
114.9	Unspecified coccidioidomycosis	181	113	0.02%	163	121	0.02%
115	Histoplasmosis	1	1	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	27	13	0.00%	10	9	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	1	1	0.00%
115.02	Histoplasma capsulatum retinitis	10	10	0.00%	1	1	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	94	54	0.01%	38	27	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	4	4	0.00%	4	4	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	1	1	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	1	1	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	27	1	0.00%	2	1	0.00%
115.92	Unspecified Histoplasmosis retinitis	27	24	0.00%	2	2	0.00%
115.93	Unspecified Histoplasmosis pericarditis	2	2	0.00%	1	1	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	40	16	0.00%	16	11	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	290	97	0.02%	120	77	0.01%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	103	43	0.01%	77	41	0.01%
116.1	Paracoccidioidomycosis	1	1	0.00%	1	1	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	1	1	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	29	26	0.00%	71	61	0.01%
117.2	Chromoblastomycosis	6	5	0.00%	2	2	0.00%
117.3	Aspergillosis	130	85	0.01%	83	66	0.01%
117.4	Mycotic mycetomas	7	6	0.00%	8	8	0.00%
117.5	Cryptococcosis	365	83	0.01%	117	69	0.01%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	2	2	0.00%	2	2	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	20	20	0.00%	30	30	0.00%
117.9	Other and unspecified mycoses	1,150	838	0.14%	1,624	1,485	0.24%
118	Opportunistic mycoses	6	6	0.00%	4	4	0.00%
185	Malignant neoplasm of prostate	3,910	1,275	0.21%	1,405	762	0.12%
233.4	Carcinoma in situ of prostate	30	27	0.00%	17	16	0.00%
255.0	Cushing's syndrome	188	102	0.02%	116	74	0.01%
V10.46	Personal history of malignant neoplasm of prostate	782	502	0.08%	328	254	0.04%

**Table 2a\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Antifungal Users</i>		-	<i>N/A</i>	<i>6,611,493</i>	<i>N/A</i>	<i>6,611,493</i>
-	Diagnosis outside of pre-determined list	Female	31,184,207	3,817,616	15,027,288	3,529,808
		Male	9,077,637	798,481	4,163,291	774,046
		Unknown	1,776	176	876	179
110	Dermatophytosis	Female	10	10	19	19
		Male	20	20	11	11
		Unknown	0	0	0	0
110.0	Dermatophytosis of scalp and beard	Female	13,147	12,349	26,317	24,904
		Male	22,504	21,168	52,101	49,929
		Unknown	2	2	4	4
110.1	Dermatophytosis of nail	Female	149,086	124,361	114,868	109,988
		Male	136,808	114,192	123,517	118,303
		Unknown	8	7	17	15
110.2	Dermatophytosis of hand	Female	870	808	1,451	1,389
		Male	2,060	1,942	3,518	3,414
		Unknown	0	0	0	0
110.3	Dermatophytosis of groin and perianal area	Female	5,040	4,667	12,651	12,153
		Male	16,142	14,916	44,383	42,327
		Unknown	1	1	2	2
110.4	Dermatophytosis of foot	Female	27,581	24,698	31,915	30,260
		Male	39,863	35,506	57,661	54,384
		Unknown	8	7	4	4
110.5	Dermatophytosis of the body	Female	25,242	23,279	51,115	49,094
		Male	30,416	28,136	69,172	66,650
		Unknown	3	3	4	4
110.6	Deep seated dermatophytosis	Female	396	370	635	607
		Male	658	615	915	885
		Unknown	0	0	0	0
110.8	Dermatophytosis of other specified sites	Female	1,607	1,518	2,171	2,062
		Male	1,839	1,721	2,886	2,788
		Unknown	0	0	0	0
110.9	Dermatophytosis of unspecified site	Female	8,866	8,375	14,405	13,999
		Male	11,515	10,857	20,278	19,711
		Unknown	0	0	2	2
111	Dermatomycosis, other and unspecified	Female	10	10	8	8
		Male	10	10	14	14
		Unknown	0	0	0	0
111.0	Pityriasis versicolor	Female	19,888	19,253	42,492	41,919
		Male	26,055	25,287	63,977	63,151
		Unknown	0	0	6	5
111.1	Tinea nigra	Female	191	171	260	254
		Male	219	208	394	383
		Unknown	0	0	0	0
111.2	Tinea blanca	Female	259	253	534	522
		Male	307	285	722	705
		Unknown	0	0	0	0
111.3	Black piedra	Female	6	6	7	7
		Male	6	6	7	7
		Unknown	0	0	0	0
111.8	Other specified dermatomycoses	Female	479	393	696	576
		Male	441	365	747	613
		Unknown	0	0	0	0
111.9	Unspecified dermatomycosis	Female	2,787	2,542	5,720	5,317
		Male	2,804	2,592	6,463	6,108
		Unknown	0	0	1	1

**Table 2a\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	Female	72	69	145	132
		Male	31	29	55	50
		Unknown	0	0	0	0
112.0	Candidiasis of mouth	Female	39,592	32,985	63,616	57,962
		Male	28,495	22,695	40,820	36,263
		Unknown	0	0	2	2
112.1	Candidiasis of vulva and vagina	Female	142,147	137,749	628,282	611,344
		Male	248	239	930	915
		Unknown	5	5	26	25
112.2	Candidiasis of other urogenital sites	Female	10,109	9,445	12,272	11,864
		Male	5,000	4,390	10,265	9,600
		Unknown	0	0	2	1
112.3	Candidiasis of skin and nails	Female	13,390	12,260	33,783	31,849
		Male	6,086	5,548	15,208	14,228
		Unknown	2	2	0	0
112.4	Candidiasis of lung	Female	731	581	305	238
		Male	755	613	195	165
		Unknown	0	0	0	0
112.5	Disseminated candidiasis	Female	1,496	1,094	843	731
		Male	1,195	774	494	354
		Unknown	0	0	0	0
112.8	Candidiasis of other specified sites	Female	9	9	27	23
		Male	12	12	6	6
		Unknown	0	0	0	0
112.81	Candidal endocarditis	Female	99	60	108	90
		Male	78	42	54	45
		Unknown	0	0	0	0
112.82	Candidal otitis externa	Female	239	201	516	447
		Male	189	146	398	327
		Unknown	0	0	0	0
112.83	Candidal meningitis	Female	19	15	12	10
		Male	30	13	16	9
		Unknown	0	0	0	0
112.84	Candidiasis of the esophagus	Female	13,428	11,050	9,651	8,424
		Male	11,629	9,514	8,475	7,304
		Unknown	2	2	2	2
112.85	Candidiasis of the intestine	Female	1,060	895	908	831
		Male	533	441	399	371
		Unknown	0	0	0	0
112.89	Other candidiasis of other specified sites	Female	4,998	4,438	7,468	6,999
		Male	3,136	2,573	3,345	2,988
		Unknown	0	0	0	0
112.9	Candidiasis of unspecified site	Female	21,434	19,980	72,647	70,484
		Male	5,892	4,909	12,733	11,929
		Unknown	1	1	1	1
114	Coccidioidomycosis	Female	0	0	0	0
		Male	2	2	2	2
		Unknown	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	Female	1,251	837	1,247	928
		Male	1,704	1,148	1,574	1,176
		Unknown	0	0	0	0
114.1	Primary extrapulmonary coccidioidomycosis	Female	29	22	32	25
		Male	50	38	64	52
		Unknown	0	0	0	0
114.2	Coccidioidal meningitis	Female	84	35	36	30
		Male	153	89	118	59
		Unknown	0	0	0	0

**Table 2a\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	Female	146	78	79	66
		Male	354	206	238	165
		Unknown	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	Female	104	85	43	33
		Male	128	98	75	62
		Unknown	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	Female	457	310	344	279
		Male	614	444	558	434
		Unknown	0	0	0	0
114.9	Unspecified coccidioidomycosis	Female	794	543	776	616
		Male	1,088	729	1,142	896
		Unknown	0	0	0	0
115	Histoplasmosis	Female	1	1	3	3
		Male	3	3	2	2
		Unknown	0	0	0	0
115.0	Histoplasma capsulatum	Female	1	1	5	4
		Male	1	1	0	0
		Unknown	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	Female	76	65	55	40
		Male	153	91	88	66
		Unknown	0	0	0	0
115.01	Histoplasma capsulatum meningitis	Female	3	2	3	3
		Male	26	2	10	5
		Unknown	0	0	0	0
115.02	Histoplasma capsulatum retinitis	Female	112	102	25	25
		Male	25	24	6	6
		Unknown	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	Female	0	0	3	3
		Male	1	1	2	2
		Unknown	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	Female	18	2	0	0
		Male	3	3	0	0
		Unknown	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	Female	271	190	107	81
		Male	354	236	163	133
		Unknown	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	Female	33	29	15	15
		Male	58	32	19	15
		Unknown	0	0	0	0
115.1	Histoplasma duboisii	Female	0	0	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	Female	3	3	2	2
		Male	1	1	1	1
		Unknown	0	0	0	0
115.11	Histoplasma duboisii meningitis	Female	0	0	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.12	Histoplasma duboisii retinitis	Female	2	2	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.13	Histoplasma duboisii pericarditis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
115.14	Histoplasma duboisii endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2a\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	Female	3	3	1	1
		Male	2	2	2	2
		Unknown	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	Female	3	2	0	0
		Male	6	1	2	1
		Unknown	0	0	0	0
115.9	Unspecified Histoplasmosis	Female	1	1	0	0
		Male	2	2	1	1
		Unknown	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	Female	9	7	3	3
		Male	39	9	4	3
		Unknown	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	Female	169	154	52	48
		Male	41	39	7	7
		Unknown	0	0	0	0
115.93	Unspecified Histoplasmosis pericarditis	Female	5	5	3	2
		Male	7	7	2	2
		Unknown	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	Female	21	3	0	0
		Male	14	3	10	2
		Unknown	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	Female	124	88	60	45
		Male	203	99	85	60
		Unknown	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	Female	954	564	547	374
		Male	1,467	632	711	453
		Unknown	1	1	0	0
116	Blastomycotic infection	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
116.0	Blastomycosis	Female	399	167	190	118
		Male	647	289	387	232
		Unknown	1	1	0	0
116.1	Paracoccidioidomycosis	Female	27	26	30	28
		Male	5	5	12	11
		Unknown	0	0	0	0
116.2	Lobomycosis	Female	2	2	1	1
		Male	1	1	2	2
		Unknown	0	0	0	0
117	Other mycoses	Female	1	1	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
117.0	Rhinosporidiosis	Female	18	17	11	11
		Male	9	8	8	8
		Unknown	0	0	0	0
117.1	Sporotrichosis	Female	198	180	364	304
		Male	148	119	257	202
		Unknown	0	0	0	0
117.2	Chromoblastomycosis	Female	10	10	13	12
		Male	40	33	12	11
		Unknown	0	0	0	0
117.3	Aspergillosis	Female	973	546	480	380
		Male	766	436	460	337
		Unknown	0	0	0	0
117.4	Mycotic mycetomas	Female	70	64	30	29
		Male	61	57	40	37
		Unknown	0	0	0	0
117.5	Cryptococcosis	Female	586	239	294	181
		Male	1,705	619	754	448
		Unknown	0	0	0	0
117.6	Allescheriosis (Petriellidiosis)	Female	5	4	3	3
		Male	5	5	12	5
		Unknown	0	0	0	0

**Table 2a\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	Female	6	6	11	10
		Male	24	18	18	17
		Unknown	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	Female	158	147	247	239
		Male	139	124	173	161
		Unknown	0	0	0	0
117.9	Other and unspecified mycoses	Female	6,130	4,869	9,485	8,877
		Male	5,015	3,747	4,693	4,127
		Unknown	0	0	1	1
118	Opportunistic mycoses	Female	78	50	48	39
		Male	65	45	32	24
		Unknown	0	0	0	0
185	Malignant neoplasm of prostate	Female	133	80	66	46
		Male	42,680	13,642	15,614	8,492
		Unknown	2	1	3	1
233.4	Carcinoma in situ of prostate	Female	3	3	3	3
		Male	503	373	203	174
		Unknown	0	0	0	0
255.0	Cushing's syndrome	Female	1,831	978	755	532
		Male	417	191	215	121
		Unknown	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	Female	12	12	7	7
		Male	7,120	4,538	2,639	2,029
		Unknown	0	0	0	0

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.



**Table 2a\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Antifungal Users</i>		-	N/A	6,611,493	N/A	6,611,493
-	Diagnosis outside of pre-determined list	0-17	1,613,469	308,810	860,324	285,589
		18-64	29,527,355	3,792,097	14,651,239	3,543,965
		65+	9,122,796	515,366	3,679,892	474,479
110	Dermatophytosis	0-17	10	10	6	6
		18-64	16	16	15	15
		65+	4	4	9	9
110.0	Dermatophytosis of scalp and beard	0-17	25,991	24,348	63,414	60,310
		18-64	8,791	8,352	13,724	13,296
		65+	871	819	1,284	1,231
110.1	Dermatophytosis of nail	0-17	8,193	6,815	7,163	6,901
		18-64	227,127	187,307	188,101	180,191
		65+	50,582	44,438	43,138	41,214
110.2	Dermatophytosis of hand	0-17	177	164	289	279
		18-64	2,344	2,196	3,924	3,801
		65+	409	390	756	723
110.3	Dermatophytosis of groin and perianal area	0-17	971	919	2,078	2,004
		18-64	16,263	15,137	44,996	43,155
		65+	3,949	3,528	9,962	9,323
110.4	Dermatophytosis of foot	0-17	3,063	2,812	4,889	4,692
		18-64	55,694	49,772	72,491	68,689
		65+	8,695	7,627	12,200	11,267
110.5	Dermatophytosis of the body	0-17	15,597	14,230	27,782	26,820
		18-64	34,618	32,209	78,830	75,965
		65+	5,446	4,979	13,679	12,963
110.6	Deep seated dermatophytosis	0-17	149	141	252	244
		18-64	730	685	1,015	976
		65+	175	159	283	272
110.8	Dermatophytosis of other specified sites	0-17	690	653	1,121	1,083
		18-64	2,171	2,055	3,276	3,149
		65+	585	531	660	618
110.9	Dermatophytosis of unspecified site	0-17	5,496	5,211	9,150	8,921
		18-64	12,823	12,089	21,949	21,369
		65+	2,062	1,932	3,586	3,422
111	Dermatomycosis, other and unspecified	0-17	1	1	1	1
		18-64	11	11	10	10
		65+	8	8	11	11
111.0	Pityriasis versicolor	0-17	4,623	4,450	10,921	10,794
		18-64	40,425	39,243	93,251	92,031
		65+	895	847	2,303	2,250
111.1	Tinea nigra	0-17	62	60	129	127
		18-64	315	290	474	464
		65+	33	29	51	46
111.2	Tinea blanca	0-17	104	98	208	206
		18-64	428	407	944	920
		65+	34	33	104	101
111.3	Black piedra	0-17	0	0	1	1
		18-64	9	9	13	13
		65+	3	3	0	0
111.8	Other specified dermatomycoses	0-17	94	80	124	110
		18-64	640	537	1,067	885
		65+	186	141	252	194
111.9	Unspecified dermatomycosis	0-17	545	528	951	910
		18-64	3,886	3,608	8,730	8,270
		65+	1,160	998	2,503	2,246
112	Candidiasis	0-17	5	5	12	11
		18-64	43	41	50	46
		65+	55	52	138	125

**Table 2a\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112.0	Candidiasis of mouth	0-17	20,443	16,516	23,720	22,604
		18-64	32,519	27,295	58,346	52,306
		65+	15,125	11,869	22,372	19,317
112.1	Candidiasis of vulva and vagina	0-17	7,292	7,045	36,432	35,538
		18-64	127,963	124,180	554,762	540,368
		65+	7,145	6,768	38,044	36,378
112.2	Candidiasis of other urogenital sites	0-17	1,814	1,687	2,966	2,875
		18-64	9,165	8,702	15,775	15,184
		65+	4,130	3,446	3,798	3,406
112.3	Candidiasis of skin and nails	0-17	2,823	2,612	4,701	4,489
		18-64	11,496	10,717	31,449	29,912
		65+	5,159	4,481	12,841	11,676
112.4	Candidiasis of lung	0-17	24	23	11	11
		18-64	743	654	306	239
		65+	719	517	183	153
112.5	Disseminated candidiasis	0-17	145	100	86	77
		18-64	1,823	1,315	1,001	825
		65+	723	453	250	183
112.8	Candidiasis of other specified sites	0-17	3	3	1	1
		18-64	15	15	31	27
		65+	3	3	1	1
112.81	Candidal endocarditis	0-17	15	3	5	4
		18-64	119	71	112	95
		65+	43	28	45	36
112.82	Candidal otitis externa	0-17	24	21	76	69
		18-64	324	262	671	564
		65+	80	64	167	141
112.83	Candidal meningitis	0-17	8	7	4	3
		18-64	38	18	22	14
		65+	3	3	2	2
112.84	Candidiasis of the esophagus	0-17	644	584	427	377
		18-64	13,778	11,805	10,513	9,298
		65+	10,637	8,177	7,188	6,055
112.85	Candidiasis of the intestine	0-17	366	300	206	194
		18-64	1,076	912	985	904
		65+	151	124	116	104
112.89	Other candidiasis of other specified sites	0-17	555	508	719	707
		18-64	5,303	4,682	7,769	7,236
		65+	2,276	1,821	2,325	2,044
112.9	Candidiasis of unspecified site	0-17	2,883	2,662	8,110	7,897
		18-64	19,751	18,343	65,386	63,409
		65+	4,693	3,885	11,885	11,108
114	Coccidioidomycosis	0-17	0	0	1	1
		18-64	1	1	1	1
		65+	1	1	0	0
114.0	Primary coccidioidomycosis (pulmonary)	0-17	114	77	107	83
		18-64	2,191	1,520	2,233	1,660
		65+	650	388	481	361
114.1	Primary extrapulmonary coccidioidomycosis	0-17	1	1	3	2
		18-64	66	47	74	60
		65+	12	12	19	15
114.2	Coccidioidal meningitis	0-17	8	7	4	4
		18-64	193	102	134	73
		65+	36	15	16	12
114.3	Other forms of progressive coccidioidomycosis	0-17	28	14	15	12
		18-64	401	230	259	186
		65+	71	40	43	33
114.4	Chronic pulmonary coccidioidomycosis	0-17	4	4	3	3
		18-64	178	133	93	72
		65+	50	46	22	20

**Table 2a\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.5	Unspecified pulmonary coccidioidomycosis	0-17	29	21	33	28
		18-64	787	561	690	545
		65+	255	172	179	140
114.9	Unspecified coccidioidomycosis	0-17	98	70	112	90
		18-64	1,463	974	1,498	1,174
		65+	321	228	308	248
115	Histoplasmosis	0-17	1	1	1	1
		18-64	3	3	3	3
		65+	0	0	1	1
115.0	Histoplasma capsulatum	0-17	1	1	1	1
		18-64	1	1	4	3
		65+	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	0-17	3	3	6	6
		18-64	196	128	110	86
		65+	30	25	27	14
115.01	Histoplasma capsulatum meningitis	0-17	0	0	0	0
		18-64	27	3	11	6
		65+	2	1	2	2
115.02	Histoplasma capsulatum retinitis	0-17	0	0	1	1
		18-64	102	94	21	21
		65+	35	32	9	9
115.03	Histoplasma capsulatum pericarditis	0-17	0	0	0	0
		18-64	1	1	4	4
		65+	0	0	1	1
115.04	Histoplasma capsulatum endocarditis	0-17	0	0	0	0
		18-64	2	2	0	0
		65+	19	3	0	0
115.05	Histoplasma capsulatum pneumonia	0-17	30	27	10	10
		18-64	447	318	206	161
		65+	148	81	54	43
115.09	Histoplasma capsulatum, with mention of other manifestation	0-17	3	3	3	3
		18-64	77	47	27	23
		65+	11	11	4	4
115.1	Histoplasma duboisii	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	0-17	1	1	0	0
		18-64	3	3	3	3
		65+	0	0	0	0
115.11	Histoplasma duboisii meningitis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
115.12	Histoplasma duboisii retinitis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	1	1	0	0
115.13	Histoplasma duboisii pericarditis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.14	Histoplasma duboisii endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.15	Histoplasma duboisii pneumonia	0-17	0	0	1	1
		18-64	4	4	1	1
		65+	1	1	1	1
115.19	Histoplasma duboisii with mention of other manifestation	0-17	0	0	0	0
		18-64	9	3	2	1
		65+	0	0	0	0
115.9	Unspecified Histoplasmosis	0-17	0	0	0	0
		18-64	3	3	0	0
		65+	0	0	1	1
115.91	Unspecified Histoplasmosis meningitis	0-17	0	0	0	0
		18-64	41	13	7	6
		65+	7	3	0	0

**Table 2a\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Antifungal Drug Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.92	Unspecified Histoplasmosis retinitis	0-17	3	3	1	1
		18-64	145	132	42	39
		65+	62	58	16	15
115.93	Unspecified Histoplasmosis pericarditis	0-17	4	4	0	0
		18-64	8	8	3	3
		65+	0	0	2	1
115.94	Unspecified Histoplasmosis endocarditis	0-17	2	1	0	0
		18-64	14	3	10	2
		65+	19	2	0	0
115.95	Unspecified Histoplasmosis pneumonia	0-17	16	15	7	5
		18-64	272	139	112	77
		65+	39	33	26	23
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0-17	150	98	85	61
		18-64	1,839	913	939	623
		65+	433	186	234	143
116	Blastomycotic infection	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	1	1	1	1
116.0	Blastomycosis	0-17	45	21	21	16
		18-64	831	362	463	283
		65+	171	74	93	51
116.1	Paracoccidioidomycosis	0-17	2	2	1	1
		18-64	30	29	37	35
		65+	0	0	4	3
116.2	Lobomycosis	0-17	0	0	0	0
		18-64	1	1	3	3
		65+	2	2	0	0
117	Other mycoses	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	1	1	0	0
117.0	Rhinosporidiosis	0-17	1	1	0	0
		18-64	20	19	9	9
		65+	6	5	10	10
117.1	Sporotrichosis	0-17	16	12	17	16
		18-64	259	226	458	373
		65+	71	61	146	117
117.2	Chromoblastomycosis	0-17	1	1	0	0
		18-64	32	28	18	17
		65+	17	14	7	6
117.3	Aspergillosis	0-17	63	49	44	37
		18-64	1,034	609	588	461
		65+	642	324	308	219
117.4	Mycotic mycetomas	0-17	4	4	2	2
		18-64	99	92	46	44
		65+	28	25	22	20
117.5	Cryptococcosis	0-17	6	6	7	5
		18-64	1,727	672	803	473
		65+	558	180	238	151
117.6	Allescheriosis (Petriellidiosis)	0-17	0	0	0	0
		18-64	8	8	12	6
		65+	2	1	3	2
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0-17	2	1	2	2
		18-64	14	14	19	18
		65+	14	9	8	7
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	0-17	26	26	37	37
		18-64	222	206	315	297
		65+	49	39	68	66
117.9	Other and unspecified mycoses	0-17	627	500	867	815
		18-64	7,844	6,142	10,743	9,962
		65+	2,674	1,974	2,569	2,228
118	Opportunistic mycoses	0-17	3	3	8	4
		18-64	118	73	50	41
		65+	22	19	22	18
185	Malignant neoplasm of prostate	0-17	9	4	4	1
		18-64	12,752	3,952	4,634	2,378
		65+	30,054	9,767	11,045	6,160
233.4	Carcinoma in situ of prostate	0-17	0	0	0	0
		18-64	161	127	67	64
		65+	345	249	139	113
255.0	Cushing's syndrome	0-17	89	41	47	27
		18-64	1,913	991	791	550
		65+	246	137	132	76
V10.46	Personal history of malignant neoplasm of prostate	0-17	2	2	1	1
		18-64	1,662	1,067	599	455
		65+	5,468	3,481	2,046	1,580

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2b. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Ketoconazole Use			0 to 14 Days Post Prevalent Ketoconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Ketoconazole Users</i>		<i>N/A</i>	<i>318,701</i>	<i>100%</i>	<i>N/A</i>	<i>318,701</i>	<i>100%</i>
-	Diagnosis outside of pre-determined list	1,096,689	180,128	56.52%	646,820	188,385	59.11%
110	Dermatophytosis	1	1	0.00%	5	5	0.00%
110.0	Dermatophytosis of scalp and beard	1,989	1,917	0.60%	3,793	3,711	1.16%
110.1	Dermatophytosis of nail	4,901	4,450	1.40%	5,487	5,290	1.66%
110.2	Dermatophytosis of hand	225	218	0.07%	463	447	0.14%
110.3	Dermatophytosis of groin and perianal area	3,141	2,875	0.90%	8,147	7,774	2.44%
110.4	Dermatophytosis of foot	3,619	3,262	1.02%	7,900	7,475	2.35%
110.5	Dermatophytosis of the body	8,641	8,071	2.53%	20,639	19,847	6.23%
110.6	Deep seated dermatophytosis	83	83	0.03%	138	135	0.04%
110.8	Dermatophytosis of other specified sites	446	413	0.13%	758	726	0.23%
110.9	Dermatophytosis of unspecified site	2,913	2,797	0.88%	5,931	5,789	1.82%
111	Dermatomycosis, other and unspecified	4	4	0.00%	12	10	0.00%
111.0	Pityriasis versicolor	32,386	31,416	9.86%	77,234	76,281	23.93%
111.1	Tinea nigra	125	119	0.04%	214	211	0.07%
111.2	Tinea blanca	154	145	0.05%	358	348	0.11%
111.3	Black piedra	4	4	0.00%	1	1	0.00%
111.8	Other specified dermatomycoses	63	58	0.02%	156	137	0.04%
111.9	Unspecified dermatomycosis	806	756	0.24%	1,923	1,845	0.58%
112	Candidiasis	7	7	0.00%	17	12	0.00%
112.0	Candidiasis of mouth	1,261	1,009	0.32%	1,613	1,429	0.45%
112.1	Candidiasis of vulva and vagina	2,273	2,017	0.63%	2,784	2,610	0.82%
112.2	Candidiasis of other urogenital sites	271	235	0.07%	436	409	0.13%
112.3	Candidiasis of skin and nails	1,529	1,372	0.43%	3,071	2,863	0.90%
112.4	Candidiasis of lung	8	7	0.00%	4	4	0.00%
112.5	Disseminated candidiasis	183	116	0.04%	129	112	0.04%
112.8	Candidiasis of other specified sites	1	1	0.00%	2	2	0.00%
112.81	Candidal endocarditis	6	6	0.00%	5	4	0.00%
112.82	Candidal otitis externa	31	23	0.01%	42	34	0.01%
112.83	Candidal meningitis	1	1	0.00%	1	1	0.00%
112.84	Candidiasis of the esophagus	159	131	0.04%	135	112	0.04%
112.85	Candidiasis of the intestine	189	153	0.05%	129	107	0.03%
112.89	Other candidiasis of other specified sites	232	196	0.06%	303	281	0.09%
112.9	Candidiasis of unspecified site	1,255	1,110	0.35%	1,843	1,748	0.55%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	24	16	0.01%	33	26	0.01%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	3	3	0.00%
114.2	Coccidioidal meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	1	1	0.00%	2	2	0.00%
114.4	Chronic pulmonary coccidioidomycosis	2	2	0.00%	1	1	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	1	1	0.00%	2	1	0.00%
114.9	Unspecified coccidioidomycosis	26	16	0.01%	16	15	0.00%
115	Histoplasmosis	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	3	2	0.00%	3	3	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	3	2	0.00%	0	0	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	4	4	0.00%	6	4	0.00%

**Table 2b. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Ketoconazole Use			0 to 14 Days Post Prevalent Ketoconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
115.09	Histoplasma capsulatum, with mention of other manifestation	1	1	0.00%	1	1	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	1	1	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	2	2	0.00%	1	1	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	6	5	0.00%	5	3	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	22	18	0.01%	18	16	0.01%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	9	7	0.00%	17	15	0.00%
116.1	Paracoccidioidomycosis	0	0	0.00%	1	1	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	2	2	0.00%	1	1	0.00%
117.1	Sporotrichosis	11	10	0.00%	22	21	0.01%
117.2	Chromoblastomycosis	0	0	0.00%	1	1	0.00%
117.3	Aspergillosis	20	18	0.01%	24	21	0.01%
117.4	Mycotic mycetomas	3	3	0.00%	0	0	0.00%
117.5	Cryptococcosis	1	1	0.00%	2	2	0.00%
117.6	Allescheriosis (Petriellidiosis)	1	1	0.00%	8	2	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	1	1	0.00%	1	1	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	24	23	0.01%	26	25	0.01%
117.9	Other and unspecified mycoses	484	384	0.12%	849	781	0.25%
118	Opportunistic mycoses	11	7	0.00%	9	8	0.00%
185	Malignant neoplasm of prostate	13,341	3,781	1.19%	5,267	2,755	0.86%
233.4	Carcinoma in situ of prostate	93	65	0.02%	37	36	0.01%
255.0	Cushing's syndrome	942	305	0.10%	450	220	0.07%
V10.46	Personal history of malignant neoplasm of prostate	695	513	0.16%	239	207	0.06%

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.









Table 2b\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Year

		2015					
		45 Days to 1 Day Prior to Prevalent Ketoconazole Use			0 to 14 Days Post Prevalent Ketoconazole Use*		
Dx Code	Diagnosis Description	Codes	Users	% of Users	Codes	Users	% of Users
Total Number of Prevalent Ketoconazole Users		N/A	18,199		N/A	18,199	
-	Diagnosis outside of pre-determined list	68,578	10,059	55.27%	42,018	11,099	60.99%
110	Dermatophytosis	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	97	94	0.52%	182	181	0.99%
110.1	Dermatophytosis of nail	244	226	1.24%	357	342	1.88%
110.2	Dermatophytosis of hand	13	12	0.07%	29	28	0.15%
110.3	Dermatophytosis of groin and perianal area	231	192	1.06%	510	481	2.64%
110.4	Dermatophytosis of foot	185	162	0.89%	495	458	2.52%
110.5	Dermatophytosis of the body	497	466	2.56%	1,334	1,284	7.06%
110.6	Deep seated dermatophytosis	4	4	0.02%	3	3	0.02%
110.8	Dermatophytosis of other specified sites	21	21	0.12%	52	49	0.27%
110.9	Dermatophytosis of unspecified site	152	146	0.80%	366	356	1.96%
111	Dermatomycosis, other and unspecified	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	1,630	1,569	8.62%	4,851	4,790	26.32%
111.1	Tinea nigra	0	0	0.00%	12	12	0.07%
111.2	Tinea blanca	6	5	0.03%	15	14	0.08%
111.3	Black piedra	0	0	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	5	5	0.03%	10	9	0.05%
111.9	Unspecified dermatomycosis	52	41	0.23%	127	120	0.66%
112	Candidiasis	0	0	0.00%	1	1	0.01%
112.0	Candidiasis of mouth	78	57	0.31%	110	99	0.54%
112.1	Candidiasis of vulva and vagina	126	120	0.66%	171	161	0.88%
112.2	Candidiasis of other urogenital sites	22	10	0.05%	34	26	0.14%
112.3	Candidiasis of skin and nails	104	89	0.49%	230	210	1.15%
112.4	Candidiasis of lung	0	0	0.00%	0	0	0.00%
112.5	Disseminated candidiasis	7	5	0.03%	7	6	0.03%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	0	0	0.00%	3	2	0.01%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	8	7	0.04%	9	6	0.03%
112.85	Candidiasis of the intestine	12	9	0.05%	11	9	0.05%
112.89	Other candidiasis of other specified sites	16	12	0.07%	25	21	0.12%
112.9	Candidiasis of unspecified site	98	82	0.45%	110	103	0.57%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	1	1	0.01%	3	3	0.02%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.2	Coccidioid meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.4	Chronic pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	1	1	0.01%	0	0	0.00%
114.9	Unspecified coccidioidomycosis	2	1	0.01%	3	3	0.02%
115	Histoplasmosis	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	0	0	0.00%	1	1	0.01%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	0	0	0.00%	0	0	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	0	0	0.00%	0	0	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	0	0	0.00%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	0	0	0.00%	3	1	0.01%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0	0	0.00%	2	2	0.01%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	0	0	0.00%	1	1	0.01%
116.1	Paracoccidioidomycosis	0	0	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	0	0	0.00%	0	0	0.00%
117.2	Chromoblastomycosis	0	0	0.00%	0	0	0.00%
117.3	Aspergillosis	2	2	0.01%	2	2	0.01%
117.4	Mycotic mycetomas	0	0	0.00%	0	0	0.00%
117.5	Cryptococcosis	0	0	0.00%	0	0	0.00%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0	0	0.00%	0	0	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	1	1	0.01%	0	0	0.00%
117.9	Other and unspecified mycoses	41	31	0.17%	72	68	0.37%
118	Opportunistic mycoses	0	0	0.00%	0	0	0.00%
185	Malignant neoplasm of prostate	398	119	0.65%	181	86	0.47%
233.4	Carcinoma in situ of prostate	1	1	0.01%	2	2	0.01%
255.0	Cushing's syndrome	59	24	0.13%	53	20	0.11%
V10.46	Personal history of malignant neoplasm of prostate	24	19	0.10%	9	7	0.04%

**Table 2b\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Ketoconazole Users</i>		-	N/A	318,701	N/A	318,701
-	Diagnosis outside of pre-determined list	Female	558,145	88,567	307,131	87,091
		Male	538,490	91,551	339,664	101,285
		Unknown	54	10	27	10
110	Dermatophytosis	Female	0	0	4	4
		Male	1	1	1	1
		Unknown	0	0	0	0
110.0	Dermatophytosis of scalp and beard	Female	847	819	1,485	1,453
		Male	1,142	1,098	2,307	2,257
		Unknown	0	0	1	1
110.1	Dermatophytosis of nail	Female	2,207	1,986	2,400	2,315
		Male	2,694	2,464	3,087	2,975
		Unknown	0	0	0	0
110.2	Dermatophytosis of hand	Female	70	67	163	156
		Male	155	151	300	291
		Unknown	0	0	0	0
110.3	Dermatophytosis of groin and perianal area	Female	522	465	1,287	1,216
		Male	2,619	2,410	6,860	6,558
		Unknown	0	0	0	0
110.4	Dermatophytosis of foot	Female	1,243	1,117	2,501	2,366
		Male	2,373	2,142	5,398	5,108
		Unknown	3	3	1	1
110.5	Dermatophytosis of the body	Female	3,822	3,544	8,622	8,266
		Male	4,818	4,526	12,016	11,580
		Unknown	1	1	1	1
110.6	Deep seated dermatophytosis	Female	35	35	53	51
		Male	48	48	85	84
		Unknown	0	0	0	0
110.8	Dermatophytosis of other specified sites	Female	201	181	328	305
		Male	245	232	430	421
		Unknown	0	0	0	0
110.9	Dermatophytosis of unspecified site	Female	1,236	1,174	2,511	2,444
		Male	1,677	1,623	3,419	3,344
		Unknown	0	0	1	1
111	Dermatomycosis, other and unspecified	Female	0	0	5	3
		Male	4	4	7	7
		Unknown	0	0	0	0
111.0	Pityriasis versicolor	Female	14,032	13,585	31,654	31,279
		Male	18,354	17,831	45,575	44,998
		Unknown	0	0	5	4
111.1	Tinea nigra	Female	44	43	75	74
		Male	81	76	139	137
		Unknown	0	0	0	0
111.2	Tinea blanca	Female	69	68	152	148
		Male	85	77	206	200
		Unknown	0	0	0	0
111.3	Black piedra	Female	3	3	1	1
		Male	1	1	0	0
		Unknown	0	0	0	0
111.8	Other specified dermatomycoses	Female	28	24	58	50
		Male	35	34	98	87
		Unknown	0	0	0	0
111.9	Unspecified dermatomycosis	Female	355	331	768	727
		Male	451	425	1,155	1,118
		Unknown	0	0	0	0

**Table 2b\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	Female	5	5	12	9
		Male	2	2	5	3
		Unknown	0	0	0	0
112.0	Candidiasis of mouth	Female	797	632	998	894
		Male	464	377	615	535
		Unknown	0	0	0	0
112.1	Candidiasis of vulva and vagina	Female	2,264	2,008	2,770	2,597
		Male	9	9	14	13
		Unknown	0	0	0	0
112.2	Candidiasis of other urogenital sites	Female	98	79	99	90
		Male	173	156	337	319
		Unknown	0	0	0	0
112.3	Candidiasis of skin and nails	Female	923	822	1,694	1,581
		Male	606	550	1,377	1,282
		Unknown	0	0	0	0
112.4	Candidiasis of lung	Female	6	5	2	2
		Male	2	2	2	2
		Unknown	0	0	0	0
112.5	Disseminated candidiasis	Female	129	97	98	85
		Male	54	19	31	27
		Unknown	0	0	0	0
112.8	Candidiasis of other specified sites	Female	0	0	2	2
		Male	1	1	0	0
		Unknown	0	0	0	0
112.81	Candidal endocarditis	Female	4	4	2	2
		Male	2	2	3	2
		Unknown	0	0	0	0
112.82	Candidal otitis externa	Female	10	9	17	16
		Male	21	14	25	18
		Unknown	0	0	0	0
112.83	Candidal meningitis	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
112.84	Candidiasis of the esophagus	Female	91	75	71	60
		Male	68	56	64	52
		Unknown	0	0	0	0
112.85	Candidiasis of the intestine	Female	125	99	81	66
		Male	64	54	48	41
		Unknown	0	0	0	0
112.89	Other candidiasis of other specified sites	Female	133	121	166	157
		Male	99	75	137	124
		Unknown	0	0	0	0
112.9	Candidiasis of unspecified site	Female	854	759	1,182	1,124
		Male	401	351	661	624
		Unknown	0	0	0	0
114	Coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	Female	8	5	10	9
		Male	16	11	23	17
		Unknown	0	0	0	0
114.1	Primary extrapulmonary coccidioidomycosis	Female	0	0	1	1
		Male	0	0	2	2
		Unknown	0	0	0	0
114.2	Coccidioidal meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.3	Other forms of progressive coccidioidomycosis	Female	1	1	1	1
		Male	0	0	1	1
		Unknown	0	0	0	0

**Table 2b\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.4	Chronic pulmonary coccidioidomycosis	Female	0	0	0	0
		Male	2	2	1	1
		Unknown	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	Female	0	0	2	1
		Male	1	1	0	0
		Unknown	0	0	0	0
114.9	Unspecified coccidioidomycosis	Female	11	8	9	8
		Male	15	8	7	7
		Unknown	0	0	0	0
115	Histoplasmosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.0	Histoplasma capsulatum	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	Female	0	0	2	2
		Male	3	2	1	1
		Unknown	0	0	0	0
115.01	Histoplasma capsulatum meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.02	Histoplasma capsulatum retinitis	Female	0	0	0	0
		Male	3	2	0	0
		Unknown	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	Female	1	1	0	0
		Male	3	3	6	4
		Unknown	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	Female	0	0	0	0
		Male	1	1	1	1
		Unknown	0	0	0	0
115.1	Histoplasma duboisii	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.11	Histoplasma duboisii meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.12	Histoplasma duboisii retinitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.13	Histoplasma duboisii pericarditis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
115.14	Histoplasma duboisii endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.15	Histoplasma duboisii pneumonia	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.9	Unspecified Histoplasmosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2b\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
			115.91	Unspecified Histoplasmosis meningitis	Female	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	Female	1	1	1	1
		Male	1	1	0	0
		Unknown	0	0	0	0
115.93	Unspecified Histoplasmosis pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	Female	5	4	2	2
		Male	1	1	3	1
		Unknown	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	Female	14	11	7	7
		Male	8	7	11	9
		Unknown	0	0	0	0
116	Blastomycotic infection	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
116.0	Blastomycosis	Female	3	3	5	5
		Male	6	4	12	10
		Unknown	0	0	0	0
116.1	Paracoccidioidomycosis	Female	0	0	0	0
		Male	0	0	1	1
		Unknown	0	0	0	0
116.2	Lobomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117	Other mycoses	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.0	Rhinosporidiosis	Female	1	1	1	1
		Male	1	1	0	0
		Unknown	0	0	0	0
117.1	Sporotrichosis	Female	9	8	17	16
		Male	2	2	5	5
		Unknown	0	0	0	0
117.2	Chromoblastomycosis	Female	0	0	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
117.3	Aspergillosis	Female	11	10	12	10
		Male	9	8	12	11
		Unknown	0	0	0	0
117.4	Mycotic mycetomas	Female	0	0	0	0
		Male	3	3	0	0
		Unknown	0	0	0	0
117.5	Cryptococcosis	Female	1	1	0	0
		Male	0	0	2	2
		Unknown	0	0	0	0
117.6	Allescheriosis (Petriellidiosis)	Female	0	0	0	0
		Male	1	1	8	2
		Unknown	0	0	0	0
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	Female	11	11	12	12
		Male	13	12	14	13
		Unknown	0	0	0	0
117.9	Other and unspecified mycoses	Female	246	184	392	349
		Male	237	199	457	432
		Unknown	1	1	0	0
118	Opportunistic mycoses	Female	8	4	6	5
		Male	3	3	3	3
		Unknown	0	0	0	0

**Table 2b\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
185	Malignant neoplasm of prostate	Female	12	6	7	4
		Male	13,327	3,774	5,257	2,750
		Unknown	2	1	3	1
233.4	Carcinoma in situ of prostate	Female	1	1	0	0
		Male	92	64	37	36
		Unknown	0	0	0	0
255.0	Cushing's syndrome	Female	705	230	316	162
		Male	237	75	134	58
		Unknown	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	Female	0	0	0	0
		Male	695	513	239	207
		Unknown	0	0	0	0

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2b\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Ketoconazole Users</i>		-	<i>N/A</i>	<i>318,701</i>	<i>N/A</i>	<i>318,701</i>
-	Diagnosis outside of pre-determined list	0-17	58,436	13,706	37,386	14,498
		18-64	847,834	149,570	518,789	158,122
		65+	190,419	16,852	90,645	15,765
110	Dermatophytosis	0-17	0	0	0	0
		18-64	1	1	5	5
		65+	0	0	0	0
110.0	Dermatophytosis of scalp and beard	0-17	306	275	548	529
		18-64	1,611	1,571	3,126	3,065
		65+	72	71	119	117
110.1	Dermatophytosis of nail	0-17	141	124	170	165
		18-64	3,927	3,538	4,565	4,403
		65+	833	788	752	722
110.2	Dermatophytosis of hand	0-17	5	5	16	16
		18-64	205	199	406	391
		65+	15	14	41	40
110.3	Dermatophytosis of groin and perianal area	0-17	84	78	185	173
		18-64	2,630	2,407	6,939	6,642
		65+	427	390	1,023	959
110.4	Dermatophytosis of foot	0-17	176	163	383	357
		18-64	3,116	2,818	6,802	6,468
		65+	327	281	715	650
110.5	Dermatophytosis of the body	0-17	948	873	1,999	1,909
		18-64	7,044	6,597	16,960	16,346
		65+	649	601	1,680	1,592
110.6	Deep seated dermatophytosis	0-17	3	3	7	7
		18-64	73	73	117	114
		65+	7	7	14	14
110.8	Dermatophytosis of other specified sites	0-17	46	45	70	69
		18-64	349	327	598	574
		65+	51	41	90	83
110.9	Dermatophytosis of unspecified site	0-17	278	271	617	604
		18-64	2,438	2,337	4,927	4,809
		65+	197	189	387	376
111	Dermatomycosis, other and unspecified	0-17	0	0	4	2
		18-64	3	3	1	1
		65+	1	1	7	7
111.0	Pityriasis versicolor	0-17	2,960	2,856	7,392	7,312
		18-64	28,916	28,068	68,386	67,546
		65+	510	492	1,456	1,423
111.1	Tinea nigra	0-17	11	11	22	22
		18-64	111	106	186	183
		65+	3	2	6	6
111.2	Tinea blanca	0-17	8	7	20	20
		18-64	141	133	326	316
		65+	5	5	12	12
111.3	Black piedra	0-17	0	0	0	0
		18-64	4	4	1	1
		65+	0	0	0	0
111.8	Other specified dermatomycoses	0-17	6	6	9	9
		18-64	49	46	122	103
		65+	8	6	25	25
111.9	Unspecified dermatomycosis	0-17	48	46	86	84
		18-64	654	617	1,605	1,545
		65+	104	93	232	216



**Table 2b\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	0-17	1	1	0	0
		18-64	2	2	0	0
		65+	4	4	17	12
112.0	Candidiasis of mouth	0-17	61	50	94	89
		18-64	934	741	1,188	1,058
		65+	266	218	331	282
112.1	Candidiasis of vulva and vagina	0-17	61	51	67	64
		18-64	2,057	1,829	2,488	2,343
		65+	155	137	229	203
112.2	Candidiasis of other urogenital sites	0-17	7	7	17	16
		18-64	217	192	350	334
		65+	47	36	69	59
112.3	Candidiasis of skin and nails	0-17	43	38	99	94
		18-64	1,144	1,032	2,224	2,095
		65+	342	302	748	674
112.4	Candidiasis of lung	0-17	0	0	0	0
		18-64	4	4	3	3
		65+	4	3	1	1
112.5	Disseminated candidiasis	0-17	2	2	7	5
		18-64	161	103	108	98
		65+	20	11	14	9
112.8	Candidiasis of other specified sites	0-17	0	0	0	0
		18-64	0	0	2	2
		65+	1	1	0	0
112.81	Candidal endocarditis	0-17	0	0	0	0
		18-64	5	5	5	4
		65+	1	1	0	0
112.82	Candidal otitis externa	0-17	1	1	1	1
		18-64	28	20	37	30
		65+	2	2	4	3
112.83	Candidal meningitis	0-17	1	1	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
112.84	Candidiasis of the esophagus	0-17	1	1	1	1
		18-64	108	91	99	83
		65+	50	39	35	28
112.85	Candidiasis of the intestine	0-17	46	41	26	22
		18-64	134	104	99	81
		65+	9	8	4	4
112.89	Other candidiasis of other specified sites	0-17	12	11	13	13
		18-64	145	139	221	212
		65+	75	46	69	56
112.9	Candidiasis of unspecified site	0-17	84	81	117	113
		18-64	952	850	1,409	1,338
		65+	219	179	317	297
114	Coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	0-17	0	0	0	0
		18-64	20	13	26	19
		65+	4	3	7	7
114.1	Primary extrapulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	2	2
114.2	Coccidioidal meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.3	Other forms of progressive coccidioidomycosis	0-17	0	0	0	0
		18-64	1	1	2	2
		65+	0	0	0	0

**Table 2b\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.4	Chronic pulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	1	1	0	0
114.5	Unspecified pulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	2	1
		65+	1	1	0	0
114.9	Unspecified coccidioidomycosis	0-17	3	1	0	0
		18-64	22	14	16	15
		65+	1	1	0	0
115	Histoplasmosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.0	Histoplasma capsulatum	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	0-17	0	0	0	0
		18-64	3	2	3	3
		65+	0	0	0	0
115.01	Histoplasma capsulatum meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.02	Histoplasma capsulatum retinitis	0-17	0	0	0	0
		18-64	3	2	0	0
		65+	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	0-17	0	0	0	0
		18-64	4	4	3	2
		65+	0	0	3	2
115.09	Histoplasma capsulatum, with mention of other manifestation	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
115.1	Histoplasma duboisii	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.11	Histoplasma duboisii meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.12	Histoplasma duboisii retinitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.13	Histoplasma duboisii pericarditis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.14	Histoplasma duboisii endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.15	Histoplasma duboisii pneumonia	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.9	Unspecified Histoplasmosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2b\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.91	Unspecified Histoplasmosis meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	1	1	0	0
115.93	Unspecified Histoplasmosis pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	0-17	0	0	0	0
		18-64	6	5	5	3
		65+	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0-17	3	3	0	0
		18-64	16	12	14	12
		65+	3	3	4	4
116	Blastomycotic infection	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
116.0	Blastomycosis	0-17	0	0	0	0
		18-64	7	5	15	13
		65+	2	2	2	2
116.1	Paracoccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
116.2	Lobomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117	Other mycoses	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117.0	Rhinosporidiosis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	1	1	1	1
117.1	Sporotrichosis	0-17	0	0	0	0
		18-64	8	8	19	18
		65+	3	2	3	3
117.2	Chromoblastomycosis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
117.3	Aspergillosis	0-17	1	1	1	1
		18-64	18	16	22	19
		65+	1	1	1	1
117.4	Mycotic mycetomas	0-17	1	1	0	0
		18-64	2	2	0	0
		65+	0	0	0	0
117.5	Cryptococcosis	0-17	0	0	0	0
		18-64	1	1	2	2
		65+	0	0	0	0
117.6	Allergic (Petriellidiosis)	0-17	0	0	0	0
		18-64	1	1	8	2
		65+	0	0	0	0
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	1	1	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	0-17	0	0	3	3
		18-64	24	23	19	18
		65+	0	0	4	4
117.9	Other and unspecified mycoses	0-17	22	19	47	44
		18-64	411	322	680	625
		65+	51	43	122	112

**Table 2b\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Ketoconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
118	Opportunistic mycoses	0-17	0	0	0	0
		18-64	10	6	7	6
		65+	1	1	2	2
185	Malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	3,578	977	1,467	712
		65+	9,763	2,804	3,800	2,043
233.4	Carcinoma in situ of prostate	0-17	0	0	0	0
		18-64	26	21	8	8
		65+	67	44	29	28
255.0	Cushing's syndrome	0-17	37	5	18	6
		18-64	823	269	369	191
		65+	82	31	63	23
V10.46	Personal history of malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	190	150	59	51
		65+	505	363	180	156

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2c. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Fluconazole Use			0 to 14 Days Post Prevalent Fluconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Fluconazole Users</i>		<i>N/A</i>	<i>5,489,965</i>	<i>100%</i>	<i>N/A</i>	<i>5,489,965</i>	<i>100%</i>
-	Diagnosis outside of pre-determined list	36,242,796	3,924,026	71.48%	17,042,197	3,686,811	67.16%
110	Dermatophytosis	6	6	0.00%	6	6	0.00%
110.0	Dermatophytosis of scalp and beard	3,391	3,016	0.05%	4,901	4,722	0.09%
110.1	Dermatophytosis of nail	43,562	39,951	0.73%	30,581	29,430	0.54%
110.2	Dermatophytosis of hand	596	546	0.01%	1,187	1,137	0.02%
110.3	Dermatophytosis of groin and perianal area	12,514	11,410	0.21%	34,857	33,163	0.60%
110.4	Dermatophytosis of foot	14,951	13,315	0.24%	25,097	23,319	0.42%
110.5	Dermatophytosis of the body	19,521	18,174	0.33%	45,723	43,916	0.80%
110.6	Deep seated dermatophytosis	190	174	0.00%	338	323	0.01%
110.8	Dermatophytosis of other specified sites	1,317	1,242	0.02%	2,033	1,933	0.04%
110.9	Dermatophytosis of unspecified site	5,897	5,597	0.10%	12,518	12,108	0.22%
111	Dermatomycosis, other and unspecified	9	9	0.00%	9	9	0.00%
111.0	Pityriasis versicolor	14,020	13,485	0.25%	32,862	32,391	0.59%
111.1	Tinea nigra	137	122	0.00%	229	221	0.00%
111.2	Tinea blanca	218	207	0.00%	524	511	0.01%
111.3	Black piedra	2	2	0.00%	8	8	0.00%
111.8	Other specified dermatomycoses	633	489	0.01%	1,077	848	0.02%
111.9	Unspecified dermatomycosis	3,184	2,858	0.05%	7,751	7,168	0.13%
112	Candidiasis	96	91	0.00%	187	173	0.00%
112.0	Candidiasis of mouth	67,742	55,315	1.01%	104,347	94,114	1.71%
112.1	Candidiasis of vulva and vagina	142,916	138,518	2.52%	634,803	617,711	11.25%
112.2	Candidiasis of other urogenital sites	14,933	13,674	0.25%	22,323	21,266	0.39%
112.3	Candidiasis of skin and nails	17,083	15,565	0.28%	45,816	43,085	0.78%
112.4	Candidiasis of lung	1,355	1,095	0.02%	497	401	0.01%
112.5	Disseminated candidiasis	2,590	1,794	0.03%	1,278	1,034	0.02%
112.8	Candidiasis of other specified sites	20	20	0.00%	31	27	0.00%
112.81	Candidal endocarditis	162	98	0.00%	156	134	0.00%
112.82	Candidal otitis externa	372	303	0.01%	862	727	0.01%
112.83	Candidal meningitis	48	27	0.00%	28	19	0.00%
112.84	Candidiasis of the esophagus	25,381	20,814	0.38%	18,335	15,912	0.29%
112.85	Candidiasis of the intestine	1,503	1,258	0.02%	1,250	1,154	0.02%
112.89	Other candidiasis of other specified sites	7,980	6,875	0.13%	10,668	9,842	0.18%
112.9	Candidiasis of unspecified site	26,568	24,153	0.44%	84,753	81,818	1.49%
114	Coccidioidomycosis	2	2	0.00%	2	2	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	2,901	1,954	0.04%	2,816	2,085	0.04%
114.1	Primary extrapulmonary coccidioidomycosis	72	54	0.00%	86	68	0.00%
114.2	Coccidioidal meningitis	232	123	0.00%	151	86	0.00%
114.3	Other forms of progressive coccidioidomycosis	441	259	0.00%	290	211	0.00%
114.4	Chronic pulmonary coccidioidomycosis	222	173	0.00%	115	92	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	1,057	747	0.01%	890	703	0.01%
114.9	Unspecified coccidioidomycosis	1,753	1,220	0.02%	1,880	1,483	0.03%
115.0	Histoplasma capsulatum	3	3	0.00%	2	2	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	23	20	0.00%	17	16	0.00%
115	Histoplasmosis	2	2	0.00%	1	1	0.00%
115.01	Histoplasma capsulatum meningitis	3	1	0.00%	2	2	0.00%
115.02	Histoplasma capsulatum retinitis	118	110	0.00%	27	27	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	1	1	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	131	62	0.00%	50	41	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	10	10	0.00%	9	9	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	1	1	0.00%
115.10	Histoplasma duboisii without mention of manifestation	1	1	0.00%	2	2	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	1	1	0.00%
115.12	Histoplasma duboisii retinitis	1	1	0.00%	1	1	0.00%

**Table 2c. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Fluconazole Use			0 to 14 Days Post Prevalent Fluconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	1	1	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	6	1	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	2	2	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	5	1	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	176	162	0.00%	43	41	0.00%
115.93	Unspecified Histoplasmosis pericarditis	2	2	0.00%	1	1	0.00%
115.94	Unspecified Histoplasmosis endocarditis	4	2	0.00%	3	1	0.00%
115.95	Unspecified Histoplasmosis pneumonia	49	34	0.00%	31	21	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	571	282	0.01%	192	158	0.00%
116	Blastomycotic infection	1	1	0.00%	1	1	0.00%
116.0	Blastomycosis	287	98	0.00%	117	73	0.00%
116.1	Paracoccidioidomycosis	20	19	0.00%	27	27	0.00%
116.2	Lobomycosis	1	1	0.00%	0	0	0.00%
117	Other mycoses	2	2	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	21	19	0.00%	16	16	0.00%
117.1	Sporotrichosis	70	64	0.00%	167	140	0.00%
117.2	Chromoblastomycosis	13	12	0.00%	16	15	0.00%
117.3	Aspergillosis	666	362	0.01%	489	372	0.01%
117.4	Mycotic mycetomas	34	31	0.00%	29	28	0.00%
117.5	Cryptococcosis	2,302	857	0.02%	1,065	635	0.01%
117.6	Allescheriosis (Petriellidiosis)	6	5	0.00%	6	5	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	18	13	0.00%	24	22	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	131	118	0.00%	263	250	0.00%
117.9	Other and unspecified mycoses	8,450	6,377	0.12%	11,386	10,410	0.19%
118	Opportunistic mycoses	89	55	0.00%	59	46	0.00%
185	Malignant neoplasm of prostate	26,574	7,857	0.14%	9,318	4,766	0.09%
233.4	Carcinoma in situ of prostate	333	242	0.00%	141	108	0.00%
255.0	Cushing's syndrome	1,403	873	0.02%	631	473	0.01%
V10.46	Personal history of malignant neoplasm of prostate	5,704	3,393	0.06%	2,010	1,477	0.03%

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.









Table 2c\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, by Year

		2015					
DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Fluconazole Use			0 to 14 Days Post Prevalent Fluconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
Total Number of Prevalent Fluconazole Users		N/A	524,489		N/A	524,489	
-	Diagnosis outside of pre-determined list	3,835,632	368,391	70.24%	1,832,695	360,572	68.75%
110	Dermatophytosis	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	302	271	0.05%	525	507	0.10%
110.1	Dermatophytosis of nail	4,649	4,261	0.81%	3,547	3,405	0.65%
110.2	Dermatophytosis of hand	64	59	0.01%	118	115	0.02%
110.3	Dermatophytosis of groin and perianal area	1,305	1,151	0.22%	3,803	3,635	0.69%
110.4	Dermatophytosis of foot	1,482	1,318	0.25%	2,863	2,668	0.51%
110.5	Dermatophytosis of the body	2,020	1,878	0.36%	5,357	5,145	0.98%
110.6	Deep seated dermatophytosis	17	14	0.00%	31	30	0.01%
110.8	Dermatophytosis of other specified sites	139	132	0.03%	247	240	0.05%
110.9	Dermatophytosis of unspecified site	582	539	0.10%	1,392	1,350	0.26%
111	Dermatomycosis, other and unspecified	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	2,141	2,054	0.39%	6,264	6,180	1.18%
111.1	Tinea nigra	8	7	0.00%	21	21	0.00%
111.2	Tinea blanca	19	18	0.00%	36	36	0.01%
111.3	Black piedra	0	0	0.00%	1	1	0.00%
111.8	Other specified dermatomycoses	84	63	0.01%	145	115	0.02%
111.9	Unspecified dermatomycosis	319	294	0.06%	944	881	0.17%
112	Candidiasis	6	6	0.00%	15	13	0.00%
112.0	Candidiasis of mouth	6,687	5,354	1.02%	11,208	10,019	1.91%
112.1	Candidiasis of vulva and vagina	12,350	11,948	2.28%	64,665	62,968	12.01%
112.2	Candidiasis of other urogenital sites	1,459	1,316	0.25%	2,637	2,505	0.48%
112.3	Candidiasis of skin and nails	2,032	1,819	0.35%	6,004	5,665	1.08%
112.4	Candidiasis of lung	113	91	0.02%	29	25	0.00%
112.5	Disseminated candidiasis	285	179	0.03%	118	86	0.02%
112.8	Candidiasis of other specified sites	1	1	0.00%	6	2	0.00%
112.81	Candidal endocarditis	29	13	0.00%	24	20	0.00%
112.82	Candidal otitis externa	37	29	0.01%	78	67	0.01%
112.83	Candidal meningitis	2	2	0.00%	3	3	0.00%
112.84	Candidiasis of the esophagus	2,959	2,318	0.44%	2,380	2,043	0.39%
112.85	Candidiasis of the intestine	89	77	0.01%	96	89	0.02%
112.89	Other candidiasis of other specified sites	808	713	0.14%	1,302	1,236	0.24%
112.9	Candidiasis of unspecified site	2,849	2,543	0.48%	11,612	11,235	2.14%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	183	139	0.03%	169	126	0.02%
114.1	Primary extrapulmonary coccidioidomycosis	8	6	0.00%	7	6	0.00%
114.2	Coccidioidal meningitis	13	6	0.00%	5	5	0.00%
114.3	Other forms of progressive coccidioidomycosis	21	18	0.00%	17	13	0.00%
114.4	Chronic pulmonary coccidioidomycosis	17	14	0.00%	11	7	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	100	62	0.01%	79	59	0.01%
114.9	Unspecified coccidioidomycosis	181	112	0.02%	164	120	0.02%
115	Histoplasmosis	1	1	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	2	2	0.00%	4	3	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	9	9	0.00%	0	0	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	48	19	0.00%	10	8	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	1	1	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	1	1	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	24	21	0.00%	2	2	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	6	6	0.00%	3	3	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	52	26	0.00%	23	21	0.00%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	23	12	0.00%	20	12	0.00%
116.1	Paracoccidioidomycosis	0	0	0.00%	1	1	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	1	1	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	8	8	0.00%	23	20	0.00%
117.2	Chromoblastomycosis	0	0	0.00%	1	1	0.00%
117.3	Aspergillosis	49	34	0.01%	47	37	0.01%
117.4	Mycotic mycetomas	0	0	0.00%	3	3	0.00%
117.5	Cryptococcosis	367	84	0.02%	121	71	0.01%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0	0	0.00%	2	2	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	10	10	0.00%	20	20	0.00%
117.9	Other and unspecified mycoses	951	660	0.13%	1,331	1,215	0.23%
118	Opportunistic mycoses	5	4	0.00%	4	4	0.00%
185	Malignant neoplasm of prostate	3,038	907	0.17%	1,086	543	0.10%
233.4	Carcinoma in situ of prostate	25	23	0.00%	12	11	0.00%
255.0	Cushing's syndrome	137	82	0.02%	79	60	0.01%
V10.46	Personal history of malignant neoplasm of prostate	651	389	0.07%	261	195	0.04%

**Table 2c\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Fluconazole Users</i>		-	<i>N/A</i>	<i>5,489,965</i>	<i>N/A</i>	<i>5,489,965</i>
-	Diagnosis outside of pre-determined list	Female	29,456,444	3,523,895	14,152,475	3,282,242
		Male	6,784,739	399,985	2,888,983	404,428
		Unknown	1,613	146	739	141
110	Dermatophytosis	Female	3	3	4	4
		Male	3	3	2	2
		Unknown	0	0	0	0
110.0	Dermatophytosis of scalp and beard	Female	1,647	1,488	2,096	2,024
		Male	1,743	1,527	2,805	2,698
		Unknown	1	1	0	0
110.1	Dermatophytosis of nail	Female	31,659	29,136	18,891	18,212
		Male	11,902	10,814	11,689	11,217
		Unknown	1	1	1	1
110.2	Dermatophytosis of hand	Female	285	265	461	441
		Male	311	281	726	696
		Unknown	0	0	0	0
110.3	Dermatophytosis of groin and perianal area	Female	3,909	3,589	9,858	9,449
		Male	8,605	7,821	24,998	23,713
		Unknown	0	0	1	1
110.4	Dermatophytosis of foot	Female	7,989	7,182	10,000	9,394
		Male	6,959	6,130	15,097	13,925
		Unknown	3	3	0	0
110.5	Dermatophytosis of the body	Female	11,297	10,559	23,028	22,076
		Male	8,223	7,614	22,695	21,840
		Unknown	1	1	0	0
110.6	Deep seated dermatophytosis	Female	91	80	188	181
		Male	99	94	150	142
		Unknown	0	0	0	0
110.8	Dermatophytosis of other specified sites	Female	725	690	1,005	953
		Male	592	552	1,028	980
		Unknown	0	0	0	0
110.9	Dermatophytosis of unspecified site	Female	3,346	3,196	6,185	5,986
		Male	2,551	2,401	6,332	6,121
		Unknown	0	0	1	1
111	Dermatomycosis, other and unspecified	Female	6	6	5	5
		Male	3	3	4	4
		Unknown	0	0	0	0
111.0	Pityriasis versicolor	Female	7,188	6,912	14,086	13,859
		Male	6,832	6,573	18,775	18,531
		Unknown	0	0	1	1
111.1	Tinea nigra	Female	91	78	125	122
		Male	46	44	104	99
		Unknown	0	0	0	0
111.2	Tinea blanca	Female	123	121	259	255
		Male	95	86	265	256
		Unknown	0	0	0	0
111.3	Black piedra	Female	1	1	4	4
		Male	1	1	4	4
		Unknown	0	0	0	0
111.8	Other specified dermatomycoses	Female	355	278	552	443
		Male	278	211	525	405
		Unknown	0	0	0	0
111.9	Unspecified dermatomycosis	Female	1,855	1,664	4,083	3,748
		Male	1,329	1,194	3,668	3,420
		Unknown	0	0	0	0

**Table 2c\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	Female	68	65	135	126
		Male	28	26	52	47
		Unknown	0	0	0	0
112.0	Candidiasis of mouth	Female	39,410	32,806	63,552	57,893
		Male	28,332	22,509	40,793	36,219
		Unknown	0	0	2	2
112.1	Candidiasis of vulva and vagina	Female	142,679	138,290	633,845	616,769
		Male	232	223	932	917
		Unknown	5	5	26	25
112.2	Candidiasis of other urogenital sites	Female	10,113	9,454	12,315	11,910
		Male	4,820	4,220	10,006	9,355
		Unknown	0	0	2	1
112.3	Candidiasis of skin and nails	Female	12,251	11,190	32,284	30,433
		Male	4,831	4,374	13,532	12,652
		Unknown	1	1	0	0
112.4	Candidiasis of lung	Female	664	533	298	234
		Male	691	562	199	167
		Unknown	0	0	0	0
112.5	Disseminated candidiasis	Female	1,407	1,024	796	692
		Male	1,183	770	482	342
		Unknown	0	0	0	0
112.8	Candidiasis of other specified sites	Female	9	9	25	21
		Male	11	11	6	6
		Unknown	0	0	0	0
112.81	Candidal endocarditis	Female	86	58	105	91
		Male	76	40	51	43
		Unknown	0	0	0	0
112.82	Candidal otitis externa	Female	219	183	488	421
		Male	153	120	374	306
		Unknown	0	0	0	0
112.83	Candidal meningitis	Female	18	14	12	10
		Male	30	13	16	9
		Unknown	0	0	0	0
112.84	Candidiasis of the esophagus	Female	13,553	11,148	9,732	8,493
		Male	11,826	9,664	8,601	7,417
		Unknown	2	2	2	2
112.85	Candidiasis of the intestine	Female	1,008	850	874	801
		Male	495	408	376	353
		Unknown	0	0	0	0
112.89	Other candidiasis of other specified sites	Female	4,937	4,376	7,426	6,956
		Male	3,043	2,499	3,242	2,886
		Unknown	0	0	0	0
112.9	Candidiasis of unspecified site	Female	21,103	19,639	72,566	70,416
		Male	5,464	4,513	12,186	11,401
		Unknown	1	1	1	1
114	Coccidioidomycosis	Female	0	0	0	0
		Male	2	2	2	2
		Unknown	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	Female	1,231	815	1,228	910
		Male	1,670	1,139	1,588	1,175
		Unknown	0	0	0	0
114.1	Primary extrapulmonary coccidioidomycosis	Female	27	20	29	22
		Male	45	34	57	46
		Unknown	0	0	0	0
114.2	Coccidioidal meningitis	Female	83	34	35	29
		Male	149	89	116	57
		Unknown	0	0	0	0

**Table 2c\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	Female	125	73	72	59
		Male	316	186	218	152
		Unknown	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	Female	99	80	43	33
		Male	123	93	72	59
		Unknown	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	Female	451	302	335	272
		Male	606	445	555	431
		Unknown	0	0	0	0
114.9	Unspecified coccidioidomycosis	Female	752	523	761	604
		Male	1,001	697	1,119	879
		Unknown	0	0	0	0
115	Histoplasmosis	Female	0	0	1	1
		Male	2	2	0	0
		Unknown	0	0	0	0
115.0	Histoplasma capsulatum	Female	2	2	2	2
		Male	1	1	0	0
		Unknown	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	Female	10	10	9	8
		Male	13	10	8	8
		Unknown	0	0	0	0
115.01	Histoplasma capsulatum meningitis	Female	3	1	1	1
		Male	0	0	1	1
		Unknown	0	0	0	0
115.02	Histoplasma capsulatum retinitis	Female	102	94	23	23
		Male	16	16	4	4
		Unknown	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	Female	0	0	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	Female	59	31	19	17
		Male	72	31	31	24
		Unknown	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	Female	8	8	6	6
		Male	2	2	3	3
		Unknown	0	0	0	0
115.1	Histoplasma duboisii	Female	0	0	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	Female	1	1	2	2
		Male	0	0	0	0
		Unknown	0	0	0	0
115.11	Histoplasma duboisii meningitis	Female	0	0	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.12	Histoplasma duboisii retinitis	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.13	Histoplasma duboisii pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.14	Histoplasma duboisii endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2c\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	Female	0	0	0	0
		Male	0	0	1	1
		Unknown	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	Female	0	0	0	0
		Male	6	1	0	0
		Unknown	0	0	0	0
115.9	Unspecified Histoplasmosis	Female	1	1	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	Female	0	0	0	0
		Male	5	1	0	0
		Unknown	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	Female	155	142	41	39
		Male	21	20	2	2
		Unknown	0	0	0	0
115.93	Unspecified Histoplasmosis pericarditis	Female	0	0	1	1
		Male	2	2	0	0
		Unknown	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	Female	1	1	0	0
		Male	3	1	3	1
		Unknown	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	Female	25	22	14	11
		Male	24	12	17	10
		Unknown	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	Female	260	162	109	92
		Male	311	120	83	66
		Unknown	0	0	0	0
116	Blastomycotic infection	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
116.0	Blastomycosis	Female	116	47	45	34
		Male	171	51	72	39
		Unknown	0	0	0	0
116.1	Paracoccidioidomycosis	Female	19	18	25	25
		Male	1	1	2	2
		Unknown	0	0	0	0
116.2	Lobomycosis	Female	1	1	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117	Other mycoses	Female	1	1	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
117.0	Rhinosporidiosis	Female	15	14	9	9
		Male	6	5	7	7
		Unknown	0	0	0	0
117.1	Sporotrichosis	Female	49	47	120	101
		Male	21	17	47	39
		Unknown	0	0	0	0
117.2	Chromoblastomycosis	Female	5	5	12	11
		Male	8	7	4	4
		Unknown	0	0	0	0
117.3	Aspergillosis	Female	395	221	252	206
		Male	271	141	237	166
		Unknown	0	0	0	0
117.4	Mycotic mycetomas	Female	22	19	17	16
		Male	12	12	12	12
		Unknown	0	0	0	0
117.5	Cryptococcosis	Female	578	233	293	180
		Male	1,724	624	772	455
		Unknown	0	0	0	0
117.6	Allescheriosis (Petriellidiosis)	Female	4	3	3	3
		Male	2	2	3	2
		Unknown	0	0	0	0

**Table 2c\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	Female	6	6	11	10
		Male	12	7	13	12
		Unknown	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	Female	87	78	183	176
		Male	44	40	80	74
		Unknown	0	0	0	0
117.9	Other and unspecified mycoses	Female	4,953	3,903	8,237	7,739
		Male	3,497	2,474	3,148	2,670
		Unknown	0	0	1	1
118	Opportunistic mycoses	Female	48	32	32	27
		Male	41	23	27	19
		Unknown	0	0	0	0
185	Malignant neoplasm of prostate	Female	102	69	55	39
		Male	26,472	7,788	9,263	4,727
		Unknown	0	0	0	0
233.4	Carcinoma in situ of prostate	Female	3	3	1	1
		Male	330	239	140	107
		Unknown	0	0	0	0
255.0	Cushing's syndrome	Female	1,238	773	536	408
		Male	165	100	95	65
		Unknown	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	Female	13	13	6	6
		Male	5,691	3,380	2,004	1,471
		Unknown	0	0	0	0

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2c\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Fluconazole Users</i>		-	N/A	5,489,965	N/A	5,489,965
-	Diagnosis outside of pre-determined list	0-17	1,295,269	215,385	678,229	206,342
		18-64	26,702,629	3,292,203	13,112,074	3,091,973
		65+	8,244,898	416,438	3,251,894	388,496
110	Dermatophytosis	0-17	0	0	0	0
		18-64	5	5	4	4
		65+	1	1	2	2
110.0	Dermatophytosis of scalp and beard	0-17	1,475	1,205	1,663	1,569
		18-64	1,724	1,631	2,918	2,845
		65+	192	180	320	308
110.1	Dermatophytosis of nail	0-17	693	615	713	690
		18-64	26,050	23,383	21,468	20,618
		65+	16,819	15,953	8,400	8,122
110.2	Dermatophytosis of hand	0-17	25	24	62	60
		18-64	485	442	951	921
		65+	86	80	174	156
110.3	Dermatophytosis of groin and perianal area	0-17	479	453	1,091	1,049
		18-64	9,287	8,550	27,102	25,929
		65+	2,748	2,407	6,664	6,185
110.4	Dermatophytosis of foot	0-17	625	580	1,360	1,296
		18-64	11,704	10,479	20,227	18,896
		65+	2,622	2,256	3,510	3,127
110.5	Dermatophytosis of the body	0-17	2,923	2,674	5,867	5,627
		18-64	14,184	13,299	33,554	32,366
		65+	2,414	2,201	6,302	5,923
110.6	Deep seated dermatophytosis	0-17	32	31	66	62
		18-64	129	117	223	214
		65+	29	26	49	47
110.8	Dermatophytosis of other specified sites	0-17	134	128	233	226
		18-64	873	836	1,481	1,416
		65+	310	278	319	291
110.9	Dermatophytosis of unspecified site	0-17	872	818	1,507	1,467
		18-64	4,235	4,048	9,333	9,059
		65+	790	731	1,678	1,582
111	Dermatomycosis, other and unspecified	0-17	1	1	0	0
		18-64	4	4	6	6
		65+	4	4	3	3
111.0	Pityriasis versicolor	0-17	1,394	1,325	3,137	3,091
		18-64	12,288	11,849	28,855	28,455
		65+	338	311	870	845
111.1	Tinea nigra	0-17	13	13	29	29
		18-64	110	97	174	170
		65+	14	12	26	22
111.2	Tinea blanca	0-17	16	16	56	55
		18-64	182	171	407	397
		65+	20	20	61	59
111.3	Black piedra	0-17	0	0	0	0
		18-64	1	1	8	8
		65+	1	1	0	0
111.8	Other specified dermatomycoses	0-17	53	42	75	65
		18-64	426	337	787	626
		65+	154	110	215	157
111.9	Unspecified dermatomycosis	0-17	191	182	393	364
		18-64	2,162	1,971	5,397	5,072
		65+	831	705	1,961	1,732



**Table 2c\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	0-17	3	3	12	11
		18-64	42	40	47	45
		65+	51	48	128	117
112.0	Candidiasis of mouth	0-17	20,339	16,421	23,636	22,524
		18-64	32,223	27,039	58,263	52,218
		65+	15,180	11,855	22,448	19,372
112.1	Candidiasis of vulva and vagina	0-17	7,290	7,044	36,677	35,782
		18-64	128,454	124,679	559,670	545,154
		65+	7,172	6,795	38,456	36,775
112.2	Candidiasis of other urogenital sites	0-17	1,768	1,644	2,936	2,846
		18-64	9,051	8,588	15,618	15,033
		65+	4,114	3,442	3,769	3,387
112.3	Candidiasis of skin and nails	0-17	2,598	2,401	4,446	4,258
		18-64	9,730	9,055	29,101	27,673
		65+	4,755	4,109	12,269	11,154
112.4	Candidiasis of lung	0-17	20	19	11	11
		18-64	669	582	301	235
		65+	666	494	185	155
112.5	Disseminated candidiasis	0-17	142	99	86	76
		18-64	1,715	1,242	948	779
		65+	733	453	244	179
112.8	Candidiasis of other specified sites	0-17	3	3	1	1
		18-64	15	15	29	25
		65+	2	2	1	1
112.81	Candidal endocarditis	0-17	15	3	5	4
		18-64	116	68	110	94
		65+	31	27	41	36
112.82	Candidal otitis externa	0-17	22	19	76	67
		18-64	276	224	627	526
		65+	74	60	159	134
112.83	Candidal meningitis	0-17	7	6	4	3
		18-64	38	18	22	14
		65+	3	3	2	2
112.84	Candidiasis of the esophagus	0-17	642	582	429	379
		18-64	13,913	11,926	10,626	9,396
		65+	10,826	8,306	7,280	6,137
112.85	Candidiasis of the intestine	0-17	341	275	191	182
		18-64	1,017	865	943	868
		65+	145	118	116	104
112.89	Other candidiasis of other specified sites	0-17	536	490	706	694
		18-64	5,200	4,575	7,656	7,124
		65+	2,244	1,810	2,306	2,024
112.9	Candidiasis of unspecified site	0-17	2,759	2,538	8,013	7,804
		18-64	19,234	17,834	64,966	63,023
		65+	4,575	3,781	11,774	10,991
114	Coccidioidomycosis	0-17	0	0	1	1
		18-64	1	1	1	1
		65+	1	1	0	0
114.0	Primary coccidioidomycosis (pulmonary)	0-17	95	75	102	80
		18-64	2,155	1,496	2,239	1,650
		65+	651	383	475	355
114.1	Primary extrapulmonary coccidioidomycosis	0-17	0	0	3	2
		18-64	61	43	67	54
		65+	11	11	16	12
114.2	Coccidioidal meningitis	0-17	8	7	4	4
		18-64	194	103	133	72
		65+	30	13	14	10

**Table 2c\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	0-17	19	11	13	10
		18-64	363	210	234	168
		65+	59	38	43	33
114.4	Chronic pulmonary coccidioidomycosis	0-17	4	4	3	3
		18-64	169	124	90	69
		65+	49	45	22	20
114.5	Unspecified pulmonary coccidioidomycosis	0-17	29	21	33	28
		18-64	773	554	679	537
		65+	255	172	178	138
114.9	Unspecified coccidioidomycosis	0-17	86	63	112	90
		18-64	1,354	935	1,468	1,151
		65+	313	222	300	242
115	Histoplasmosis	0-17	1	1	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
115.0	Histoplasma capsulatum	0-17	1	1	1	1
		18-64	2	2	1	1
		65+	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	0-17	0	0	0	0
		18-64	20	17	15	14
		65+	3	3	2	2
115.01	Histoplasma capsulatum meningitis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	3	1	1	1
115.02	Histoplasma capsulatum retinitis	0-17	0	0	0	0
		18-64	92	86	19	19
		65+	26	24	8	8
115.03	Histoplasma capsulatum pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	1	1
115.04	Histoplasma capsulatum endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	0-17	2	2	1	1
		18-64	77	41	36	32
		65+	52	19	13	8
115.09	Histoplasma capsulatum, with mention of other manifestation	0-17	0	0	0	0
		18-64	7	7	7	7
		65+	3	3	2	2
115.1	Histoplasma duboisii	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	0-17	1	1	0	0
		18-64	0	0	2	2
		65+	0	0	0	0
115.11	Histoplasma duboisii meningitis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
115.12	Histoplasma duboisii retinitis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	1	1	0	0
115.13	Histoplasma duboisii pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.14	Histoplasma duboisii endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2c\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	1	1
115.19	Histoplasma duboisii with mention of other manifestation	0-17	0	0	0	0
		18-64	6	1	0	0
		65+	0	0	0	0
115.9	Unspecified Histoplasmosis	0-17	0	0	0	0
		18-64	2	2	0	0
		65+	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	5	1	0	0
115.92	Unspecified Histoplasmosis retinitis	0-17	2	2	0	0
		18-64	125	114	33	31
		65+	49	46	10	10
115.93	Unspecified Histoplasmosis pericarditis	0-17	0	0	0	0
		18-64	2	2	1	1
		65+	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	0-17	0	0	0	0
		18-64	3	1	3	1
		65+	1	1	0	0
115.95	Unspecified Histoplasmosis pneumonia	0-17	0	0	0	0
		18-64	36	21	26	16
		65+	13	13	5	5
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0-17	11	7	5	4
		18-64	373	200	128	107
		65+	187	75	59	47
116	Blastomycotic infection	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	1	1	1	1
116.0	Blastomycosis	0-17	3	3	4	4
		18-64	212	75	85	57
		65+	72	20	28	12
116.1	Paracoccidioidomycosis	0-17	1	1	1	1
		18-64	18	17	25	25
		65+	1	1	1	1
116.2	Lobomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	1	1	0	0
117	Other mycoses	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	1	1	0	0
117.0	Rhinosporidiosis	0-17	1	1	0	0
		18-64	16	15	8	8
		65+	4	3	8	8
117.1	Sporotrichosis	0-17	3	3	3	3
		18-64	54	49	127	107
		65+	13	12	37	30
117.2	Chromoblastomycosis	0-17	1	1	0	0
		18-64	8	8	14	13
		65+	4	3	2	2
117.3	Aspergillosis	0-17	18	15	22	20
		18-64	409	240	313	245
		65+	239	107	154	107
117.4	Mycotic mycetomas	0-17	0	0	2	2
		18-64	23	22	16	15
		65+	11	9	11	11
117.5	Cryptococcosis	0-17	6	6	7	5
		18-64	1,723	665	815	476
		65+	573	186	243	154
117.6	Allescheriosis (Petriellidiosis)	0-17	0	0	0	0
		18-64	4	4	3	3
		65+	2	1	3	2

**Table 2c\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Fluconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0-17	0	0	0	0
		18-64	8	8	16	15
		65+	10	5	8	7
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	0-17	8	8	9	9
		18-64	105	94	216	204
		65+	18	16	38	37
117.9	Other and unspecified mycoses	0-17	394	298	583	547
		18-64	5,801	4,454	8,691	8,050
		65+	2,255	1,625	2,112	1,813
118	Opportunistic mycoses	0-17	1	1	7	3
		18-64	71	40	33	28
		65+	17	14	19	15
185	Malignant neoplasm of prostate	0-17	9	4	4	1
		18-64	8,071	2,175	2,753	1,294
		65+	18,494	5,678	6,561	3,471
233.4	Carcinoma in situ of prostate	0-17	0	0	0	0
		18-64	104	82	39	36
		65+	229	160	102	72
255.0	Cushing's syndrome	0-17	59	35	34	23
		18-64	1,169	735	508	391
		65+	175	103	89	59
V10.46	Personal history of malignant neoplasm of prostate	0-17	2	2	1	1
		18-64	1,262	732	424	301
		65+	4,440	2,659	1,585	1,175

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2d. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Griseofulvin Use			0 to 14 Days Post Prevalent Griseofulvin Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Griseofulvin Users</i>		<i>N/A</i>	<i>204,729</i>	<i>100%</i>	<i>N/A</i>	<i>204,729</i>	<i>100%</i>
-	Diagnosis outside of pre-determined list	459,400	108,902	53.19%	244,526	91,480	44.68%
110	Dermatophytosis	14	13	0.01%	8	8	0.00%
110.0	Dermatophytosis of scalp and beard	26,507	24,848	12.14%	64,682	61,546	30.06%
110.1	Dermatophytosis of nail	6,502	5,717	2.79%	6,162	5,913	2.89%
110.2	Dermatophytosis of hand	339	320	0.16%	522	504	0.25%
110.3	Dermatophytosis of groin and perianal area	2,254	2,034	0.99%	3,780	3,623	1.77%
110.4	Dermatophytosis of foot	6,370	5,508	2.69%	7,924	7,430	3.63%
110.5	Dermatophytosis of the body	16,087	14,553	7.11%	26,237	25,300	12.36%
110.6	Deep seated dermatophytosis	163	150	0.07%	192	189	0.09%
110.8	Dermatophytosis of other specified sites	729	677	0.33%	1,006	971	0.47%
110.9	Dermatophytosis of unspecified site	5,398	5,102	2.49%	8,437	8,230	4.02%
111	Dermatormycosis, other and unspecified	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	888	850	0.42%	1,293	1,274	0.62%
111.1	Tinea nigra	53	51	0.02%	114	111	0.05%
111.2	Tinea blanca	117	112	0.05%	188	183	0.09%
111.3	Black piedra	1	1	0.00%	2	2	0.00%
111.8	Other specified dermatomycoses	45	41	0.02%	61	57	0.03%
111.9	Unspecified dermatomycosis	558	514	0.25%	717	694	0.34%
112	Candidiasis	1	1	0.00%	0	0	0.00%
112.0	Candidiasis of mouth	196	153	0.07%	131	118	0.06%
112.1	Candidiasis of vulva and vagina	247	226	0.11%	155	145	0.07%
112.2	Candidiasis of other urogenital sites	98	91	0.04%	58	57	0.03%
112.3	Candidiasis of skin and nails	442	408	0.20%	399	373	0.18%
112.4	Candidiasis of lung	1	1	0.00%	1	1	0.00%
112.5	Disseminated candidiasis	1	1	0.00%	4	4	0.00%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	7	6	0.00%	6	6	0.00%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	6	6	0.00%	2	2	0.00%
112.85	Candidiasis of the intestine	11	4	0.00%	2	2	0.00%
112.89	Other candidiasis of other specified sites	54	49	0.02%	33	33	0.02%
112.9	Candidiasis of unspecified site	209	195	0.10%	174	169	0.08%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	1	1	0.00%	1	1	0.00%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.2	Coccidioidal meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.4	Chronic pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.9	Unspecified coccidioidomycosis	1	1	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	0	0	0.00%	0	0	0.00%
115	Histoplasmosis	0	0	0.00%	1	1	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	1	1	0.00%	1	1	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	0	0	0.00%	0	0	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%

**Table 2d. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Griseofulvin Use			0 to 14 Days Post Prevalent Griseofulvin Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	4	3	0.00%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	0	0	0.00%	0	0	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	2	2	0.00%	0	0	0.00%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	2	2	0.00%	1	1	0.00%
116.1	Paracoccidioidomycosis	0	0	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	1	1	0.00%
117	Other mycoses	2	1	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	2	2	0.00%	6	6	0.00%
117.2	Chromoblastomycosis	1	1	0.00%	1	1	0.00%
117.3	Aspergillosis	1	1	0.00%	1	1	0.00%
117.4	Mycotic mycetomas	1	1	0.00%	1	1	0.00%
117.5	Cryptococcosis	0	0	0.00%	0	0	0.00%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0	0	0.00%	0	0	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	27	26	0.01%	40	39	0.02%
117.9	Other and unspecified mycoses	264	249	0.12%	340	330	0.16%
118	Opportunistic mycoses	14	2	0.00%	3	2	0.00%
185	Malignant neoplasm of prostate	379	160	0.08%	119	82	0.04%
233.4	Carcinoma in situ of prostate	7	7	0.00%	3	3	0.00%
255.0	Cushing's syndrome	8	5	0.00%	3	3	0.00%
V10.46	Personal history of malignant neoplasm of prostate	60	52	0.03%	31	21	0.01%

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.







Table 2d\_year.Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Year

DX Code	Diagnosis Description	2013						2014					
		45 Days to 1 Day Prior to Prevalent Griseofulvin Use			0 to 14 Days Post Prevalent Griseofulvin Use*			45 Days to 1 Day Prior to Prevalent Griseofulvin Use			0 to 14 Days Post Prevalent Griseofulvin Use*		
		Codes	Users	% of Users	Codes	Users	% of Users	Codes	Users	% of Users	Codes	Users	% of Users
Total Number of Prevalent Griseofulvin Users	-	N/A	25,526	54.29%	N/A	25,526	45.30%	N/A	22,774	53.31%	N/A	22,774	45.98%
-	Diagnosis outside of pre-determined list	60,829	13,858		32,265	11,563		54,913	12,141		29,950	10,472	
110	Dermatophytosis	1	1	0.00%	0	0	0.00%	3	2	0.01%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	3,479	3,263	12.78%	8,490	8,036	31.48%	3,096	2,928	12.86%	7,702	7,296	32.04%
110.1	Dermatophytosis of nail	730	633	2.48%	671	644	2.52%	670	586	2.57%	617	596	2.62%
110.2	Dermatophytosis of hand	49	44	0.17%	62	58	0.23%	38	36	0.16%	38	37	0.16%
110.3	Dermatophytosis of groin and perianal area	362	320	1.25%	485	462	1.81%	313	290	1.27%	475	456	2.00%
110.4	Dermatophytosis of foot	672	597	2.34%	797	751	2.94%	568	497	2.18%	629	590	2.59%
110.5	Dermatophytosis of the body	2,203	1,990	7.80%	3,421	3,283	12.86%	1,854	1,673	7.35%	2,933	2,839	12.47%
110.6	Deep seated dermatophytosis	24	21	0.08%	29	28	0.11%	19	17	0.07%	19	19	0.08%
110.8	Dermatophytosis of other specified sites	97	89	0.35%	159	154	0.60%	83	76	0.33%	140	137	0.60%
110.9	Dermatophytosis of unspecified site	723	684	2.68%	1,093	1,069	4.19%	646	613	2.69%	1,012	983	4.32%
111	Dermatormycosis, other and unspecified	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	134	127	0.50%	171	168	0.66%	105	98	0.43%	174	170	0.75%
111.1	Tinea nigra	7	7	0.03%	6	6	0.02%	5	4	0.02%	12	12	0.05%
111.2	Tinea blanca	15	15	0.06%	15	14	0.05%	16	16	0.07%	28	27	0.12%
111.3	Black piedra	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	12	9	0.04%	11	9	0.04%	6	5	0.02%	7	7	0.03%
111.9	Unspecified dermatomycosis	76	69	0.27%	67	66	0.26%	56	49	0.22%	69	68	0.30%
112	Candidiasis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.0	Candidiasis of mouth	24	19	0.07%	11	10	0.04%	27	23	0.10%	15	14	0.06%
112.1	Candidiasis of vulva and vagina	39	35	0.14%	19	17	0.07%	23	22	0.10%	23	23	0.10%
112.2	Candidiasis of other urogenital sites	10	10	0.04%	12	12	0.05%	19	16	0.07%	10	10	0.04%
112.3	Candidiasis of skin and nails	55	52	0.20%	45	42	0.16%	66	59	0.26%	64	63	0.28%
112.4	Candidiasis of lung	1	1	0.00%	1	1	0.00%	0	0	0.00%	0	0	0.00%
112.5	Disseminated candidiasis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	0	0	0.00%	2	2	0.01%	0	0	0.00%	1	1	0.00%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	1	1	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.85	Candidiasis of the intestine	0	0	0.00%	0	0	0.00%	3	3	0.01%	1	1	0.00%
112.89	Other candidiasis of other specified sites	5	4	0.02%	1	1	0.00%	10	10	0.04%	9	9	0.04%
112.9	Candidiasis of unspecified site	31	31	0.12%	19	19	0.07%	27	26	0.11%	26	24	0.11%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.2	Coccidioidal meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.4	Chronic pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.9	Unspecified coccidioidomycosis	1	1	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115	Histoplasmosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	1	1	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	1	1	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	1	1	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
116.1	Paracoccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.0	Rhinospodriosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.2	Chromoblastomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.3	Aspergillosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.4	Mycotic mycetomas	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.5	Cryptococcosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	4	4	0.02%	2	2	0.01%	4	4	0.02%	4	4	0.02%
117.9	Other and unspecified mycoses	53	49	0.19%	43	41	0.16%	31	29	0.13%	41	40	0.18%
118	Opportunistic mycoses	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
185	Malignant neoplasm of prostate	42	21	0.08%	13	10	0.04%	33	18	0.08%	15	8	0.04%
233.4	Carcinoma in situ of prostate	1	1	0.00%	0	0	0.00%	2	2	0.01%	1	1	0.00%
255.0	Cushing's syndrome	2	1	0.00%	2	2	0.01%	0	0	0.00%	0	0	0.00%
V10.46	Personal history of malignant neoplasm of prostate	9	7	0.03%	13	3	0.01%	2	2	0.01%	4	4	0.02%

Table 2d\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Year

		2015					
		45 Days to 1 Day Prior to Prevalent Griseofulvin Use			0 to 14 Days Post Prevalent Griseofulvin Use*		
Dx Code	Diagnosis Description	Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Griseofulvin Users</i>		<i>N/A</i>	<i>11,135</i>		<i>N/A</i>	<i>11,135</i>	
-	Diagnosis outside of pre-determined list	29,563	6,009	53.96%	15,423	4,903	44.03%
110	Dermatophytosis	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	1,650	1,537	13.80%	3,550	3,356	30.14%
110.1	Dermatophytosis of nail	388	340	3.05%	353	345	3.10%
110.2	Dermatophytosis of hand	27	23	0.21%	23	22	0.20%
110.3	Dermatophytosis of groin and perianal area	237	203	1.82%	315	294	2.64%
110.4	Dermatophytosis of foot	383	320	2.87%	378	354	3.18%
110.5	Dermatophytosis of the body	1,135	1,016	9.12%	1,602	1,531	13.75%
110.6	Deep seated dermatophytosis	10	10	0.09%	14	14	0.13%
110.8	Dermatophytosis of other specified sites	56	52	0.47%	76	74	0.66%
110.9	Dermatophytosis of unspecified site	322	304	2.73%	404	396	3.56%
111	Dermatormycosis, other and unspecified	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	52	49	0.44%	71	70	0.63%
111.1	Tinea nigra	5	4	0.04%	4	4	0.04%
111.2	Tinea blanca	14	11	0.10%	10	10	0.09%
111.3	Black piedra	0	0	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	2	2	0.02%	3	3	0.03%
111.9	Unspecified dermatomycosis	42	29	0.26%	32	32	0.29%
112	Candidiasis	0	0	0.00%	0	0	0.00%
112.0	Candidiasis of mouth	9	7	0.06%	6	6	0.05%
112.1	Candidiasis of vulva and vagina	23	19	0.17%	11	10	0.09%
112.2	Candidiasis of other urogenital sites	3	3	0.03%	1	1	0.01%
112.3	Candidiasis of skin and nails	30	29	0.26%	25	24	0.22%
112.4	Candidiasis of lung	0	0	0.00%	0	0	0.00%
112.5	Disseminated candidiasis	1	1	0.01%	0	0	0.00%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	0	0	0.00%	0	0	0.00%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	1	1	0.01%	0	0	0.00%
112.85	Candidiasis of the intestine	0	0	0.00%	0	0	0.00%
112.89	Other candidiasis of other specified sites	7	7	0.06%	4	4	0.04%
112.9	Candidiasis of unspecified site	20	15	0.13%	17	16	0.14%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	0	0	0.00%	0	0	0.00%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.2	Coccidioid meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.4	Chronic pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.9	Unspecified coccidioidomycosis	0	0	0.00%	0	0	0.00%
115	Histoplasmosis	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	0	0	0.00%	0	0	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	0	0	0.00%	0	0	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	0	0	0.00%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	0	0	0.00%	0	0	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0	0	0.00%	0	0	0.00%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	0	0	0.00%	0	0	0.00%
116.1	Paracoccidioidomycosis	0	0	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	0	0	0.00%	0	0	0.00%
117.2	Chromoblastomycosis	0	0	0.00%	1	1	0.01%
117.3	Aspergillosis	0	0	0.00%	0	0	0.00%
117.4	Mycotic mycetomas	0	0	0.00%	1	1	0.01%
117.5	Cryptococcosis	0	0	0.00%	0	0	0.00%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0	0	0.00%	0	0	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	4	4	0.04%	2	2	0.02%
117.9	Other and unspecified mycoses	19	19	0.17%	32	31	0.28%
118	Opportunistic mycoses	0	0	0.00%	0	0	0.00%
185	Malignant neoplasm of prostate	13	9	0.08%	5	5	0.04%
233.4	Carcinoma in situ of prostate	0	0	0.00%	0	0	0.00%
255.0	Cushing's syndrome	0	0	0.00%	0	0	0.00%
V10.46	Personal history of malignant neoplasm of prostate	5	5	0.04%	2	2	0.02%

**Table 2d\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Griseofulvin Users</i>		-	<i>N/A</i>	<i>204,729</i>	<i>N/A</i>	<i>204,729</i>
-	Diagnosis outside of pre-determined list	Female	195,193	44,252	98,192	35,795
		Male	264,198	64,647	146,320	55,681
		Unknown	9	3	14	4
110	Dermatophytosis	Female	5	4	5	5
		Male	9	9	3	3
		Unknown	0	0	0	0
110.0	Dermatophytosis of scalp and beard	Female	9,219	8,606	21,256	20,011
		Male	17,287	16,241	43,423	41,532
		Unknown	1	1	3	3
110.1	Dermatophytosis of nail	Female	3,103	2,720	2,714	2,616
		Male	3,399	2,997	3,448	3,297
		Unknown	0	0	0	0
110.2	Dermatophytosis of hand	Female	116	104	172	164
		Male	223	216	350	340
		Unknown	0	0	0	0
110.3	Dermatophytosis of groin and perianal area	Female	400	353	639	611
		Male	1,854	1,681	3,140	3,011
		Unknown	0	0	1	1
110.4	Dermatophytosis of foot	Female	2,456	2,120	2,786	2,606
		Male	3,914	3,388	5,138	4,824
		Unknown	0	0	0	0
110.5	Dermatophytosis of the body	Female	6,791	6,093	10,860	10,462
		Male	9,294	8,458	15,376	14,837
		Unknown	2	2	1	1
110.6	Deep seated dermatophytosis	Female	63	56	76	75
		Male	100	94	116	114
		Unknown	0	0	0	0
110.8	Dermatophytosis of other specified sites	Female	332	301	416	397
		Male	397	376	590	574
		Unknown	0	0	0	0
110.9	Dermatophytosis of unspecified site	Female	2,059	1,941	3,218	3,130
		Male	3,339	3,161	5,219	5,100
		Unknown	0	0	0	0
111	Dermatomycosis, other and unspecified	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
111.0	Pityriasis versicolor	Female	337	327	504	494
		Male	551	523	789	780
		Unknown	0	0	0	0
111.1	Tinea nigra	Female	15	15	42	41
		Male	38	36	72	70
		Unknown	0	0	0	0
111.2	Tinea blanca	Female	52	50	75	70
		Male	65	62	113	113
		Unknown	0	0	0	0
111.3	Black piedra	Female	0	0	2	2
		Male	1	1	0	0
		Unknown	0	0	0	0
111.8	Other specified dermatomycoses	Female	16	16	27	25
		Male	29	25	34	32
		Unknown	0	0	0	0

**Table 2d\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
111.9	Unspecified dermatomycosis	Female	231	204	287	275
		Male	327	310	430	419
		Unknown	0	0	0	0
112	Candidiasis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
112.0	Candidiasis of mouth	Female	108	76	67	60
		Male	88	77	64	58
		Unknown	0	0	0	0
112.1	Candidiasis of vulva and vagina	Female	244	223	153	143
		Male	3	3	2	2
		Unknown	0	0	0	0
112.2	Candidiasis of other urogenital sites	Female	36	34	13	13
		Male	62	57	45	44
		Unknown	0	0	0	0
112.3	Candidiasis of skin and nails	Female	212	194	191	183
		Male	230	214	208	190
		Unknown	0	0	0	0
112.4	Candidiasis of lung	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
112.5	Disseminated candidiasis	Female	1	1	2	2
		Male	0	0	2	2
		Unknown	0	0	0	0
112.8	Candidiasis of other specified sites	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.81	Candidal endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.82	Candidal otitis externa	Female	4	4	5	5
		Male	3	2	1	1
		Unknown	0	0	0	0
112.83	Candidal meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.84	Candidiasis of the esophagus	Female	3	3	1	1
		Male	3	3	1	1
		Unknown	0	0	0	0
112.85	Candidiasis of the intestine	Female	1	1	0	0
		Male	10	3	2	2
		Unknown	0	0	0	0
112.89	Other candidiasis of other specified sites	Female	28	28	20	20
		Male	26	21	13	13
		Unknown	0	0	0	0
112.9	Candidiasis of unspecified site	Female	90	83	86	84
		Male	119	112	88	85
		Unknown	0	0	0	0
114	Coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	Female	0	0	1	1
		Male	1	1	0	0
		Unknown	0	0	0	0

**Table 2d\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.1	Primary extrapulmonary coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.2	Coccidioidal meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.3	Other forms of progressive coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.9	Unspecified coccidioidomycosis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
115	Histoplasmosis	Female	0	0	0	0
		Male	0	0	1	1
		Unknown	0	0	0	0
115.0	Histoplasma capsulatum	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.01	Histoplasma capsulatum meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.02	Histoplasma capsulatum retinitis	Female	0	0	1	1
		Male	1	1	0	0
		Unknown	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.1	Histoplasma duboisii	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.11	Histoplasma duboisii meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.12	Histoplasma duboisii retinitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2d\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.13	Histoplasma duboisii pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.14	Histoplasma duboisii endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.15	Histoplasma duboisii pneumonia	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.9	Unspecified Histoplasmosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	Female	2	2	0	0
		Male	2	1	0	0
		Unknown	0	0	0	0
115.93	Unspecified Histoplasmosis pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	Female	2	2	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
116	Blastomycotic infection	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
116.0	Blastomycosis	Female	1	1	0	0
		Male	1	1	1	1
		Unknown	0	0	0	0
116.1	Paracoccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
116.2	Lobomycosis	Female	0	0	0	0
		Male	0	0	1	1
		Unknown	0	0	0	0
117	Other mycoses	Female	0	0	0	0
		Male	2	1	0	0
		Unknown	0	0	0	0
117.0	Rhinosporidiosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.1	Sporotrichosis	Female	0	0	5	5
		Male	2	2	1	1
		Unknown	0	0	0	0
117.2	Chromoblastomycosis	Female	0	0	1	1
		Male	1	1	0	0
		Unknown	0	0	0	0
117.3	Aspergillosis	Female	0	0	0	0
		Male	1	1	1	1
		Unknown	0	0	0	0
117.4	Mycotic mycetomas	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2d\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.5	Cryptococcosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.6	Allescheriosis (Petriellidiosis)	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	Female	14	14	17	17
		Male	13	12	23	22
		Unknown	0	0	0	0
117.9	Other and unspecified mycoses	Female	96	92	145	141
		Male	168	157	195	189
		Unknown	0	0	0	0
118	Opportunistic mycoses	Female	13	1	2	1
		Male	1	1	1	1
		Unknown	0	0	0	0
185	Malignant neoplasm of prostate	Female	0	0	0	0
		Male	379	160	119	82
		Unknown	0	0	0	0
233.4	Carcinoma in situ of prostate	Female	0	0	0	0
		Male	7	7	3	3
		Unknown	0	0	0	0
255.0	Cushing's syndrome	Female	5	3	1	1
		Male	3	2	2	2
		Unknown	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	Female	0	0	0	0
		Male	60	52	31	21
		Unknown	0	0	0	0

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2d\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Griseofulvin Users</i>		-	N/A	204,729	N/A	204,729
-	Diagnosis outside of pre-determined list	0-17	224,567	70,398	127,348	57,970
		18-64	187,760	33,559	97,033	29,441
		65+	47,073	4,945	20,145	4,069
110	Dermatophytosis	0-17	9	9	6	6
		18-64	2	2	1	1
		65+	3	2	1	1
110.0	Dermatophytosis of scalp and beard	0-17	24,137	22,658	60,535	57,572
		18-64	2,197	2,037	3,918	3,756
		65+	173	153	229	218
110.1	Dermatophytosis of nail	0-17	1,746	1,588	2,180	2,129
		18-64	4,097	3,539	3,480	3,313
		65+	659	590	502	471
110.2	Dermatophytosis of hand	0-17	86	79	129	123
		18-64	213	204	344	335
		65+	40	37	49	46
110.3	Dermatophytosis of groin and perianal area	0-17	343	322	581	571
		18-64	1,627	1,466	2,746	2,622
		65+	284	246	453	430
110.4	Dermatophytosis of foot	0-17	993	904	1,461	1,406
		18-64	4,738	4,089	5,752	5,371
		65+	639	515	711	653
110.5	Dermatophytosis of the body	0-17	10,549	9,617	17,071	16,564
		18-64	4,912	4,394	8,172	7,796
		65+	626	542	994	940
110.6	Deep seated dermatophytosis	0-17	64	56	123	122
		18-64	84	80	52	50
		65+	15	14	17	17
110.8	Dermatophytosis of other specified sites	0-17	422	391	675	654
		18-64	272	252	285	273
		65+	35	34	46	44
110.9	Dermatophytosis of unspecified site	0-17	3,903	3,717	6,372	6,220
		18-64	1,321	1,230	1,852	1,808
		65+	174	155	213	202
111	Dermatomycosis, other and unspecified	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
111.0	Pityriasis versicolor	0-17	402	385	605	600
		18-64	460	442	664	650
		65+	26	23	24	24
111.1	Tinea nigra	0-17	37	35	78	76
		18-64	15	15	35	34
		65+	1	1	1	1
111.2	Tinea blanca	0-17	74	70	123	122
		18-64	41	40	62	59
		65+	2	2	3	2
111.3	Black piedra	0-17	0	0	1	1
		18-64	0	0	1	1
		65+	1	1	0	0
111.8	Other specified dermatomycoses	0-17	30	27	34	31
		18-64	14	13	25	24
		65+	1	1	2	2
111.9	Unspecified dermatomycosis	0-17	263	258	365	357
		18-64	247	213	311	299
		65+	48	43	41	38



**Table 2d\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	0-17	1	1	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.0	Candidiasis of mouth	0-17	99	88	60	56
		18-64	74	52	57	48
		65+	23	13	14	14
112.1	Candidiasis of vulva and vagina	0-17	39	38	43	41
		18-64	187	171	104	96
		65+	21	17	8	8
112.2	Candidiasis of other urogenital sites	0-17	51	48	27	27
		18-64	37	34	25	24
		65+	10	9	6	6
112.3	Candidiasis of skin and nails	0-17	184	173	159	152
		18-64	228	208	208	192
		65+	30	27	32	29
112.4	Candidiasis of lung	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
112.5	Disseminated candidiasis	0-17	0	0	0	0
		18-64	1	1	3	3
		65+	0	0	1	1
112.8	Candidiasis of other specified sites	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.81	Candidal endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.82	Candidal otitis externa	0-17	1	1	4	4
		18-64	6	5	2	2
		65+	0	0	0	0
112.83	Candidal meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.84	Candidiasis of the esophagus	0-17	2	2	0	0
		18-64	3	3	2	2
		65+	1	1	0	0
112.85	Candidiasis of the intestine	0-17	1	1	0	0
		18-64	9	2	2	2
		65+	1	1	0	0
112.89	Other candidiasis of other specified sites	0-17	18	17	11	11
		18-64	27	27	19	19
		65+	9	5	3	3
112.9	Candidiasis of unspecified site	0-17	76	75	61	59
		18-64	104	98	87	85
		65+	29	22	26	25
114	Coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
114.1	Primary extrapulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.2	Coccidioidal meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2d\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.9	Unspecified coccidioidomycosis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115	Histoplasmosis	0-17	0	0	1	1
		18-64	0	0	0	0
		65+	0	0	0	0
115.0	Histoplasma capsulatum	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.01	Histoplasma capsulatum meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.02	Histoplasma capsulatum retinitis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.1	Histoplasma duboisii	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.11	Histoplasma duboisii meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.12	Histoplasma duboisii retinitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.13	Histoplasma duboisii pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.14	Histoplasma duboisii endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2d\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.9	Unspecified Histoplasmosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	0-17	0	0	0	0
		18-64	3	2	0	0
		65+	1	1	0	0
115.93	Unspecified Histoplasmosis pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0-17	1	1	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
116	Blastomycotic infection	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
116.0	Blastomycosis	0-17	1	1	1	1
		18-64	1	1	0	0
		65+	0	0	0	0
116.1	Paracoccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
116.2	Lobomycosis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
117	Other mycoses	0-17	0	0	0	0
		18-64	2	1	0	0
		65+	0	0	0	0
117.0	Rhinosporidiosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117.1	Sporotrichosis	0-17	1	1	1	1
		18-64	1	1	4	4
		65+	0	0	1	1
117.2	Chromoblastomycosis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	1	1
117.3	Aspergillosis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
117.4	Mycotic mycetomas	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
117.5	Cryptococcosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117.6	Allescheriosis (Petriellidiosis)	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2d\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Griseofulvin Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	0-17	15	15	23	23
		18-64	10	9	14	13
		65+	2	2	3	3
117.9	Other and unspecified mycoses	0-17	122	113	168	165
		18-64	120	115	156	149
		65+	22	21	16	16
118	Opportunistic mycoses	0-17	1	1	0	0
		18-64	13	1	3	2
		65+	0	0	0	0
185	Malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	111	58	30	20
		65+	268	102	89	62
233.4	Carcinoma in situ of prostate	0-17	0	0	0	0
		18-64	2	2	1	1
		65+	5	5	2	2
255.0	Cushing's syndrome	0-17	3	2	0	0
		18-64	5	3	3	3
		65+	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	14	12	16	7
		65+	46	40	15	14

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2e. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Itraconazole Use			0 to 14 Days Post Prevalent Itraconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Itraconazole Users</i>		<i>N/A</i>	<i>54,465</i>	<i>100%</i>	<i>N/A</i>	<i>54,465</i>	<i>100%</i>
-	Diagnosis outside of pre-determined list	467,512	41,679	76.52%	151,176	28,882	53.03%
110	Dermatophytosis	2	2	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	778	666	1.22%	438	410	0.75%
110.1	Dermatophytosis of nail	12,544	10,313	18.94%	4,776	4,553	8.36%
110.2	Dermatophytosis of hand	158	147	0.27%	78	77	0.14%
110.3	Dermatophytosis of groin and perianal area	539	461	0.85%	437	407	0.75%
110.4	Dermatophytosis of foot	2,244	1,891	3.47%	1,195	1,115	2.05%
110.5	Dermatophytosis of the body	1,903	1,660	3.05%	1,439	1,345	2.47%
110.6	Deep seated dermatophytosis	77	67	0.12%	42	41	0.08%
110.8	Dermatophytosis of other specified sites	147	132	0.24%	69	65	0.12%
110.9	Dermatophytosis of unspecified site	744	666	1.22%	372	354	0.65%
111	Dermatomycosis, other and unspecified	1	1	0.00%	1	1	0.00%
111.0	Pityriasis versicolor	2,433	2,323	4.27%	2,165	2,124	3.90%
111.1	Tinea nigra	14	11	0.02%	14	14	0.03%
111.2	Tinea blanca	20	20	0.04%	18	18	0.03%
111.3	Black piedra	1	1	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	63	41	0.08%	44	34	0.06%
111.9	Unspecified dermatomycosis	228	188	0.35%	141	127	0.23%
112	Candidiasis	1	1	0.00%	1	1	0.00%
112.0	Candidiasis of mouth	1,047	718	1.32%	357	308	0.57%
112.1	Candidiasis of vulva and vagina	622	475	0.87%	298	274	0.50%
112.2	Candidiasis of other urogenital sites	53	45	0.08%	44	39	0.07%
112.3	Candidiasis of skin and nails	477	421	0.77%	274	232	0.43%
112.4	Candidiasis of lung	185	138	0.25%	20	15	0.03%
112.5	Disseminated candidiasis	106	65	0.12%	38	26	0.05%
112.8	Candidiasis of other specified sites	1	1	0.00%	1	1	0.00%
112.81	Candidal endocarditis	14	3	0.01%	6	2	0.00%
112.82	Candidal otitis externa	17	15	0.03%	7	6	0.01%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	200	135	0.25%	64	48	0.09%
112.85	Candidiasis of the intestine	79	55	0.10%	25	23	0.04%
112.89	Other candidiasis of other specified sites	123	102	0.19%	44	39	0.07%
112.9	Candidiasis of unspecified site	479	321	0.59%	188	174	0.32%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	277	141	0.26%	83	62	0.11%
114.1	Primary extrapulmonary coccidioidomycosis	24	14	0.03%	18	6	0.01%
114.2	Coccidioidal meningitis	19	10	0.02%	21	8	0.01%
114.3	Other forms of progressive coccidioidomycosis	183	86	0.16%	71	48	0.09%
114.4	Chronic pulmonary coccidioidomycosis	27	23	0.04%	26	11	0.02%
114.5	Unspecified pulmonary coccidioidomycosis	103	60	0.11%	56	39	0.07%
114.9	Unspecified coccidioidomycosis	324	152	0.28%	87	69	0.13%
115.0	Histoplasma capsulatum	0	0	0.00%	3	2	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	240	168	0.31%	147	108	0.20%
115	Histoplasmosis	1	1	0.00%	3	3	0.01%
115.01	Histoplasma capsulatum meningitis	30	5	0.01%	13	8	0.01%
115.02	Histoplasma capsulatum retinitis	2	2	0.00%	6	6	0.01%
115.03	Histoplasma capsulatum pericarditis	1	1	0.00%	4	4	0.01%
115.04	Histoplasma capsulatum endocarditis	20	4	0.01%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	656	445	0.82%	285	213	0.39%
115.09	Histoplasma capsulatum, with mention of other manifestation	93	62	0.11%	33	28	0.05%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%

**Table 2e. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Itraconazole Use			0 to 14 Days Post Prevalent Itraconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
115.10	Histoplasma duboisii without mention of manifestation	3	3	0.01%	1	1	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	1	1	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	4	4	0.01%	2	2	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	3	2	0.00%	2	1	0.00%
115.9	Unspecified Histoplasmosis	1	1	0.00%	2	2	0.00%
115.91	Unspecified Histoplasmosis meningitis	47	17	0.03%	8	7	0.01%
115.92	Unspecified Histoplasmosis retinitis	13	12	0.02%	7	7	0.01%
115.93	Unspecified Histoplasmosis pericarditis	11	11	0.02%	6	4	0.01%
115.94	Unspecified Histoplasmosis endocarditis	31	4	0.01%	7	1	0.00%
115.95	Unspecified Histoplasmosis pneumonia	356	188	0.35%	140	101	0.19%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	2,421	1,169	2.15%	1,293	818	1.50%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	946	431	0.79%	531	317	0.58%
116.1	Paracoccidioidomycosis	2	2	0.00%	5	2	0.00%
116.2	Lobomycosis	1	1	0.00%	2	2	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	5	5	0.01%	1	1	0.00%
117.1	Sporotrichosis	313	264	0.48%	464	366	0.67%
117.2	Chromoblastomycosis	34	28	0.05%	15	12	0.02%
117.3	Aspergillosis	1,298	759	1.39%	562	434	0.80%
117.4	Mycotic mycetomas	40	24	0.04%	11	8	0.01%
117.5	Cryptococcosis	68	38	0.07%	27	18	0.03%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	7	6	0.01%	5	4	0.01%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	55	41	0.08%	20	18	0.03%
117.9	Other and unspecified mycoses	1,582	962	1.77%	668	508	0.93%
118	Opportunistic mycoses	63	20	0.04%	13	9	0.02%
185	Malignant neoplasm of prostate	375	156	0.29%	117	69	0.13%
233.4	Carcinoma in situ of prostate	7	6	0.01%	4	4	0.01%
255.0	Cushing's syndrome	43	28	0.05%	7	7	0.01%
V10.46	Personal history of malignant neoplasm of prostate	114	75	0.14%	20	18	0.03%

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.



Table 2e\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Year

DX Code	Diagnosis Description	2011						2012					
		45 Days to 1 Day Prior to Prevalent Itraconazole Use			0 to 14 Days Post Prevalent Itraconazole Use*			45 Days to 1 Day Prior to Prevalent Itraconazole Use			0 to 14 Days Post Prevalent Itraconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users	Codes	Users	% of Users	Codes	Users	% of Users
Total Number of Prevalent Itraconazole Users		N/A	7,255		N/A	7,255		N/A	7,331		N/A	7,331	
-	Diagnosis outside of pre-determined list	64,209	5,680	78.29%	19,663	3,911	53.91%	66,247	5,696	77.70%	21,323	3,912	53.36%
110	Dermatophytosis	1	1	0.01%	0	0	0.00%	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	92	78	1.08%	44	40	0.55%	113	96	1.31%	55	54	0.74%
110.1	Dermatophytosis of nail	1,748	1,429	19.70%	694	663	9.14%	1,625	1,331	18.16%	645	611	8.33%
110.2	Dermatophytosis of hand	16	14	0.19%	8	8	0.11%	27	26	0.35%	15	14	0.19%
110.3	Dermatophytosis of groin and perianal area	61	51	0.70%	53	51	0.70%	85	75	1.02%	56	53	0.72%
110.4	Dermatophytosis of foot	322	270	3.72%	167	151	2.08%	315	261	3.56%	156	149	2.03%
110.5	Dermatophytosis of the body	221	194	2.67%	185	175	2.41%	278	247	3.37%	197	181	2.47%
110.6	Deep seated dermatophytosis	5	5	0.07%	4	4	0.06%	10	10	0.14%	1	1	0.01%
110.8	Dermatophytosis of other specified sites	28	23	0.32%	6	6	0.08%	17	17	0.23%	8	8	0.11%
110.9	Dermatophytosis of unspecified site	102	94	1.30%	48	45	0.62%	106	93	1.27%	55	53	0.72%
111	Dermatophytosis, other and unspecified	0	0	0.00%	1	1	0.01%	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	269	258	3.56%	248	243	3.35%	339	321	4.38%	289	281	3.83%
111.1	Tinea nigra	2	2	0.03%	4	4	0.06%	0	0	0.00%	0	0	0.00%
111.2	Tinea blanca	2	2	0.03%	3	3	0.04%	4	4	0.05%	1	1	0.01%
111.3	Black piedra	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	5	4	0.06%	2	2	0.03%	12	8	0.11%	16	11	0.15%
111.9	Unspecified dermatomycosis	43	36	0.50%	23	20	0.28%	48	31	0.42%	22	19	0.26%
112	Candidiasis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.0	Candidiasis of mouth	166	101	1.39%	43	41	0.57%	128	88	1.20%	51	43	0.59%
112.1	Candidiasis of vulva and vagina	86	67	0.92%	33	31	0.43%	93	72	0.98%	59	54	0.74%
112.2	Candidiasis of other urogenital sites	7	6	0.08%	3	3	0.04%	7	7	0.10%	5	4	0.05%
112.3	Candidiasis of skin and nails	64	56	0.77%	31	27	0.37%	70	63	0.86%	33	29	0.40%
112.4	Candidiasis of lung	28	26	0.36%	2	2	0.03%	16	15	0.20%	3	2	0.03%
112.5	Disseminated candidiasis	26	9	0.12%	17	7	0.10%	10	7	0.10%	4	4	0.05%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	2	2	0.03%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	0	0	0.00%	1	1	0.01%	3	2	0.03%	2	2	0.03%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	39	19	0.26%	6	5	0.07%	23	16	0.22%	8	7	0.10%
112.85	Candidiasis of the intestine	18	12	0.17%	5	4	0.06%	11	9	0.12%	3	3	0.04%
112.89	Other candidiasis of other specified sites	18	13	0.18%	9	8	0.11%	30	20	0.27%	6	5	0.07%
112.9	Candidiasis of unspecified site	45	40	0.55%	24	23	0.32%	70	52	0.71%	29	22	0.30%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	40	20	0.28%	14	13	0.18%	79	32	0.44%	15	12	0.16%
114.1	Primary extrapulmonary coccidioidomycosis	3	3	0.04%	0	0	0.00%	2	1	0.01%	2	1	0.01%
114.2	Coccidioidal meningitis	3	1	0.01%	10	2	0.03%	5	3	0.04%	5	1	0.01%
114.3	Other forms of progressive coccidioidomycosis	25	11	0.15%	7	7	0.10%	48	19	0.26%	12	6	0.08%
114.4	Chronic pulmonary coccidioidomycosis	4	4	0.06%	2	2	0.03%	3	3	0.04%	3	2	0.03%
114.5	Unspecified pulmonary coccidioidomycosis	14	8	0.11%	3	3	0.04%	17	9	0.12%	5	5	0.07%
114.9	Unspecified coccidioidomycosis	28	19	0.26%	14	12	0.17%	43	25	0.34%	16	15	0.20%
115	Histoplasmosis	0	0	0.00%	2	2	0.03%	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	2	1	0.01%	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	28	26	0.36%	27	19	0.26%	38	26	0.35%	25	16	0.22%
115.01	Histoplasma capsulatum meningitis	5	1	0.01%	5	1	0.01%	22	2	0.03%	3	2	0.03%
115.02	Histoplasma capsulatum retinitis	1	1	0.01%	0	0	0.00%	1	1	0.01%	2	2	0.03%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	1	1	0.01%	1	1	0.01%	2	2	0.03%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	124	73	1.01%	48	36	0.50%	103	70	0.95%	53	31	0.42%
115.09	Histoplasma capsulatum, with mention of other manifestation	15	12	0.17%	6	4	0.06%	12	10	0.14%	6	4	0.05%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	1	1	0.01%	0	0	0.00%	1	1	0.01%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	1	1	0.01%	0	0	0.00%	1	1	0.01%
115.91	Unspecified Histoplasmosis meningitis	3	3	0.04%	1	1	0.01%	7	4	0.05%	1	1	0.01%
115.92	Unspecified Histoplasmosis retinitis	2	2	0.03%	1	1	0.01%	1	1	0.01%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	3	3	0.04%	2	1	0.01%	4	4	0.05%	2	1	0.01%
115.94	Unspecified Histoplasmosis endocarditis	1	1	0.01%	0	0	0.00%	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	83	31	0.43%	25	19	0.26%	48	33	0.45%	26	18	0.25%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	340	165	2.27%	200	122	1.68%	416	207	2.82%	212	141	1.92%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	119	58	0.80%	67	45	0.62%	103	58	0.79%	85	43	0.59%
116.1	Paracoccidioidomycosis	0	0	0.00%	2	1	0.01%	0	0	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	4	4	0.06%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	47	41	0.57%	49	41	0.57%	58	51	0.70%	99	71	0.97%
117.2	Chromoblastomycosis	5	5	0.07%	1	1	0.01%	4	2	0.03%	1	1	0.01%
117.3	Aspergilliosis	216	102	1.41%	95	73	1.01%	194	105	1.43%	71	61	0.83%
117.4	Mycotic mycetomas	1	1	0.01%	1	1	0.01%	4	3	0.04%	3	2	0.03%
117.5	Cryptococcosis	7	5	0.07%	0	0	0.00%	6	4	0.05%	0	0	0.00%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	1	1	0.01%	0	0	0.00%	1	1	0.01%	2	1	0.01%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	7	6	0.08%	2	2	0.03%	15	11	0.15%	7	6	0.08%
117.9	Other and unspecified mycoses	252	145	2.00%	85	64	0.88%	192	145	1.98%	75	61	0.83%
118	Opportunistic mycoses	4	3	0.04%	2	1	0.01%	2	2	0.03%	4	3	0.04%
185	Malignant neoplasm of prostate	41	26	0.36%	12	8	0.11%	25	13	0.18%	4	3	0.04%
233.4	Carcinoma in situ of prostate	4	3	0.04%	1	1	0.01%	1	1	0.01%	1	1	0.01%
255.0	Cushing's syndrome	7	5	0.07%	1	1	0.01%	2	2	0.03%	3	3	0.04%
V10.46	Personal history of malignant neoplasm of prostate	14	12	0.17%	0	0	0.00%	9	9	0.12%	0	0	0.00%





Table 2e\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Year

		2015					
DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Itraconazole Use			0 to 14 Days Post Prevalent Itraconazole Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Itraconazole Users</i>		<i>N/A</i>	<i>4,997</i>		<i>N/A</i>	<i>4,997</i>	
-	Diagnosis outside of pre-determined list	47,125	3,770	75.45%	14,905	2,672	53.47%
110	Dermatophytosis	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	63	57	1.14%	41	38	0.76%
110.1	Dermatophytosis of nail	1,125	930	18.61%	418	400	8.00%
110.2	Dermatophytosis of hand	19	18	0.36%	11	11	0.22%
110.3	Dermatophytosis of groin and perianal area	51	44	0.88%	32	30	0.60%
110.4	Dermatophytosis of foot	221	190	3.80%	114	99	1.98%
110.5	Dermatophytosis of the body	175	150	3.00%	149	140	2.80%
110.6	Deep seated dermatophytosis	6	6	0.12%	5	5	0.10%
110.8	Dermatophytosis of other specified sites	17	15	0.30%	6	6	0.12%
110.9	Dermatophytosis of unspecified site	64	55	1.10%	36	31	0.62%
111	Dermatomycosis, other and unspecified	0	0	0.00%	0	0	0.00%
111.0	Pityriasis versicolor	317	302	6.04%	327	322	6.44%
111.1	Tinea nigra	0	0	0.00%	2	2	0.04%
111.2	Tinea blanca	2	2	0.04%	3	3	0.06%
111.3	Black piedra	0	0	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	5	4	0.08%	2	1	0.02%
111.9	Unspecified dermatomycosis	18	13	0.26%	18	14	0.28%
112	Candidiasis	0	0	0.00%	0	0	0.00%
112.0	Candidiasis of mouth	96	67	1.34%	28	25	0.50%
112.1	Candidiasis of vulva and vagina	61	47	0.94%	35	27	0.54%
112.2	Candidiasis of other urogenital sites	3	3	0.06%	7	5	0.10%
112.3	Candidiasis of skin and nails	40	40	0.80%	20	17	0.34%
112.4	Candidiasis of lung	16	15	0.30%	5	4	0.08%
112.5	Disseminated candidiasis	2	1	0.02%	1	1	0.02%
112.8	Candidiasis of other specified sites	1	1	0.02%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	2	2	0.04%	0	0	0.00%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	8	5	0.10%	10	7	0.14%
112.85	Candidiasis of the intestine	10	6	0.12%	3	2	0.04%
112.89	Other candidiasis of other specified sites	10	10	0.20%	3	3	0.06%
112.9	Candidiasis of unspecified site	34	25	0.50%	20	19	0.38%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	7	7	0.14%	4	4	0.08%
114.1	Primary extrapulmonary coccidioidomycosis	5	2	0.04%	2	2	0.04%
114.2	Coccidioidal meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	5	4	0.08%	1	1	0.02%
114.4	Chronic pulmonary coccidioidomycosis	1	1	0.02%	2	1	0.02%
114.5	Unspecified pulmonary coccidioidomycosis	14	8	0.16%	6	4	0.08%
114.9	Unspecified coccidioidomycosis	20	12	0.24%	8	5	0.10%
115	Histoplasmosis	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	31	17	0.34%	9	8	0.16%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	1	1	0.02%
115.02	Histoplasma capsulatum retinitis	0	0	0.00%	1	1	0.02%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	83	46	0.92%	45	26	0.52%
115.09	Histoplasma capsulatum, with mention of other manifestation	4	4	0.08%	4	4	0.08%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	1	1	0.02%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	27	1	0.02%	2	1	0.02%
115.92	Unspecified Histoplasmosis retinitis	1	1	0.02%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	2	2	0.04%	1	1	0.02%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	38	14	0.28%	13	9	0.18%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	292	93	1.86%	123	74	1.48%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	96	39	0.78%	62	31	0.62%
116.1	Paracoccidioidomycosis	0	0	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	29	25	0.50%	61	52	1.04%
117.2	Chromoblastomycosis	6	5	0.10%	2	2	0.04%
117.3	Aspergillosis	111	71	1.42%	57	46	0.92%
117.4	Mycotic mycetomas	3	2	0.04%	3	2	0.04%
117.5	Cryptococcosis	5	4	0.08%	2	2	0.04%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	1	1	0.02%	0	0	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	2	2	0.04%	2	2	0.04%
117.9	Other and unspecified mycoses	132	96	1.92%	60	49	0.98%
118	Opportunistic mycoses	2	2	0.04%	0	0	0.00%
185	Malignant neoplasm of prostate	18	11	0.22%	18	10	0.20%
233.4	Carcinoma in situ of prostate	0	0	0.00%	0	0	0.00%
255.0	Cushing's syndrome	2	1	0.02%	0	0	0.00%
V10.46	Personal history of malignant neoplasm of prostate	10	7	0.14%	1	1	0.02%

**Table 2e\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Itraconazole Users</i>		-	<i>N/A</i>	<i>54,465</i>	<i>N/A</i>	<i>54,465</i>
-	Diagnosis outside of pre-determined list	Female	242,037	21,571	77,975	14,938
		Male	225,438	20,103	73,180	13,940
		Unknown	37	5	21	4
110	Dermatophytosis	Female	1	1	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
110.0	Dermatophytosis of scalp and beard	Female	354	305	173	162
		Male	424	361	265	248
		Unknown	0	0	0	0
110.1	Dermatophytosis of nail	Female	6,822	5,530	2,499	2,373
		Male	5,720	4,781	2,277	2,180
		Unknown	2	2	0	0
110.2	Dermatophytosis of hand	Female	53	49	16	16
		Male	105	98	62	61
		Unknown	0	0	0	0
110.3	Dermatophytosis of groin and perianal area	Female	82	77	62	60
		Male	457	384	375	347
		Unknown	0	0	0	0
110.4	Dermatophytosis of foot	Female	823	707	416	391
		Male	1,421	1,184	779	724
		Unknown	0	0	0	0
110.5	Dermatophytosis of the body	Female	792	679	635	593
		Male	1,111	981	803	751
		Unknown	0	0	1	1
110.6	Deep seated dermatophytosis	Female	36	31	23	22
		Male	41	36	19	19
		Unknown	0	0	0	0
110.8	Dermatophytosis of other specified sites	Female	67	61	32	31
		Male	80	71	37	34
		Unknown	0	0	0	0
110.9	Dermatophytosis of unspecified site	Female	325	284	166	156
		Male	419	382	206	198
		Unknown	0	0	0	0
111	Dermatomycosis, other and unspecified	Female	0	0	0	0
		Male	1	1	1	1
		Unknown	0	0	0	0
111.0	Pityriasis versicolor	Female	931	892	800	781
		Male	1,502	1,431	1,365	1,343
		Unknown	0	0	0	0
111.1	Tinea nigra	Female	10	7	6	6
		Male	4	4	8	8
		Unknown	0	0	0	0
111.2	Tinea blanca	Female	8	8	6	6
		Male	12	12	12	12
		Unknown	0	0	0	0
111.3	Black piedra	Female	1	1	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
111.8	Other specified dermatomycoses	Female	35	26	23	18
		Male	28	15	21	16
		Unknown	0	0	0	0
111.9	Unspecified dermatomycosis	Female	103	80	66	60
		Male	125	108	75	67
		Unknown	0	0	0	0

**Table 2e\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
112.0	Candidiasis of mouth	Female	599	429	233	205
		Male	448	289	124	103
		Unknown	0	0	0	0
112.1	Candidiasis of vulva and vagina	Female	620	473	296	272
		Male	2	2	2	2
		Unknown	0	0	0	0
112.2	Candidiasis of other urogenital sites	Female	28	23	22	19
		Male	25	22	22	20
		Unknown	0	0	0	0
112.3	Candidiasis of skin and nails	Female	301	269	147	130
		Male	176	152	127	102
		Unknown	0	0	0	0
112.4	Candidiasis of lung	Female	90	63	15	10
		Male	95	75	5	5
		Unknown	0	0	0	0
112.5	Disseminated candidiasis	Female	78	48	32	20
		Male	28	17	6	6
		Unknown	0	0	0	0
112.8	Candidiasis of other specified sites	Female	1	1	1	1
		Male	0	0	0	0
		Unknown	0	0	0	0
112.81	Candidal endocarditis	Female	13	2	6	2
		Male	1	1	0	0
		Unknown	0	0	0	0
112.82	Candidal otitis externa	Female	10	8	7	6
		Male	7	7	0	0
		Unknown	0	0	0	0
112.83	Candidal meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.84	Candidiasis of the esophagus	Female	132	83	43	30
		Male	68	52	21	18
		Unknown	0	0	0	0
112.85	Candidiasis of the intestine	Female	48	31	17	16
		Male	31	24	8	7
		Unknown	0	0	0	0
112.89	Other candidiasis of other specified sites	Female	67	54	24	21
		Male	56	48	20	18
		Unknown	0	0	0	0
112.9	Candidiasis of unspecified site	Female	313	217	126	122
		Male	166	104	62	52
		Unknown	0	0	0	0
114	Coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	Female	131	68	36	32
		Male	146	73	47	30
		Unknown	0	0	0	0
114.1	Primary extrapulmonary coccidioidomycosis	Female	12	6	13	2
		Male	12	8	5	4
		Unknown	0	0	0	0
114.2	Coccidioidal meningitis	Female	6	5	5	3
		Male	13	5	16	5
		Unknown	0	0	0	0

**Table 2e\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	Female	73	28	24	15
		Male	110	58	47	33
		Unknown	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	Female	14	11	16	4
		Male	13	12	10	7
		Unknown	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	Female	46	31	20	16
		Male	57	29	36	23
		Unknown	0	0	0	0
114.9	Unspecified coccidioidomycosis	Female	124	62	30	28
		Male	200	90	57	41
		Unknown	0	0	0	0
115	Histoplasmosis	Female	1	1	2	2
		Male	0	0	1	1
		Unknown	0	0	0	0
115.0	Histoplasma capsulatum	Female	0	0	3	2
		Male	0	0	0	0
		Unknown	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	Female	86	73	59	43
		Male	154	95	88	65
		Unknown	0	0	0	0
115.01	Histoplasma capsulatum meningitis	Female	3	2	3	3
		Male	27	3	10	5
		Unknown	0	0	0	0
115.02	Histoplasma capsulatum retinitis	Female	2	2	3	3
		Male	0	0	3	3
		Unknown	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	Female	0	0	2	2
		Male	1	1	2	2
		Unknown	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	Female	18	2	0	0
		Male	2	2	0	0
		Unknown	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	Female	297	206	129	89
		Male	359	239	156	124
		Unknown	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	Female	34	29	14	14
		Male	59	33	19	14
		Unknown	0	0	0	0
115.1	Histoplasma duboisii	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	Female	1	1	0	0
		Male	2	2	1	1
		Unknown	0	0	0	0
115.11	Histoplasma duboisii meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.12	Histoplasma duboisii retinitis	Female	1	1	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.13	Histoplasma duboisii pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.14	Histoplasma duboisii endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2e\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	Female	2	2	1	1
		Male	2	2	1	1
		Unknown	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	Female	3	2	0	0
		Male	0	0	2	1
		Unknown	0	0	0	0
115.9	Unspecified Histoplasmosis	Female	0	0	0	0
		Male	1	1	2	2
		Unknown	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	Female	11	8	4	4
		Male	36	9	4	3
		Unknown	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	Female	7	6	5	5
		Male	6	6	2	2
		Unknown	0	0	0	0
115.93	Unspecified Histoplasmosis pericarditis	Female	5	5	4	2
		Male	6	6	2	2
		Unknown	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	Female	20	2	0	0
		Male	11	2	7	1
		Unknown	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	Female	118	81	59	42
		Male	238	107	81	59
		Unknown	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	Female	982	554	577	377
		Male	1,438	614	716	441
		Unknown	1	1	0	0
116	Blastomycotic infection	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
116.0	Blastomycosis	Female	359	156	188	107
		Male	586	274	343	210
		Unknown	1	1	0	0
116.1	Paracoccidioidomycosis	Female	2	2	3	1
		Male	0	0	2	1
		Unknown	0	0	0	0
116.2	Lobomycosis	Female	1	1	1	1
		Male	0	0	1	1
		Unknown	0	0	0	0
117	Other mycoses	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.0	Rhinosporidiosis	Female	4	4	0	0
		Male	1	1	1	1
		Unknown	0	0	0	0
117.1	Sporotrichosis	Female	187	163	269	219
		Male	126	101	195	147
		Unknown	0	0	0	0
117.2	Chromoblastomycosis	Female	6	6	1	1
		Male	28	22	14	11
		Unknown	0	0	0	0
117.3	Aspergillosis	Female	724	424	297	234
		Male	574	335	265	200
		Unknown	0	0	0	0
117.4	Mycotic mycetomas	Female	22	9	3	2
		Male	18	15	8	6
		Unknown	0	0	0	0
117.5	Cryptococcosis	Female	25	16	6	5
		Male	43	22	21	13
		Unknown	0	0	0	0
117.6	Allescheriosis (Petriellidiosis)	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2e\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	Female	2	2	2	1
		Male	5	4	3	3
		Unknown	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	Female	23	19	6	6
		Male	32	22	14	12
		Unknown	0	0	0	0
117.9	Other and unspecified mycoses	Female	812	509	356	269
		Male	770	453	312	239
		Unknown	0	0	0	0
118	Opportunistic mycoses	Female	50	9	10	7
		Male	13	11	3	2
		Unknown	0	0	0	0
185	Malignant neoplasm of prostate	Female	0	0	1	1
		Male	375	156	116	68
		Unknown	0	0	0	0
233.4	Carcinoma in situ of prostate	Female	0	0	0	0
		Male	7	6	4	4
		Unknown	0	0	0	0
255.0	Cushing's syndrome	Female	26	16	4	4
		Male	17	12	3	3
		Unknown	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	Female	0	0	0	0
		Male	114	75	20	18
		Unknown	0	0	0	0

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2e\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Itraconazole Users</i>		-	<i>N/A</i>	<i>54,465</i>	<i>N/A</i>	<i>54,465</i>
-	Diagnosis outside of pre-determined list	0-17	20,925	2,377	6,580	1,514
		18-64	346,014	33,889	113,168	23,301
		65+	100,573	5,413	31,428	4,067
110	Dermatophytosis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	1	1	0	0
110.0	Dermatophytosis of scalp and beard	0-17	325	248	148	137
		18-64	426	395	269	256
		65+	27	23	21	17
110.1	Dermatophytosis of nail	0-17	364	296	135	131
		18-64	10,746	8,840	4,071	3,887
		65+	1,434	1,177	570	535
110.2	Dermatophytosis of hand	0-17	1	1	3	3
		18-64	135	126	71	71
		65+	22	20	4	3
110.3	Dermatophytosis of groin and perianal area	0-17	19	17	10	9
		18-64	437	379	369	346
		65+	83	65	58	52
110.4	Dermatophytosis of foot	0-17	103	89	64	59
		18-64	1,946	1,641	1,018	955
		65+	195	161	113	101
110.5	Dermatophytosis of the body	0-17	237	198	179	171
		18-64	1,469	1,297	1,131	1,063
		65+	197	165	129	111
110.6	Deep seated dermatophytosis	0-17	12	9	5	4
		18-64	59	52	33	33
		65+	6	6	4	4
110.8	Dermatophytosis of other specified sites	0-17	17	15	8	5
		18-64	103	95	54	53
		65+	27	22	7	7
110.9	Dermatophytosis of unspecified site	0-17	98	86	43	41
		18-64	600	536	304	289
		65+	46	44	25	24
111	Dermatomycosis, other and unspecified	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
111.0	Pityriasis versicolor	0-17	178	166	148	145
		18-64	2,221	2,123	1,984	1,946
		65+	34	34	33	33
111.1	Tinea nigra	0-17	0	0	0	0
		18-64	14	11	12	12
		65+	0	0	2	2
111.2	Tinea blanca	0-17	3	3	2	2
		18-64	16	16	15	15
		65+	1	1	1	1
111.3	Black piedra	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
111.8	Other specified dermatomycoses	0-17	2	2	2	2
		18-64	50	30	33	25
		65+	11	9	9	7
111.9	Unspecified dermatomycosis	0-17	12	12	10	9
		18-64	184	150	110	98
		65+	32	26	21	20



**Table 2e\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
112.0	Candidiasis of mouth	0-17	52	26	10	8
		18-64	800	561	263	234
		65+	195	131	84	66
112.1	Candidiasis of vulva and vagina	0-17	6	6	2	2
		18-64	585	445	271	249
		65+	31	24	25	23
112.2	Candidiasis of other urogenital sites	0-17	2	2	1	1
		18-64	34	31	28	26
		65+	17	12	15	12
112.3	Candidiasis of skin and nails	0-17	18	16	12	2
		18-64	366	325	211	186
		65+	93	80	51	44
112.4	Candidiasis of lung	0-17	4	4	0	0
		18-64	99	92	10	7
		65+	82	42	10	8
112.5	Disseminated candidiasis	0-17	8	2	1	1
		18-64	93	58	34	22
		65+	5	5	3	3
112.8	Candidiasis of other specified sites	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	0	0
112.81	Candidal endocarditis	0-17	0	0	0	0
		18-64	2	2	1	1
		65+	12	1	5	1
112.82	Candidal otitis externa	0-17	1	1	0	0
		18-64	15	13	6	5
		65+	1	1	1	1
112.83	Candidal meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.84	Candidiasis of the esophagus	0-17	6	5	1	1
		18-64	151	102	49	34
		65+	43	28	14	13
112.85	Candidiasis of the intestine	0-17	25	20	7	6
		18-64	54	35	18	17
		65+	0	0	0	0
112.89	Other candidiasis of other specified sites	0-17	3	3	1	1
		18-64	88	75	36	32
		65+	32	24	7	6
112.9	Candidiasis of unspecified site	0-17	19	17	16	14
		18-64	412	266	149	138
		65+	48	38	23	22
114	Coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	0-17	31	8	5	3
		18-64	216	114	65	49
		65+	30	19	13	10
114.1	Primary extrapulmonary coccidioidomycosis	0-17	1	1	0	0
		18-64	16	8	18	6
		65+	7	5	0	0
114.2	Coccidioidal meningitis	0-17	1	1	2	1
		18-64	12	7	15	4
		65+	6	2	4	3

**Table 2e\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	0-17	17	7	11	5
		18-64	139	69	58	41
		65+	27	10	2	2
114.4	Chronic pulmonary coccidioidomycosis	0-17	1	1	0	0
		18-64	21	17	24	9
		65+	5	5	2	2
114.5	Unspecified pulmonary coccidioidomycosis	0-17	4	2	2	2
		18-64	86	48	48	31
		65+	13	10	6	6
114.9	Unspecified coccidioidomycosis	0-17	23	15	2	2
		18-64	259	113	71	54
		65+	42	24	14	13
115	Histoplasmosis	0-17	0	0	0	0
		18-64	1	1	2	2
		65+	0	0	1	1
115.0	Histoplasma capsulatum	0-17	0	0	0	0
		18-64	0	0	3	2
		65+	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	0-17	6	4	7	7
		18-64	203	138	114	88
		65+	31	26	26	13
115.01	Histoplasma capsulatum meningitis	0-17	0	0	0	0
		18-64	28	4	12	7
		65+	2	1	1	1
115.02	Histoplasma capsulatum retinitis	0-17	0	0	1	1
		18-64	1	1	4	4
		65+	1	1	1	1
115.03	Histoplasma capsulatum pericarditis	0-17	0	0	0	0
		18-64	1	1	4	4
		65+	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	0-17	0	0	0	0
		18-64	2	2	0	0
		65+	18	2	0	0
115.05	Histoplasma capsulatum pneumonia	0-17	32	29	9	9
		18-64	481	337	231	167
		65+	143	79	45	37
115.09	Histoplasma capsulatum, with mention of other manifestation	0-17	3	3	3	3
		18-64	81	50	27	22
		65+	9	9	3	3
115.1	Histoplasma duboisii	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	0-17	0	0	0	0
		18-64	3	3	1	1
		65+	0	0	0	0
115.11	Histoplasma duboisii meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.12	Histoplasma duboisii retinitis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.13	Histoplasma duboisii pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.14	Histoplasma duboisii endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2e\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	0-17	0	0	1	1
		18-64	3	3	1	1
		65+	1	1	0	0
115.19	Histoplasma duboisii with mention of other manifestation	0-17	0	0	0	0
		18-64	3	2	2	1
		65+	0	0	0	0
115.9	Unspecified Histoplasmosis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	0	0	1	1
115.91	Unspecified Histoplasmosis meningitis	0-17	0	0	0	0
		18-64	45	15	7	6
		65+	2	2	1	1
115.92	Unspecified Histoplasmosis retinitis	0-17	1	1	1	1
		18-64	11	10	5	5
		65+	1	1	1	1
115.93	Unspecified Histoplasmosis pericarditis	0-17	4	4	0	0
		18-64	7	7	4	3
		65+	0	0	2	1
115.94	Unspecified Histoplasmosis endocarditis	0-17	2	1	0	0
		18-64	11	2	7	1
		65+	18	1	0	0
115.95	Unspecified Histoplasmosis pneumonia	0-17	16	15	7	5
		18-64	278	144	103	74
		65+	62	29	30	22
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0-17	149	97	89	62
		18-64	1,921	924	1,000	645
		65+	351	148	204	111
116	Blastomycotic infection	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
116.0	Blastomycosis	0-17	41	17	16	11
		18-64	755	344	422	255
		65+	150	70	93	51
116.1	Paracoccidioidomycosis	0-17	1	1	0	0
		18-64	1	1	3	1
		65+	0	0	2	1
116.2	Lobomycosis	0-17	0	0	0	0
		18-64	1	1	2	2
		65+	0	0	0	0
117	Other mycoses	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117.0	Rhinosporidiosis	0-17	0	0	0	0
		18-64	3	3	0	0
		65+	2	2	1	1
117.1	Sporotrichosis	0-17	12	8	12	11
		18-64	236	203	342	271
		65+	65	53	110	84
117.2	Chromoblastomycosis	0-17	0	0	0	0
		18-64	20	18	7	5
		65+	14	10	8	7
117.3	Aspergillosis	0-17	51	39	27	21
		18-64	763	452	348	266
		65+	484	268	187	147
117.4	Mycotic mycetomas	0-17	1	1	0	0
		18-64	36	21	8	6
		65+	3	2	3	2
117.5	Cryptococcosis	0-17	2	1	1	1
		18-64	48	28	17	11
		65+	18	9	9	6
117.6	Allescheriosis (Petriellidiosis)	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2e\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Itraconazole Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0-17	2	1	2	2
		18-64	4	4	3	2
		65+	1	1	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	0-17	2	1	2	1
		18-64	34	29	13	12
		65+	19	11	5	5
117.9	Other and unspecified mycoses	0-17	88	45	37	28
		18-64	1,201	735	509	383
		65+	293	182	122	97
118	Opportunistic mycoses	0-17	1	1	1	1
		18-64	58	16	7	5
		65+	4	3	5	3
185	Malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	183	65	54	29
		65+	192	91	63	40
233.4	Carcinoma in situ of prostate	0-17	0	0	0	0
		18-64	1	1	2	2
		65+	6	5	2	2
255.0	Cushing's syndrome	0-17	6	4	0	0
		18-64	32	19	6	6
		65+	5	5	1	1
V10.46	Personal history of malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	42	24	6	6
		65+	72	51	14	12

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2f. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Terbinafine Use			0 to 14 Days Post Prevalent Terbinafine Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Terbinafine Users</i>		<i>N/A</i>	<i>773,190</i>	<i>100%</i>	<i>N/A</i>	<i>773,190</i>	<i>100%</i>
-	Diagnosis outside of pre-determined list	3,454,084	529,941	68.54%	1,758,481	455,848	58.96%
110	Dermatophytosis	14	14	0.00%	15	15	0.00%
110.0	Dermatophytosis of scalp and beard	8,589	7,539	0.98%	9,141	8,758	1.13%
110.1	Dermatophytosis of nail	250,495	204,449	26.44%	216,032	206,665	26.73%
110.2	Dermatophytosis of hand	2,052	1,905	0.25%	3,158	3,064	0.40%
110.3	Dermatophytosis of groin and perianal area	6,929	6,361	0.82%	15,071	14,472	1.87%
110.4	Dermatophytosis of foot	49,689	43,953	5.68%	56,281	53,518	6.92%
110.5	Dermatophytosis of the body	20,402	18,371	2.38%	39,167	37,657	4.87%
110.6	Deep seated dermatophytosis	775	706	0.09%	1,053	1,000	0.13%
110.8	Dermatophytosis of other specified sites	1,391	1,316	0.17%	1,702	1,652	0.21%
110.9	Dermatophytosis of unspecified site	8,825	8,119	1.05%	10,723	10,413	1.35%
111	Dermatormycosis, other and unspecified	7	7	0.00%	4	4	0.00%
111.0	Pityriasis versicolor	3,403	3,222	0.42%	5,065	4,968	0.64%
111.1	Tinea nigra	134	128	0.02%	152	147	0.02%
111.2	Tinea blanca	145	139	0.02%	290	285	0.04%
111.3	Black piedra	4	4	0.00%	4	4	0.00%
111.8	Other specified dermatomycoses	222	205	0.03%	203	195	0.03%
111.9	Unspecified dermatomycosis	1,656	1,535	0.20%	2,600	2,486	0.32%
112	Candidiasis	2	2	0.00%	5	3	0.00%
112.0	Candidiasis of mouth	845	688	0.09%	696	643	0.08%
112.1	Candidiasis of vulva and vagina	1,564	1,453	0.19%	1,019	984	0.13%
112.2	Candidiasis of other urogenital sites	274	255	0.03%	301	280	0.04%
112.3	Candidiasis of skin and nails	2,216	2,023	0.26%	2,215	2,112	0.27%
112.4	Candidiasis of lung	5	5	0.00%	4	4	0.00%
112.5	Disseminated candidiasis	44	39	0.01%	31	27	0.00%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	31	24	0.00%	29	27	0.00%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	78	63	0.01%	44	39	0.01%
112.85	Candidiasis of the intestine	36	32	0.00%	20	18	0.00%
112.89	Other candidiasis of other specified sites	194	177	0.02%	166	163	0.02%
112.9	Candidiasis of unspecified site	973	870	0.11%	862	807	0.10%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	21	17	0.00%	10	9	0.00%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	2	2	0.00%
114.2	Coccidioidal meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	4	3	0.00%	0	0	0.00%
114.4	Chronic pulmonary coccidioidomycosis	3	2	0.00%	0	0	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	0	0	0.00%	3	3	0.00%
114.9	Unspecified coccidioidomycosis	10	9	0.00%	10	9	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	1	1	0.00%	0	0	0.00%
115	Histoplasmosis	1	1	0.00%	0	0	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	17	14	0.00%	2	2	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	1	1	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	1	1	0.00%	1	1	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii without mention of manifestation	1	1	0.00%	0	0	0.00%

**Table 2f. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database**

DX Code	Diagnosis Description	45 Days to 1 Day Prior to Prevalent Terbinafine Use			0 to 14 Days Post Prevalent Terbinafine Use*		
		Codes	Users	% of Users	Codes	Users	% of Users
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	1	1	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	25	23	0.00%	9	7	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	0	0	0.00%	1	1	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	11	11	0.00%	9	9	0.00%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	3	3	0.00%	4	4	0.00%
116.1	Paracoccidioidomycosis	12	12	0.00%	11	11	0.00%
116.2	Lobomycosis	1	1	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	2	2	0.00%	2	2	0.00%
117.1	Sporotrichosis	51	28	0.00%	53	47	0.01%
117.2	Chromoblastomycosis	17	13	0.00%	3	3	0.00%
117.3	Aspergillosis	42	20	0.00%	43	19	0.00%
117.4	Mycotic mycetomas	83	79	0.01%	37	36	0.00%
117.5	Cryptococcosis	5	5	0.00%	4	4	0.00%
117.6	Allescheriosis (Petriellidiosis)	3	3	0.00%	1	1	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	8	8	0.00%	11	3	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	106	99	0.01%	100	94	0.01%
117.9	Other and unspecified mycoses	1,826	1,635	0.21%	1,900	1,799	0.23%
118	Opportunistic mycoses	25	24	0.00%	7	6	0.00%
185	Malignant neoplasm of prostate	5,150	2,519	0.33%	1,886	1,353	0.17%
233.4	Carcinoma in situ of prostate	83	72	0.01%	34	34	0.00%
255.0	Cushing's syndrome	79	53	0.01%	34	31	0.00%
V10.46	Personal history of malignant neoplasm of prostate	917	762	0.10%	465	410	0.05%

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.









Table 2f\_year. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Databases

		2015					
		45 Days to 1 Day Prior to Prevalent Terbinafine Use			0 to 14 Days Post Prevalent Terbinafine Use*		
Dx Code	Diagnosis Description	Codes	Users	% of Users	Codes	Users	% of Users
<i>Total Number of Prevalent Terbinafine Users</i>		<i>N/A</i>	<i>87,940</i>		<i>N/A</i>	<i>87,940</i>	
-	Diagnosis outside of pre-determined list	419,683	58,847	66.92%	235,330	55,437	63.04%
110	Dermatophytosis	0	0	0.00%	0	0	0.00%
110.0	Dermatophytosis of scalp and beard	745	647	0.74%	1,008	969	1.10%
110.1	Dermatophytosis of nail	25,464	20,927	23.80%	28,874	27,677	31.47%
110.2	Dermatophytosis of hand	171	159	0.18%	371	359	0.41%
110.3	Dermatophytosis of groin and perianal area	797	730	0.83%	1,838	1,760	2.00%
110.4	Dermatophytosis of foot	5,044	4,492	5.11%	7,097	6,801	7.73%
110.5	Dermatophytosis of the body	2,114	1,892	2.15%	4,840	4,639	5.28%
110.6	Deep seated dermatophytosis	69	59	0.07%	133	124	0.14%
110.8	Dermatophytosis of other specified sites	152	141	0.16%	232	228	0.26%
110.9	Dermatophytosis of unspecified site	813	744	0.85%	1,078	1,039	1.18%
111	Dermatomycosis, other and unspecified	2	2	0.00%	1	1	0.00%
111.0	Pityriasis versicolor	355	336	0.38%	665	654	0.74%
111.1	Tinea nigra	3	3	0.00%	17	17	0.02%
111.2	Tinea blanca	16	15	0.02%	37	37	0.04%
111.3	Black piedra	0	0	0.00%	0	0	0.00%
111.8	Other specified dermatomycoses	9	9	0.01%	10	10	0.01%
111.9	Unspecified dermatomycosis	147	137	0.16%	288	270	0.31%
112	Candidiasis	0	0	0.00%	0	0	0.00%
112.0	Candidiasis of mouth	114	88	0.10%	89	81	0.09%
112.1	Candidiasis of vulva and vagina	170	157	0.18%	119	112	0.13%
112.2	Candidiasis of other urogenital sites	41	38	0.04%	30	29	0.03%
112.3	Candidiasis of skin and nails	267	245	0.28%	310	301	0.34%
112.4	Candidiasis of lung	1	1	0.00%	0	0	0.00%
112.5	Disseminated candidiasis	1	1	0.00%	3	3	0.00%
112.8	Candidiasis of other specified sites	0	0	0.00%	0	0	0.00%
112.81	Candidal endocarditis	0	0	0.00%	0	0	0.00%
112.82	Candidal otitis externa	5	4	0.00%	5	5	0.01%
112.83	Candidal meningitis	0	0	0.00%	0	0	0.00%
112.84	Candidiasis of the esophagus	10	9	0.01%	6	4	0.00%
112.85	Candidiasis of the intestine	1	1	0.00%	1	1	0.00%
112.89	Other candidiasis of other specified sites	21	19	0.02%	16	16	0.02%
112.9	Candidiasis of unspecified site	119	115	0.13%	91	91	0.10%
114	Coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.0	Primary coccidioidomycosis (pulmonary)	3	2	0.00%	1	1	0.00%
114.1	Primary extrapulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.2	Coccidioidal meningitis	0	0	0.00%	0	0	0.00%
114.3	Other forms of progressive coccidioidomycosis	1	1	0.00%	0	0	0.00%
114.4	Chronic pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.5	Unspecified pulmonary coccidioidomycosis	0	0	0.00%	0	0	0.00%
114.9	Unspecified coccidioidomycosis	2	1	0.00%	2	2	0.00%
115	Histoplasmosis	0	0	0.00%	0	0	0.00%
115.0	Histoplasma capsulatum	0	0	0.00%	0	0	0.00%
115.00	Histoplasma capsulatum, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.01	Histoplasma capsulatum meningitis	0	0	0.00%	0	0	0.00%
115.02	Histoplasma capsulatum retinitis	1	1	0.00%	1	1	0.00%
115.03	Histoplasma capsulatum pericarditis	0	0	0.00%	0	0	0.00%
115.04	Histoplasma capsulatum endocarditis	0	0	0.00%	0	0	0.00%
115.05	Histoplasma capsulatum pneumonia	0	0	0.00%	1	1	0.00%
115.09	Histoplasma capsulatum, with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.1	Histoplasma duboisii	0	0	0.00%	0	0	0.00%
115.10	Histoplasma duboisii, without mention of manifestation	0	0	0.00%	0	0	0.00%
115.11	Histoplasma duboisii meningitis	0	0	0.00%	0	0	0.00%
115.12	Histoplasma duboisii retinitis	0	0	0.00%	0	0	0.00%
115.13	Histoplasma duboisii pericarditis	0	0	0.00%	0	0	0.00%
115.14	Histoplasma duboisii endocarditis	0	0	0.00%	0	0	0.00%
115.15	Histoplasma duboisii pneumonia	0	0	0.00%	0	0	0.00%
115.19	Histoplasma duboisii with mention of other manifestation	0	0	0.00%	0	0	0.00%
115.9	Unspecified Histoplasmosis	0	0	0.00%	0	0	0.00%
115.91	Unspecified Histoplasmosis meningitis	0	0	0.00%	0	0	0.00%
115.92	Unspecified Histoplasmosis retinitis	3	3	0.00%	0	0	0.00%
115.93	Unspecified Histoplasmosis pericarditis	0	0	0.00%	0	0	0.00%
115.94	Unspecified Histoplasmosis endocarditis	0	0	0.00%	0	0	0.00%
115.95	Unspecified Histoplasmosis pneumonia	0	0	0.00%	1	1	0.00%
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	1	1	0.00%	1	1	0.00%
116	Blastomycotic infection	0	0	0.00%	0	0	0.00%
116.0	Blastomycosis	0	0	0.00%	1	1	0.00%
116.1	Paracoccidioidomycosis	1	1	0.00%	0	0	0.00%
116.2	Lobomycosis	0	0	0.00%	0	0	0.00%
117	Other mycoses	0	0	0.00%	0	0	0.00%
117.0	Rhinosporidiosis	0	0	0.00%	0	0	0.00%
117.1	Sporotrichosis	4	4	0.00%	7	5	0.01%
117.2	Chromoblastomycosis	0	0	0.00%	0	0	0.00%
117.3	Aspergillosis	5	4	0.00%	15	4	0.00%
117.4	Mycotic mycetomas	6	6	0.01%	6	6	0.01%
117.5	Cryptococcosis	0	0	0.00%	0	0	0.00%
117.6	Allescheriosis (Petriellidiosis)	0	0	0.00%	0	0	0.00%
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	1	1	0.00%	0	0	0.00%
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	6	5	0.01%	7	7	0.01%
117.9	Other and unspecified mycoses	158	142	0.16%	233	216	0.25%
118	Opportunistic mycoses	1	1	0.00%	1	1	0.00%
185	Malignant neoplasm of prostate	749	323	0.37%	245	181	0.21%
233.4	Carcinoma in situ of prostate	6	5	0.01%	3	3	0.00%
255.0	Cushing's syndrome	7	6	0.01%	4	4	0.00%
V10.46	Personal history of malignant neoplasm of prostate	138	117	0.13%	64	58	0.07%

**Table 2f\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Terbinafine Users</i>		-	<i>N/A</i>	<i>773,190</i>	<i>N/A</i>	<i>773,190</i>
-	Diagnosis outside of pre-determined list	Female	1,745,409	259,570	843,499	214,070
		Male	1,708,574	270,349	914,872	241,748
		Unknown	101	22	110	30
110	Dermatophytosis	Female	6	6	9	9
		Male	8	8	6	6
		Unknown	0	0	0	0
110.0	Dermatophytosis of scalp and beard	Female	3,610	3,185	3,464	3,326
		Male	4,979	4,354	5,676	5,431
		Unknown	0	0	1	1
110.1	Dermatophytosis of nail	Female	129,102	104,490	106,455	101,753
		Male	121,387	99,954	109,561	104,898
		Unknown	6	5	16	14
110.2	Dermatophytosis of hand	Female	532	491	844	809
		Male	1,520	1,414	2,314	2,255
		Unknown	0	0	0	0
110.3	Dermatophytosis of groin and perianal area	Female	1,096	1,001	2,201	2,113
		Male	5,832	5,359	12,870	12,359
		Unknown	1	1	0	0
110.4	Dermatophytosis of foot	Female	20,131	17,886	20,966	19,983
		Male	29,555	26,065	35,311	33,531
		Unknown	3	2	4	4
110.5	Dermatophytosis of the body	Female	8,048	7,167	14,793	14,170
		Male	12,353	11,203	24,372	23,485
		Unknown	1	1	2	2
110.6	Deep seated dermatophytosis	Female	294	266	403	378
		Male	481	440	650	622
		Unknown	0	0	0	0
110.8	Dermatophytosis of other specified sites	Female	593	567	688	663
		Male	798	749	1,014	989
		Unknown	0	0	0	0
110.9	Dermatophytosis of unspecified site	Female	3,674	3,385	4,126	4,015
		Male	5,151	4,734	6,597	6,398
		Unknown	0	0	0	0
111	Dermatomycosis, other and unspecified	Female	4	4	2	2
		Male	3	3	2	2
		Unknown	0	0	0	0
111.0	Pityriasis versicolor	Female	1,191	1,121	1,726	1,692
		Male	2,212	2,101	3,339	3,276
		Unknown	0	0	0	0
111.1	Tinea nigra	Female	62	58	45	44
		Male	72	70	107	103
		Unknown	0	0	0	0
111.2	Tinea blanca	Female	61	59	104	103
		Male	84	80	186	182
		Unknown	0	0	0	0
111.3	Black piedra	Female	1	1	1	1
		Male	3	3	3	3
		Unknown	0	0	0	0
111.8	Other specified dermatomycoses	Female	95	90	87	82
		Male	127	115	116	113
		Unknown	0	0	0	0
111.9	Unspecified dermatomycosis	Female	679	636	1,030	991
		Male	977	899	1,569	1,494
		Unknown	0	0	1	1

**Table 2f\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	Female	2	2	4	2
		Male	0	0	1	1
		Unknown	0	0	0	0
112.0	Candidiasis of mouth	Female	469	389	397	372
		Male	376	299	299	271
		Unknown	0	0	0	0
112.1	Candidiasis of vulva and vagina	Female	1,549	1,438	1,007	972
		Male	15	15	12	12
		Unknown	0	0	0	0
112.2	Candidiasis of other urogenital sites	Female	60	60	61	59
		Male	214	195	240	221
		Unknown	0	0	0	0
112.3	Candidiasis of skin and nails	Female	1,188	1,078	1,180	1,120
		Male	1,027	944	1,035	992
		Unknown	1	1	0	0
112.4	Candidiasis of lung	Female	3	3	4	4
		Male	2	2	0	0
		Unknown	0	0	0	0
112.5	Disseminated candidiasis	Female	30	27	17	16
		Male	14	12	14	11
		Unknown	0	0	0	0
112.8	Candidiasis of other specified sites	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.81	Candidal endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.82	Candidal otitis externa	Female	13	11	14	12
		Male	18	13	15	15
		Unknown	0	0	0	0
112.83	Candidal meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
112.84	Candidiasis of the esophagus	Female	39	34	31	27
		Male	39	29	13	12
		Unknown	0	0	0	0
112.85	Candidiasis of the intestine	Female	20	18	10	10
		Male	16	14	10	8
		Unknown	0	0	0	0
112.89	Other candidiasis of other specified sites	Female	108	101	87	86
		Male	86	76	79	77
		Unknown	0	0	0	0
112.9	Candidiasis of unspecified site	Female	595	522	475	440
		Male	378	348	387	367
		Unknown	0	0	0	0
114	Coccidioidomycosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	Female	11	9	3	3
		Male	10	8	7	6
		Unknown	0	0	0	0
114.1	Primary extrapulmonary coccidioidomycosis	Female	0	0	1	1
		Male	0	0	1	1
		Unknown	0	0	0	0
114.2	Coccidioidal meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2f\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	Female	0	0	0	0
		Male	4	3	0	0
		Unknown	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	Female	2	1	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	Female	0	0	2	2
		Male	0	0	1	1
		Unknown	0	0	0	0
114.9	Unspecified coccidioidomycosis	Female	6	6	6	5
		Male	4	3	4	4
		Unknown	0	0	0	0
115	Histoplasmosis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
115.0	Histoplasma capsulatum	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	Female	1	1	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.01	Histoplasma capsulatum meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.02	Histoplasma capsulatum retinitis	Female	12	9	1	1
		Male	5	5	1	1
		Unknown	0	0	0	0
115.03	Histoplasma capsulatum pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
115.05	Histoplasma capsulatum pneumonia	Female	0	0	0	0
		Male	1	1	1	1
		Unknown	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.1	Histoplasma duboisii	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	Female	1	1	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.11	Histoplasma duboisii meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.12	Histoplasma duboisii retinitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.13	Histoplasma duboisii pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.14	Histoplasma duboisii endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0

**Table 2f\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
			115.15	Histoplasma duboisii pneumonia	Female	1
		Male	0	0	0	0
		Unknown	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.9	Unspecified Histoplasmosis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	Female	13	11	6	4
		Male	12	12	3	3
		Unknown	0	0	0	0
115.93	Unspecified Histoplasmosis pericarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	Female	0	0	0	0
		Male	0	0	1	1
		Unknown	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	Female	7	7	3	3
		Male	4	4	6	6
		Unknown	0	0	0	0
116	Blastomycotic infection	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
116.0	Blastomycosis	Female	0	0	3	3
		Male	3	3	1	1
		Unknown	0	0	0	0
116.1	Paracoccidioidomycosis	Female	7	7	3	3
		Male	5	5	8	8
		Unknown	0	0	0	0
116.2	Lobomycosis	Female	0	0	0	0
		Male	1	1	0	0
		Unknown	0	0	0	0
117	Other mycoses	Female	0	0	0	0
		Male	0	0	0	0
		Unknown	0	0	0	0
117.0	Rhinosporidiosis	Female	0	0	1	1
		Male	2	2	1	1
		Unknown	0	0	0	0
117.1	Sporotrichosis	Female	15	12	25	22
		Male	36	16	28	25
		Unknown	0	0	0	0
117.2	Chromoblastomycosis	Female	1	1	1	1
		Male	16	12	2	2
		Unknown	0	0	0	0
117.3	Aspergillosis	Female	5	5	17	11
		Male	37	15	26	8
		Unknown	0	0	0	0
117.4	Mycotic mycetomas	Female	49	46	15	15
		Male	34	33	22	21
		Unknown	0	0	0	0
117.5	Cryptococcosis	Female	3	3	3	3
		Male	2	2	1	1
		Unknown	0	0	0	0

**Table 2f\_sex. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Sex**

DX Code	Diagnosis Description	Sex	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.6	Allescheriosis (Petriellidiosis)	Female	1	1	0	0
		Male	2	2	1	1
		Unknown	0	0	0	0
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	Female	0	0	0	0
		Male	8	8	11	3
		Unknown	0	0	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	Female	47	45	44	43
		Male	59	54	56	51
		Unknown	0	0	0	0
117.9	Other and unspecified mycoses	Female	889	787	957	902
		Male	937	848	943	897
		Unknown	0	0	0	0
118	Opportunistic mycoses	Female	12	12	4	4
		Male	13	12	3	2
		Unknown	0	0	0	0
185	Malignant neoplasm of prostate	Female	24	8	6	4
		Male	5,126	2,511	1,880	1,349
		Unknown	0	0	0	0
233.4	Carcinoma in situ of prostate	Female	0	0	2	2
		Male	83	72	32	32
		Unknown	0	0	0	0
255.0	Cushing's syndrome	Female	54	34	25	22
		Male	25	19	9	9
		Unknown	0	0	0	0
V10.46	Personal history of malignant neoplasm of prostate	Female	0	0	1	1
		Male	917	762	464	409
		Unknown	0	0	0	0

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Table 2f\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
<i>Total Number of Prevalent Terbinafine Users</i>		-	<i>N/A</i>	<i>773,190</i>	<i>N/A</i>	<i>773,190</i>
-	Diagnosis outside of pre-determined list	0-17	66,519	16,686	32,983	12,718
		18-64	2,518,589	419,078	1,304,849	361,098
		65+	868,976	94,177	420,649	82,032
110	Dermatophytosis	0-17	1	1	1	1
		18-64	10	10	7	7
		65+	3	3	7	7
110.0	Dermatophytosis of scalp and beard	0-17	3,313	2,610	2,972	2,791
		18-64	4,684	4,380	5,418	5,247
		65+	592	549	751	720
110.1	Dermatophytosis of nail	0-17	6,043	4,830	4,458	4,258
		18-64	209,453	170,190	175,150	167,715
		65+	34,999	29,429	36,424	34,692
110.2	Dermatophytosis of hand	0-17	71	65	89	87
		18-64	1,670	1,547	2,523	2,444
		65+	311	293	546	533
110.3	Dermatophytosis of groin and perianal area	0-17	164	154	341	326
		18-64	5,577	5,138	11,950	11,514
		65+	1,188	1,069	2,780	2,632
110.4	Dermatophytosis of foot	0-17	1,490	1,343	1,887	1,818
		18-64	42,082	37,278	46,093	43,930
		65+	6,117	5,332	8,301	7,770
110.5	Dermatophytosis of the body	0-17	2,743	2,365	4,114	3,930
		18-64	14,898	13,522	28,942	27,891
		65+	2,761	2,484	6,111	5,836
110.6	Deep seated dermatophytosis	0-17	66	62	77	71
		18-64	554	507	753	717
		65+	155	137	223	212
110.8	Dermatophytosis of other specified sites	0-17	161	151	200	192
		18-64	992	934	1,235	1,199
		65+	238	231	267	261
110.9	Dermatophytosis of unspecified site	0-17	925	837	1,031	995
		18-64	6,667	6,146	8,060	7,846
		65+	1,233	1,136	1,632	1,572
111	Dermatomycosis, other and unspecified	0-17	0	0	0	0
		18-64	4	4	2	2
		65+	3	3	2	2
111.0	Pityriasis versicolor	0-17	223	212	398	395
		18-64	3,025	2,868	4,462	4,370
		65+	155	142	205	203
111.1	Tinea nigra	0-17	5	5	7	7
		18-64	114	109	125	122
		65+	15	14	20	18
111.2	Tinea blanca	0-17	13	12	19	19
		18-64	118	114	240	235
		65+	14	13	31	31
111.3	Black piedra	0-17	0	0	0	0
		18-64	3	3	4	4
		65+	1	1	0	0
111.8	Other specified dermatomycoses	0-17	10	10	8	7
		18-64	181	165	168	163
		65+	31	30	27	25
111.9	Unspecified dermatomycosis	0-17	88	84	140	135
		18-64	1,254	1,177	2,007	1,925
		65+	314	274	453	426



**Table 2f\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
112	Candidiasis	0-17	0	0	0	0
		18-64	0	0	4	2
		65+	2	2	1	1
112.0	Candidiasis of mouth	0-17	10	9	7	6
		18-64	589	471	512	480
		65+	246	208	177	157
112.1	Candidiasis of vulva and vagina	0-17	17	17	15	14
		18-64	1,394	1,294	869	842
		65+	153	142	135	128
112.2	Candidiasis of other urogenital sites	0-17	5	4	3	3
		18-64	212	202	215	207
		65+	57	49	83	70
112.3	Candidiasis of skin and nails	0-17	47	47	55	51
		18-64	1,645	1,517	1,681	1,606
		65+	524	459	479	455
112.4	Candidiasis of lung	0-17	0	0	0	0
		18-64	3	3	3	3
		65+	2	2	1	1
112.5	Disseminated candidiasis	0-17	2	1	1	1
		18-64	39	35	25	22
		65+	3	3	5	4
112.8	Candidiasis of other specified sites	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.81	Candidal endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.82	Candidal otitis externa	0-17	0	0	0	0
		18-64	19	15	23	21
		65+	12	9	6	6
112.83	Candidal meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
112.84	Candidiasis of the esophagus	0-17	1	1	0	0
		18-64	50	41	23	23
		65+	27	21	21	16
112.85	Candidiasis of the intestine	0-17	15	13	5	5
		18-64	18	16	15	13
		65+	3	3	0	0
112.89	Other candidiasis of other specified sites	0-17	6	5	3	3
		18-64	140	127	119	117
		65+	48	45	44	43
112.9	Candidiasis of unspecified site	0-17	16	16	17	16
		18-64	747	666	641	598
		65+	210	188	204	193
114	Coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
114.0	Primary coccidioidomycosis (pulmonary)	0-17	0	0	0	0
		18-64	19	15	8	7
		65+	2	2	2	2
114.1	Primary extrapulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	1	1
114.2	Coccidioidal meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2f\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
114.3	Other forms of progressive coccidioidomycosis	0-17	0	0	0	0
		18-64	4	3	0	0
		65+	0	0	0	0
114.4	Chronic pulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	3	2	0	0
		65+	0	0	0	0
114.5	Unspecified pulmonary coccidioidomycosis	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	2	2
114.9	Unspecified coccidioidomycosis	0-17	0	0	0	0
		18-64	8	7	7	7
		65+	2	2	3	2
115	Histoplasmosis	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.0	Histoplasma capsulatum	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.00	Histoplasma capsulatum, without mention of manifestation	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.01	Histoplasma capsulatum meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.02	Histoplasma capsulatum retinitis	0-17	0	0	0	0
		18-64	9	7	1	1
		65+	8	7	1	1
115.03	Histoplasma capsulatum pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.04	Histoplasma capsulatum endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	1	1	0	0
115.05	Histoplasma capsulatum pneumonia	0-17	0	0	1	1
		18-64	1	1	0	0
		65+	0	0	0	0
115.09	Histoplasma capsulatum, with mention of other manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.1	Histoplasma duboisii	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.10	Histoplasma duboisii, without mention of manifestation	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.11	Histoplasma duboisii meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.12	Histoplasma duboisii retinitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.13	Histoplasma duboisii pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.14	Histoplasma duboisii endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0

**Table 2f\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
115.15	Histoplasma duboisii pneumonia	0-17	0	0	0	0
		18-64	1	1	0	0
		65+	0	0	0	0
115.19	Histoplasma duboisii with mention of other manifestation	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.9	Unspecified Histoplasmosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.91	Unspecified Histoplasmosis meningitis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.92	Unspecified Histoplasmosis retinitis	0-17	0	0	0	0
		18-64	14	13	4	3
		65+	11	10	5	4
115.93	Unspecified Histoplasmosis pericarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.94	Unspecified Histoplasmosis endocarditis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
115.95	Unspecified Histoplasmosis pneumonia	0-17	0	0	0	0
		18-64	0	0	1	1
		65+	0	0	0	0
115.90 or 115.99	Unspecified Histoplasmosis with or without mention of manifestation	0-17	0	0	0	0
		18-64	5	5	8	8
		65+	6	6	1	1
116	Blastomycotic infection	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
116.0	Blastomycosis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	2	2	3	3
116.1	Paracoccidioidomycosis	0-17	0	0	0	0
		18-64	12	12	9	9
		65+	0	0	2	2
116.2	Lobomycosis	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	1	1	0	0
117	Other mycoses	0-17	0	0	0	0
		18-64	0	0	0	0
		65+	0	0	0	0
117.0	Rhinosporidiosis	0-17	0	0	0	0
		18-64	1	1	1	1
		65+	1	1	1	1
117.1	Sporotrichosis	0-17	0	0	1	1
		18-64	43	22	35	31
		65+	8	6	17	15
117.2	Chromoblastomycosis	0-17	0	0	0	0
		18-64	11	8	1	1
		65+	6	5	2	2
117.3	Aspergillosis	0-17	0	0	2	2
		18-64	26	12	31	14
		65+	16	8	10	3
117.4	Mycotic mycetomas	0-17	2	2	0	0
		18-64	63	60	28	28
		65+	18	17	9	8
117.5	Cryptococcosis	0-17	0	0	0	0
		18-64	3	3	4	4
		65+	2	2	0	0
117.6	Allescheriosis (Petriellidiosis)	0-17	0	0	0	0
		18-64	3	3	1	1
		65+	0	0	0	0

**Table 2f\_age. Number of Codes and Number and Percent of Users with Prevalent Diagnoses in the 45 Days Before and 14 Days After Prevalent Terbinafine Use in the Sentinel Distributed Database, By Age Group**

DX Code	Diagnosis Description	Age Group	45 Days to 1 Day Prior to Prevalent Antifungal Use		0 to 14 Days Post Prevalent Antifungal Use*	
			Codes	Users	Codes	Users
117.7	Zygomycosis (Phycomycosis or Mucormycosis)	0-17	0	0	0	0
		18-64	5	5	11	3
		65+	3	3	0	0
117.8	Infection by dematiaceous fungi (Phaeohyphomycosis)	0-17	4	4	3	3
		18-64	89	83	73	69
		65+	13	12	24	22
117.9	Other and unspecified mycoses	0-17	84	74	63	60
		18-64	1,451	1,287	1,465	1,394
		65+	291	274	372	345
118	Opportunistic mycoses	0-17	0	0	0	0
		18-64	23	22	6	5
		65+	2	2	1	1
185	Malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	1,843	904	668	472
		65+	3,307	1,615	1,218	881
233.4	Carcinoma in situ of prostate	0-17	0	0	0	0
		18-64	33	26	18	18
		65+	50	46	16	16
255.0	Cushing's syndrome	0-17	0	0	0	0
		18-64	63	42	32	29
		65+	16	11	2	2
V10.46	Personal history of malignant neoplasm of prostate	0-17	0	0	0	0
		18-64	245	210	124	115
		65+	672	552	341	295

\* The post-index assessment period captured diagnoses that occurred on the index date and up to 14 days after the index date.

**Appendix A. Data Partner Data Availability End Dates as of Request Distribution Date**

<b>Data Partner ID</b>	<b>End Date</b>
DP001	9/16/2015
DP002	9/16/2015
DP003	9/16/2015
DP004	6/30/2015
DP005	2/28/2015
DP006	5/31/2015
DP007	6/30/2012
DP008	9/16/2015
DP009	9/16/2015
DP010	9/16/2015
DP011	9/16/2015
DP012	9/16/2015
DP013	9/16/2015
DP014	9/16/2015
DP015	12/31/2014
DP016	6/30/2015

**Appendix B. Generic and Brand Names used to Define Oral Antifungal Drugs in this Request**


---

Generic Name	Brand Name
FLUCONAZOLE	fluconazole
FLUCONAZOLE	Diflucan
GRISEOFULVIN ULTRAMICROSIZED	griseofulvin ultramicrosize
GRISEOFULVIN ULTRAMICROSIZED	Fulvicin P/G
GRISEOFULVIN ULTRAMICROSIZED	Gris-PEG (ultramicrosize)
GRISEOFULVIN, MICROSIZED	Grisactin
GRISEOFULVIN, MICROSIZED	griseofulvin microsize
GRISEOFULVIN, MICROSIZED	Grifulvin V
GRISEOFULVIN, MICROSIZED	Fulvicin U/F
ITRACONAZOLE	Sporanox Pulsepak
ITRACONAZOLE	itraconazole
ITRACONAZOLE	Sporanox
ITRACONAZOLE	Onmel
KETOCONAZOLE	Nizoral
KETOCONAZOLE	ketoconazole
TERBINAFLINE HCL	Lamisil
TERBINAFLINE HCL	terbinafine HCl

**Appendix C. Procedure Codes, Generic Names, and Brand Names used to Define Antifungal Incidence Criteria in this Request**

Procedure Codes		
Code	Code Type	Full Description
J1450	HCPCS	Injection, fluconazole, 200 mg
J1835	HCPCS	Injection, itraconazole, 50 mg
Drug Names		
Generic Name	Brand Name	
FLUCONAZOLE	fluconazole	
FLUCONAZOLE	Diflucan	
FLUCONAZOLE	fluconazole (bulk)	
FLUCONAZOLE IN DEXTROSE, ISO-OSMOTIC	fluconazole in dextrose(iso-o)	
FLUCONAZOLE IN DEXTROSE, ISO-OSMOTIC	Diflucan in dextrose (iso-osm)	
FLUCONAZOLE IN SODIUM CHLORIDE, ISO-OSMOTIC	fluconazole in NaCl (iso-osm)	
FLUCONAZOLE IN SODIUM CHLORIDE, ISO-OSMOTIC	Diflucan in NaCl (iso-osm)	
GRISEOFULVIN	griseofulvin (bulk)	
GRISEOFULVIN ULTRAMICROSIZED	griseofulvin ultramicrosize	
GRISEOFULVIN ULTRAMICROSIZED	Fulvicin P/G	
GRISEOFULVIN ULTRAMICROSIZED	Gris-PEG (ultramicrosize)	
GRISEOFULVIN, MICROSIZED	Grisactin	
GRISEOFULVIN, MICROSIZED	griseofulvin microsize	
GRISEOFULVIN, MICROSIZED	Grifulvin V	
GRISEOFULVIN, MICROSIZED	Fulvicin U/F	
ITRACONAZOLE	Sporanox Pulsepak	
ITRACONAZOLE	itraconazole	
ITRACONAZOLE	Sporanox	
ITRACONAZOLE	Onmel	
ITRACONAZOLE	itraconazole (bulk)	
ITRACONAZOLE, MICRONIZED	itraconazole, micronized(bulk)	
KETOCONAZOLE	Nizoral	
KETOCONAZOLE	ketoconazole	
KETOCONAZOLE	Kuric	
KETOCONAZOLE	Ketodan	
KETOCONAZOLE	Extina	
KETOCONAZOLE	Xolegel	
KETOCONAZOLE	Nizoral A-D	
KETOCONAZOLE	ketoconazole (bulk)	
KETOCONAZOLE/HYDROCORTISONE	ketoconazole-hydrocortisone	
KETOCONAZOLE/HYDROCORTISONE	Ketocon + Plus	
KETOCONAZOLE/HYDROCORTISONE	Xolegel Corepak	
KETOCONAZOLE/PYRITHIONE ZINC	Xolegel Duo	
KETOCONAZOLE/SKIN CLEANSER COMBINATION NO.28	Ketodan Kit	
TERBINAFINA	Lamisil AT	
TERBINAFINA HCL	Lamisil	
TERBINAFINA HCL	terbinafine HCl	
TERBINAFINA HCL	Lamisil (Aerosol)	
TERBINAFINA HCL	Athlete's Foot (terbinafine)	
TERBINAFINA HCL	Lamisil AT	
TERBINAFINA HCL	Foot Antifungal	
TERBINAFINA HCL	Desenex Max	
TERBINAFINA HCL	Athlete's Foot AF	
TERBINAFINA HCL	Antifungal (terbinafine)	
TERBINAFINA HCL	Jock Itch (terbinafine)	
TERBINAFINA HCL	terbinafine (bulk)	
TERBINAFINA HCL/HYDROXYPROPYL CHITOSAN	Terbinex	

**Appendix D. Diagnosis Codes used to Define Indications in this Request**

Code	Code Type	Full Description
110	ICD-9-CM	Dermatophytosis
110.0	ICD-9-CM	Dermatophytosis of scalp and beard
110.1	ICD-9-CM	Dermatophytosis of nail
110.2	ICD-9-CM	Dermatophytosis of hand
110.3	ICD-9-CM	Dermatophytosis of groin and perianal area
110.4	ICD-9-CM	Dermatophytosis of foot
110.5	ICD-9-CM	Dermatophytosis of the body
110.6	ICD-9-CM	Deep seated dermatophytosis
110.8	ICD-9-CM	Dermatophytosis of other specified sites
110.9	ICD-9-CM	Dermatophytosis of unspecified site
111	ICD-9-CM	Dermatormycosis, other and unspecified
111.0	ICD-9-CM	Pityriasis versicolor
111.1	ICD-9-CM	Tinea nigra
111.2	ICD-9-CM	Tinea blanca
111.3	ICD-9-CM	Black piedra
111.8	ICD-9-CM	Other specified dermatomycoses
111.9	ICD-9-CM	Unspecified dermatomycosis
112	ICD-9-CM	Candidiasis
112.0	ICD-9-CM	Candidiasis of mouth
112.1	ICD-9-CM	Candidiasis of vulva and vagina
112.2	ICD-9-CM	Candidiasis of other urogenital sites
112.3	ICD-9-CM	Candidiasis of skin and nails
112.4	ICD-9-CM	Candidiasis of lung
112.5	ICD-9-CM	Disseminated candidiasis
112.8	ICD-9-CM	Candidiasis of other specified sites
112.81	ICD-9-CM	Candidal endocarditis
112.82	ICD-9-CM	Candidal otitis externa
112.83	ICD-9-CM	Candidal meningitis
112.84	ICD-9-CM	Candidiasis of the esophagus
112.85	ICD-9-CM	Candidiasis of the intestine
112.89	ICD-9-CM	Other candidiasis of other specified sites
112.9	ICD-9-CM	Candidiasis of unspecified site
114	ICD-9-CM	Coccidioidomycosis
114.0	ICD-9-CM	Primary coccidioidomycosis (pulmonary)
114.1	ICD-9-CM	Primary extrapulmonary coccidioidomycosis
114.2	ICD-9-CM	Coccidioidal meningitis
114.3	ICD-9-CM	Other forms of progressive coccidioidomycosis
114.4	ICD-9-CM	Chronic pulmonary coccidioidomycosis
114.5	ICD-9-CM	Unspecified pulmonary coccidioidomycosis



**Appendix D. Diagnosis Codes used to Define Indications in this Request**

Code	Code Type	Full Description
114.9	ICD-9-CM	Unspecified coccidioidomycosis
115	ICD-9-CM	Histoplasmosis
115.0	ICD-9-CM	Histoplasma capsulatum
115.00	ICD-9-CM	Histoplasma capsulatum, without mention of manifestation
115.01	ICD-9-CM	Histoplasma capsulatum meningitis
115.02	ICD-9-CM	Histoplasma capsulatum retinitis
115.03	ICD-9-CM	Histoplasma capsulatum pericarditis
115.04	ICD-9-CM	Histoplasma capsulatum endocarditis
115.05	ICD-9-CM	Histoplasma capsulatum pneumonia
115.09	ICD-9-CM	Histoplasma capsulatum, with mention of other manifestation
115.1	ICD-9-CM	Histoplasma duboisii
115.10	ICD-9-CM	Histoplasma duboisii, without mention of manifestation
115.11	ICD-9-CM	Histoplasma duboisii meningitis
115.12	ICD-9-CM	Histoplasma duboisii retinitis
115.13	ICD-9-CM	Histoplasma duboisii pericarditis
115.14	ICD-9-CM	Histoplasma duboisii endocarditis
115.15	ICD-9-CM	Histoplasma duboisii pneumonia
115.19	ICD-9-CM	Histoplasma duboisii with mention of other manifestation
115.9	ICD-9-CM	Unspecified Histoplasmosis
115.90	ICD-9-CM	Unspecified Histoplasmosis without mention of manifestation
115.91	ICD-9-CM	Unspecified Histoplasmosis meningitis
115.92	ICD-9-CM	Unspecified Histoplasmosis retinitis
115.93	ICD-9-CM	Unspecified Histoplasmosis pericarditis
115.94	ICD-9-CM	Unspecified Histoplasmosis endocarditis
115.95	ICD-9-CM	Unspecified Histoplasmosis pneumonia
115.99	ICD-9-CM	Unspecified Histoplasmosis with mention of other manifestation
116	ICD-9-CM	Blastomycotic infection
116.0	ICD-9-CM	Blastomycosis
116.1	ICD-9-CM	Paracoccidioidomycosis
116.2	ICD-9-CM	Lobomycosis
117	ICD-9-CM	Other mycoses
117.0	ICD-9-CM	Rhinosporidiosis
117.1	ICD-9-CM	Sporotrichosis
117.2	ICD-9-CM	Chromoblastomycosis
117.3	ICD-9-CM	Aspergillosis
117.4	ICD-9-CM	Mycotic mycetomas
117.5	ICD-9-CM	Cryptococcosis
117.6	ICD-9-CM	Allescheriosis (Petriellidiosis)
117.7	ICD-9-CM	Zygomycosis (Phycomycosis or Mucormycosis)
117.8	ICD-9-CM	Infection by dematiaceous fungi (Phaeohyphomycosis)
117.9	ICD-9-CM	Other and unspecified mycoses
118	ICD-9-CM	Opportunistic mycoses
255.0	ICD-9-CM	Cushing's syndrome
185	ICD-9-CM	Malignant neoplasm of prostate
233.4	ICD-9-CM	Carcinoma in situ of prostate
V10.46	ICD-9-CM	Personal history of malignant neoplasm of prostate

**Appendix E: Specifications for Request ID cder\_mpl1r\_wp029\_nsdg\_v01**

The Center for Drug Evaluation and Research (CDER) requested execution of Modular Program #7 (MP7), version 5.1, to investigate indications of use for all antifungal users and for each oral antifungal drug in the Sentinel Distributed Database (SDD). The query period was from January 1, 2009 - September 16, 2015 and the enrollment gap was set at 45 days. Age groups were set as follows: 0-17, 18-64, and 65+ years. In total, 24 different scenarios were examined in this report.

**Query Period:** January 1, 2009 - September 16, 2015  
**Age Stratifications:** 0-17, 18-64, 65+  
**Enrollment Gap:** 45 days  
**Coverage Requirement:** Medical and Drug Coverage  
**Post-Index Enrollment (days):** 14

Scenario	Pre-Index Enrollment (days)	Exposure					Pre/Post-Index Diagnoses					
		Index Date	Care Setting	Incident w/ respect to:	Washout (days)	Incidence Type	Most Frequent Diagnoses	Care Setting	Principal Discharge Diagnosis	Incidence Type	Pre-Index Lookup Period	Post-Index Lookup Period
1	45	All oral antifungals	Any	N/A	N/A	First valid exposure during the query period	See Appendix D	Any	Any	Include all valid codes	45 days to day before index date	Index date to 14 days after index date
2	90	All oral antifungals	Any	All antifungals	90	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
3	180	All oral antifungals	Any	All antifungals	180	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
4	365	All oral antifungals	Any	All antifungals	365	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
5	45	Oral ketoconazole	Any	N/A	N/A	First valid exposure during the query period	See Appendix D	Any	Any	Include all valid codes	45 days to day before index date	Index date to 14 days after index date
6	90	Oral ketoconazole	Any	All antifungals	90	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
7	180	Oral ketoconazole	Any	All antifungals	180	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
8	365	Oral ketoconazole	Any	All antifungals	365	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
9	45	Oral Fluconazole	Any	N/A	N/A	First valid exposure during the query period	See Appendix D	Any	Any	Include all valid codes	45 days to day before index date	Index date to 14 days after index date
10	90	Oral Fluconazole	Any	All antifungals	90	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
11	180	Oral Fluconazole	Any	All antifungals	180	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
12	365	Oral Fluconazole	Any	All antifungals	365	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
13	45	Oral Griseofulvin	Any	N/A	N/A	First valid exposure during the query period	See Appendix D	Any	Any	Include all valid codes	45 days to day before index date	Index date to 14 days after index date
14	90	Oral Griseofulvin	Any	All antifungals	90	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
15	180	Oral Griseofulvin	Any	All antifungals	180	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
16	365	Oral Griseofulvin	Any	All antifungals	365	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
17	45	Oral Itraconazole	Any	N/A	N/A	First valid exposure during the query period	See Appendix D	Any	Any	Include all valid codes	45 days to day before index date	Index date to 14 days after index date
18	90	Oral Itraconazole	Any	All antifungals	90	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
19	180	Oral Itraconazole	Any	All antifungals	180	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
20	365	Oral Itraconazole	Any	All antifungals	365	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
21	45	Oral Terbinafine	Any	N/A	N/A	First valid exposure during the query period	See Appendix D	Any	Any	Include all valid codes	45 days to day before index date	Index date to 14 days after index date
22	90	Oral Terbinafine	Any	All antifungals	90	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
23	180	Oral Terbinafine	Any	All antifungals	180	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A
24	365	Oral Terbinafine	Any	All antifungals	365	First valid incident exposure during the query period	N/A	N/A	N/A	N/A	N/A	N/A